# EDGAR Filing Document

**Accession Number:** 0000832101
**File Stem:** 0000832101-26-000003
**Filing Date:** 2026-2
**Character Count:** 408458
**Document Hash:** 783b5339577fec62e201c7e840c4c37e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000832101-26-000003.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0000832101-26-000003

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 157

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IDEX CORP /DE/
- **CENTRAL INDEX KEY:** 0000832101
- **STANDARD INDUSTRIAL CLASSIFICATION:** PUMPS & PUMPING EQUIPMENT [3561]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 363555336
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-10235
- **FILM NUMBER:** 26654980

**BUSINESS ADDRESS:**
- **STREET 1:** 3100 SANDERS ROAD
- **STREET 2:** SUITE 301
- **CITY:** NORTHBROOK
- **STATE:** IL
- **ZIP:** 60062
- **BUSINESS PHONE:** 8474987070

**MAIL ADDRESS:**
- **STREET 1:** 3100 SANDERS ROAD
- **STREET 2:** SUITE 301
- **CITY:** NORTHBROOK
- **STATE:** IL
- **ZIP:** 60062

?xml version='1.0' encoding='ASCII'? iex-20251231

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-K** 

---

| | |
|:---|:---|
| ☑ | **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

For the fiscal year ended December 31, 2025

---

| | |
|:---|:---|
| ☐ | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| | For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; |

---

Commission file number 1-10235

**IDEX CORPORATION**

*(Exact name of registrant as specified in its charter)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **Delaware** | **36-3555336** |
| *(State or other jurisdiction of<br>incorporation or organization)* | *(State or other jurisdiction of<br>incorporation or organization)* | *(State or other jurisdiction of<br>incorporation or organization)* | *(State or other jurisdiction of<br>incorporation or organization)* | *(I.R.S. Employer<br>Identification No.)* |
| **3100 Sanders Road,** | **Suite 301,** | **Northbrook,** | **Illinois** | **60062** |
| *(Address of principal executive offices)* | *(Address of principal executive offices)* | *(Address of principal executive offices)* | *(Address of principal executive offices)* | *(Zip Code)* |

---

Registrant's telephone number, including area code: (847) 498-7070

Securities Registered Pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | IEX | New York Stock Exchange |

---

Securities Registered Pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes 🗹&nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes ◻&nbsp;&nbsp;&nbsp;&nbsp;No 🗹

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes 🗹&nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes 🗹&nbsp;&nbsp;&nbsp;&nbsp;No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ☑ | Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ | | | | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |

---

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☑

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No 🗹

The aggregate market value, as of the last business day of the registrant's most recently completed second fiscal quarter, of the common stock (based on the June 30, 2025 closing price of $175.57) held by non-affiliates of IDEX Corporation was $13,228,549,364.

The number of shares outstanding of IDEX Corporation's common stock, par value $0.01 per share, as of February 13, 2026 was 74,347,824.

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of the proxy statement with respect to the IDEX Corporation 2026 annual meeting of stockholders (the "2026 Proxy Statement") are incorporated by reference into <u>[Part III](#ibaf335d4459d4d2499897b1ecd08d11c_172)</u> of this Form 10-K.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Cautionary Statement Under the Private Securities Litigation Reform Act**

This annual report on Form 10-K, including the "Overview," "Results of Operations," "Liquidity and Capital Resources" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other things, the Company's business strategy, outlook and full year 2026 focus and the assumptions underlying these expectations, capital return strategy, plant and equipment capacity for future growth, planned production, anticipated future acquisition behavior, resource and capital deployment and focus on organic and inorganic growth, the Company's ability to adapt to macroeconomic challenges and anticipated adaptability of resource deployment, anticipated impacts of tariffs and global trade policies and changes in law, including the One, Big, Beautiful Bill Act, the Company's future market positioning, anticipated trends in end markets, including expectations regarding market sector contraction, recovery, stabilization or growth and underlying drivers of such expectations, expectations regarding future order volumes and order patterns, demand within end markets, availability and sufficiency of cash and financing alternatives, the impacts of any pending or threatened legal, regulatory and other proceedings involving the Company and its subsidiaries, anticipated benefits and restructuring charges, including severance charges, related to the Company's organizational changes, the anticipated tax treatment of the Company's recent acquisitions, the expected contingent consideration payable related to the Company's recent acquisitions, the anticipated benefits and performance of the Company's recent or future acquisitions, anticipated growth initiatives and expansions and the anticipated benefits of the Company's productivity and cost containment efforts, and are indicated by words or phrases such as "anticipates," "estimates," "plans," "guidance," "expects," "projects," "forecasts," "should," "could," "will," "likely to be," "management believes," "the Company believes," "the Company intends" and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this report.

The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries; the impact of severe weather events, natural disasters and public health threats; economic and political consequences resulting from terrorist attacks, wars and global conflicts; the Company's ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; cybersecurity incidents; the continued growth of artificial intelligence ("AI") and any related changes to demand in AI-driven markets served by the Company's customers; the relationship of the U.S. Dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in countries in which the Company operates; developments with respect to trade policy and existing, new or increased tariffs or other similar measures; changes to applicable laws and regulations, including tax laws; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters, and the other risk factors discussed in <u>[Item 1A](#ibaf335d4459d4d2499897b1ecd08d11c_19)</u>, "Risk Factors" of this annual report on Form 10-K. The forward-looking statements included here are only made as of the date of this report, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

The Company also routinely posts important information for investors on its website at www.idexcorp.com under "Investors." The Company may use this website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD adopted by the United States Securities and Exchange Commission (the "SEC"). Accordingly, investors should monitor the Investor Relations portion of the Company's website noted above, in addition to following the Company's press releases, SEC filings, and public conference calls and webcasts. Our website and the information contained therein or connected thereto shall not be deemed to be incorporated into this annual report on Form 10-K.

------

 **Table of Contents**

---

| | | | |
|:---|:---|:---|:---|
| **PART I.** | **Item 1.** | <u>[Business](#ibaf335d4459d4d2499897b1ecd08d11c_16)</u> | [1](#ibaf335d4459d4d2499897b1ecd08d11c_16) |
|  | **Item 1A.** | <u>[Risk Factors](#ibaf335d4459d4d2499897b1ecd08d11c_19)</u> | [13](#ibaf335d4459d4d2499897b1ecd08d11c_19) |
|  | **Item 1B.** | <u>[Unresolved Staff Comments](#ibaf335d4459d4d2499897b1ecd08d11c_22)</u> | [19](#ibaf335d4459d4d2499897b1ecd08d11c_22) |
|  | **Item 1C.** | <u>[Cybersecurity](#ibaf335d4459d4d2499897b1ecd08d11c_25)</u> | [19](#ibaf335d4459d4d2499897b1ecd08d11c_25) |
|  | **Item 2.** | <u>[Properties](#ibaf335d4459d4d2499897b1ecd08d11c_28)</u> | [21](#ibaf335d4459d4d2499897b1ecd08d11c_28) |
|  | **Item 3.** | <u>[Legal Proceedings](#ibaf335d4459d4d2499897b1ecd08d11c_31)</u> | [21](#ibaf335d4459d4d2499897b1ecd08d11c_31) |
|  | **Item 4.** | <u>[Mine Safety Disclosures](#ibaf335d4459d4d2499897b1ecd08d11c_34)</u> | [21](#ibaf335d4459d4d2499897b1ecd08d11c_34) |
| **PART II.** | **Item 5.** | <u>[Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#ibaf335d4459d4d2499897b1ecd08d11c_40)</u> | [22](#ibaf335d4459d4d2499897b1ecd08d11c_40) |
|  | **Item 6.** | <u>[\[Reserved\]](#ibaf335d4459d4d2499897b1ecd08d11c_43)</u> | [23](#ibaf335d4459d4d2499897b1ecd08d11c_43) |
|  | **Item 7.** | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ibaf335d4459d4d2499897b1ecd08d11c_46)</u> | [24](#ibaf335d4459d4d2499897b1ecd08d11c_46) |
|  | **Item 7A.** | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ibaf335d4459d4d2499897b1ecd08d11c_67)</u> | [33](#ibaf335d4459d4d2499897b1ecd08d11c_67) |
|  | **Item 8.** | <u>[Financial Statements and Supplementary Data](#ibaf335d4459d4d2499897b1ecd08d11c_70)</u> | [35](#ibaf335d4459d4d2499897b1ecd08d11c_70) |
|  |  | &nbsp;&nbsp;<u>[Management's Report on Internal Control Over Financial Reporting](#ibaf335d4459d4d2499897b1ecd08d11c_73)</u> | [35](#ibaf335d4459d4d2499897b1ecd08d11c_73) |
|  |  | &nbsp;&nbsp;<u>[Report of Independent Registered Public Accounting Firm (PCAOB ID No.](#ibaf335d4459d4d2499897b1ecd08d11c_76)</u><u>34</u><u>[)](#ibaf335d4459d4d2499897b1ecd08d11c_76)</u> | [36](#ibaf335d4459d4d2499897b1ecd08d11c_76) |
|  |  | &nbsp;&nbsp;<u>[Consolidated Statements of Income](#ibaf335d4459d4d2499897b1ecd08d11c_82)</u> | [39](#ibaf335d4459d4d2499897b1ecd08d11c_82) |
|  |  | &nbsp;&nbsp;<u>[Consolidated Statements of Comprehensive Income](#ibaf335d4459d4d2499897b1ecd08d11c_85)</u> | [40](#ibaf335d4459d4d2499897b1ecd08d11c_85) |
|  |  | &nbsp;&nbsp;<u>[Consolidated Balance Sheets](#ibaf335d4459d4d2499897b1ecd08d11c_88)</u> | [41](#ibaf335d4459d4d2499897b1ecd08d11c_88) |
|  |  | &nbsp;&nbsp;<u>[Consolidated Statements of Equity](#ibaf335d4459d4d2499897b1ecd08d11c_91)</u> | [42](#ibaf335d4459d4d2499897b1ecd08d11c_91) |
|  |  | &nbsp;&nbsp;<u>[Consolidated Statements of Cash Flows](#ibaf335d4459d4d2499897b1ecd08d11c_94)</u> | [43](#ibaf335d4459d4d2499897b1ecd08d11c_94) |
|  |  | &nbsp;&nbsp;<u>[Notes to Consolidated Financial Statements](#ibaf335d4459d4d2499897b1ecd08d11c_97)</u> | [44](#ibaf335d4459d4d2499897b1ecd08d11c_97) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1. Significant Accounting Policies](#ibaf335d4459d4d2499897b1ecd08d11c_100)</u> | [44](#ibaf335d4459d4d2499897b1ecd08d11c_100) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 2. Acquisitions and Divestitures](#ibaf335d4459d4d2499897b1ecd08d11c_103)</u> | [49](#ibaf335d4459d4d2499897b1ecd08d11c_103) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 3. Collaborative Investments](#ibaf335d4459d4d2499897b1ecd08d11c_106)</u> | [54](#ibaf335d4459d4d2499897b1ecd08d11c_106) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 4. Balance Sheet Components](#ibaf335d4459d4d2499897b1ecd08d11c_109)</u> | [55](#ibaf335d4459d4d2499897b1ecd08d11c_109) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 5. Revenue](#ibaf335d4459d4d2499897b1ecd08d11c_112)</u> | [55](#ibaf335d4459d4d2499897b1ecd08d11c_112) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 6. Goodwill and Intangible Assets](#ibaf335d4459d4d2499897b1ecd08d11c_115)</u> | [58](#ibaf335d4459d4d2499897b1ecd08d11c_115) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 7. Borrowings](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u> | [60](#ibaf335d4459d4d2499897b1ecd08d11c_118) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 8. Fair Value Measurements](#ibaf335d4459d4d2499897b1ecd08d11c_121)</u> | [62](#ibaf335d4459d4d2499897b1ecd08d11c_121) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 9. Leases](#ibaf335d4459d4d2499897b1ecd08d11c_124)</u> | [63](#ibaf335d4459d4d2499897b1ecd08d11c_124) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 10. Commitments and Contingencies](#ibaf335d4459d4d2499897b1ecd08d11c_127)</u> | [65](#ibaf335d4459d4d2499897b1ecd08d11c_127) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 11. Share Repurchases](#ibaf335d4459d4d2499897b1ecd08d11c_130)</u> | [65](#ibaf335d4459d4d2499897b1ecd08d11c_130) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 12. Income Taxes](#ibaf335d4459d4d2499897b1ecd08d11c_133)</u> | [65](#ibaf335d4459d4d2499897b1ecd08d11c_133) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 13. Business Segments and Geographic Information](#ibaf335d4459d4d2499897b1ecd08d11c_136)</u> | [68](#ibaf335d4459d4d2499897b1ecd08d11c_136) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 14. Restructuring Expenses and Asset Impairments](#ibaf335d4459d4d2499897b1ecd08d11c_139)</u> | [72](#ibaf335d4459d4d2499897b1ecd08d11c_139) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 15. Share-Based Compensation](#ibaf335d4459d4d2499897b1ecd08d11c_142)</u> | [73](#ibaf335d4459d4d2499897b1ecd08d11c_142) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 16. Accumulated Other Comprehensive Income (Loss)](#ibaf335d4459d4d2499897b1ecd08d11c_145)</u> | [78](#ibaf335d4459d4d2499897b1ecd08d11c_145) |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 17. Retirement Benefits](#ibaf335d4459d4d2499897b1ecd08d11c_148)</u> | [78](#ibaf335d4459d4d2499897b1ecd08d11c_148) |
|  | **Item 9.** | <u>[Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#ibaf335d4459d4d2499897b1ecd08d11c_160)</u> | [85](#ibaf335d4459d4d2499897b1ecd08d11c_160) |
|  | **Item 9A.** | <u>[Controls and Procedures](#ibaf335d4459d4d2499897b1ecd08d11c_163)</u> | [85](#ibaf335d4459d4d2499897b1ecd08d11c_163) |
|  | **Item 9B.** | <u>[Other Information](#ibaf335d4459d4d2499897b1ecd08d11c_166)</u> | [85](#ibaf335d4459d4d2499897b1ecd08d11c_166) |
|  | **Item 9C.** | <u>[Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#ibaf335d4459d4d2499897b1ecd08d11c_169)</u> | [85](#ibaf335d4459d4d2499897b1ecd08d11c_169) |
| **PART III.** | **Item 10.** | <u>[Directors, Executive Officers and Corporate Governance](#ibaf335d4459d4d2499897b1ecd08d11c_175)</u> | [86](#ibaf335d4459d4d2499897b1ecd08d11c_175) |
|  | **Item 11.** | <u>[Executive Compensation](#ibaf335d4459d4d2499897b1ecd08d11c_178)</u> | [86](#ibaf335d4459d4d2499897b1ecd08d11c_178) |
|  | **Item 12.** | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#ibaf335d4459d4d2499897b1ecd08d11c_181)</u> | [86](#ibaf335d4459d4d2499897b1ecd08d11c_181) |
|  | **Item 13.** | <u>[Certain Relationships and Related Transactions, and Director Independence](#ibaf335d4459d4d2499897b1ecd08d11c_184)</u> | [86](#ibaf335d4459d4d2499897b1ecd08d11c_184) |
|  | **Item 14.** | <u>[Principal Accountant Fees and Services](#ibaf335d4459d4d2499897b1ecd08d11c_187)</u> | [86](#ibaf335d4459d4d2499897b1ecd08d11c_187) |
| **PART IV.** | **Item 15.** | <u>[Exhibits and Financial Statement Schedules](#ibaf335d4459d4d2499897b1ecd08d11c_193)</u> | [87](#ibaf335d4459d4d2499897b1ecd08d11c_193) |
|  | **Item 16.** | <u>[Form 10-K Summary](#ibaf335d4459d4d2499897b1ecd08d11c_196)</u> | [87](#ibaf335d4459d4d2499897b1ecd08d11c_196) |
|  |  | <u>[Signatures](#ibaf335d4459d4d2499897b1ecd08d11c_202)</u> | [91](#ibaf335d4459d4d2499897b1ecd08d11c_202) |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**PART I**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business.**

*Overview*

IDEX Corporation ("IDEX," the "Company," "we," or "our") is a global applied solutions provider serving niche markets with mission critical components for everyday life. Substantially all of the Company's business activities are carried out through over 50 wholly-owned subsidiaries with shared values of Trust, Team and Excellence. IDEX's diverse family of businesses is committed to making trusted solutions that improve lives and is innovative and inquisitive in its quest to solve customers' most challenging applied technology problems. These businesses operate with a high degree of autonomy, yet are all united by employing The IDEX Difference, a philosophy of great teams who embrace the 8020 principle while remaining hyper-focused on serving customers. IDEX was incorporated in Delaware on September 24, 1987.

*End Markets and Products*

The following table summarizes the percentage of total IDEX sales generated by each end market served:

![988](iex-20251231_g1.jpg)

<sup>\*</sup>Beginning in 2025, Life Sciences also includes analytical instruments, pharmaceutical and medical/dental end market sales.

The Company has three reportable segments: Health & Science Technologies ("HST"), Fluid & Metering Technologies ("FMT") and Fire & Safety/Diversified Products ("FSDP"). The segments are structured around how to best serve customer needs, with each segment consisting of businesses that have product and end market similarities as well as common distribution methods and production processes. This structure enables management efficiency, aligns IDEX's operations with its focus on organic growth, strategic acquisitions and capital allocation priorities and provides transparency about the Company's performance to external stakeholders.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The table below illustrates the share of Net sales and Adjusted EBITDA contributed by each segment on the basis of total segments (not total Company) for the years ended December 31, 2025 and 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | **HST** | **FMT** | **FSDP** | **HST** | **FMT** | **FSDP** |
| Net sales | 43% | 35% | 22% | 39% | 38% | 23% |
| Adjusted EBITDA<sup>(1)</sup> | 39% | 40% | 21% | 36% | 42% | 22% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Segment Adjusted EBITDA excludes the impact of unallocated corporate costs of $92.2 million and $93.0 million for the years ended December 31, 2025 and 2024, respectively.

IDEX believes that each of its reporting units is a leader in its products and services. The Company also believes that its strong financial performance has been attributable to its ability to design and engineer specialized quality products coupled with its ability to successfully identify, acquire and integrate strategic acquisitions. The table below illustrates the three reportable segments and the reporting units within each segment.

---

| | | |
|:---|:---|:---|
| **HST** | **FMT** | **FSDP** |
| Scientific Fluidics & Optics | Pumps | Fire & Safety |
| Performance Pneumatic Technologies | Water | Dispensing |
| Sealing Solutions | Energy | BAND-IT |
| Material Processing Technologies | Agriculture | |
| | Valves | |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**HEALTH & SCIENCE TECHNOLOGIES SEGMENT** 

The HST segment designs, produces and distributes a wide range of precision fluidics, positive displacement pumps, powder and liquid processing technologies, drying systems, micro-precision components, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, ultra-precision diamond tools, laboratory and commercial equipment and precision photonic solutions, technical ceramics and hermetic sealing products and porous material structures and flow control solutions.

The following table summarizes the percentage of total HST sales generated by each end market served:

![2777](iex-20251231_g2.jpg)

\*Beginning in 2025, Life Sciences also includes analytical instruments, pharmaceutical and medical/dental end market sales.

The following discussion describes the reporting units included in the HST segment:

*Scientific Fluidics & Optics.* Scientific Fluidics & Optics is a global authority in life science fluidics, optics, microfluidics and photonics and the movement of liquids and gases in critical applications, offering a diverse set of technologies, expertise, capabilities and product solutions across numerous market segments. Scientific Fluidics & Optics is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IDEX Health & Science ("IH&S") consists of IH&S Life Science Fluidics, IH&S Life Science Optics and IH&S Microfluidics. The IH&S Life Science Fluidics technology and product portfolio consists of column hardware, degassers, fluidic connections, fluidic manifolds, pumps and pump components, sensors, refractive index detectors, valves and fluidics sub-systems. The IH&S Life Science Optics technology and product portfolio consists of illumination light engines, optical filters, optical subsystems, sensors, cameras and camera imaging objectives. IH&S Microfluidics includes thinXXS Microtechnology, a global leader in developing and producing microfluidic systems, components and consumables serving the point of care diagnostic and digital polymerase chain reaction markets. IH&S serves the life science optics, chromatography, mass spectrometry, in-vitro diagnostics/biotech fluidics and fluidic connections markets. IH&S maintains operations in Bristol, Connecticut; Carlsbad, California; Middleboro, Massachusetts; Oak Harbor, Washington; Rochester, New York; Rohnert Park, California; Zweibrücken, Germany and Saitama, Japan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• IDEX Materials Science Solutions platform is formed from the precision processing businesses of IDEX Optical Technologies, Muon Group (Millux, LouwersHanique, Veco and Tecan) and STC Material Solutions. The IDEX

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Optical Technologies businesses of Advanced Thin Films, CVI Laser Optics, CVI Infrared Optics, Iridian Spectral Technologies and Micro-LAM (acquired in July 2025) specialize in precision substrate forming, complex optical coatings and optical assemblies. Solutions include optical filters, polarization optics, beamsplitters, waveplates, objectives and mirrors for application in semiconductor metrology, satellite laser communications, data communications, high-power industrial and defense optical systems, earth observation and remote sensing. The precision components and ceramics businesses of Millux, LouwersHanique, Veco, Tecan and STC Material Solutions have expertise in ultra-precision forming of advanced materials, from ceramics and glass to metals and plastics. Applications primarily include thermal management, fluid and energy flow control, filtration, and precision motion applications within the semiconductor, aerospace, medical, food processing and industrial markets. The businesses maintain global operations in the United States (Albuquerque, New Mexico; Longmont, Colorado; Portage, Michigan; Keene, New Hampshire; St. Albans, Vermont and Santa Ana, California), Canada (Ottawa), England (Dorset, Stevenage and Whetstone), the Netherlands (Didam, Eerbeek, Hapert and Wijchen) and India (Pune).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Mott Corporation specializes in the design, customization and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications within the medical, energy, industrial technology, semiconductor, water and space and defense markets. The business maintains operations in Farmington, Connecticut, with additional operations in Plymouth, Michigan and Binasco, Italy.

*Performance Pneumatic Technologies.* Performance Pneumatic Technologies provides specialized, high-performing air-moving technologies across a wide array of industries. Performance Pneumatic Technologies is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Gast is a leading manufacturer of air-moving products, with a core technology around fractional horsepower (under 1 hp) air compressors, vacuum pumps and air motors. Gast products are used in a variety of long-life applications requiring a quiet, clean source of moderate vacuum or pressure and primarily serve the medical equipment, environmental equipment, computers and electronics, printing machinery, paint mixing machinery, packaging machinery, graphic arts and industrial manufacturing markets. Gast maintains operations in Benton Harbor, Michigan and has a logistics and commercial center in Redditch, England.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Airtech designs and manufactures a wide range of highly engineered pressure technology products, with a core technology around high performance blowers (2 hp and above) and pneumatic valves for a variety of end markets, including alternative energy, food processing, medical, packaging and transportation. Airtech maintains operations in Rutherford, New Jersey and has other manufacturing operations in Linthicum Heights, Maryland and Schweinfurt, Germany.

*Sealing Solutions.* Sealing Solutions focuses on providing special seals and related products and solutions in diversified markets. Sealing Solutions is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* Precision Polymer Engineering ("PPE") is a provider of proprietary high performance seals and advanced sealing solutions for a diverse range of global industries and applications, including hazardous duty, analytical instrumentation, semiconductor, process technologies, oil and gas, pharmaceutical, electronics and food applications. PPE maintains operations in Blackburn, England and has an additional manufacturing facility in Brenham, Texas. PPE also entered into a joint venture with a third party to manufacture and sell high performance elastomer seals for the oil and gas industry to customers within the Kingdom of Saudi Arabia as well as export these high performance elastomer seals outside of the Kingdom of Saudi Arabia. The joint venture maintains operations in Dammam, Saudi Arabia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* FTL Seals Technology specializes in the design and application of high integrity rotary seals, specialty bearings and other custom products for the mining, power generation and marine markets. FTL Seals Technology maintains operations in Leeds, England.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* SFC Koenig is a producer of highly engineered expanders and check valves for critical applications across the transportation, hydraulic, aviation and medical markets. SFC Koenig maintains operations in Dietikon, Switzerland and has additional facilities in North Haven, Connecticut; Illerrieden, Germany and Suzhou, China.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* The Roplan businesses are global manufacturers of custom mechanical and shaft seals for a variety of end markets including food and beverage, marine, chemical, wastewater and water treatment. Roplan maintains operations in Sweden and also has operations in Ningbo, China; Berkshire, England and Madison, Wisconsin.

*Material Processing Technologies.* Material Processing Technologies provides process equipment and global support service solutions that meet customer specific requirements with a focus in the pharmaceutical, food, battery and chemical markets. Material Processing Technologies is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* IDEX MPT, Inc., which includes Quadro, Fitzpatrick, Microfluidics, and Matcon, maintains operations in Waterloo, Canada; Middleborough, Massachusetts; Evesham, England; Ahmedabad, India and Shanghai, China.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Quadro is a leading provider of powder processing solutions for the pharmaceutical, food, personal care and chemical markets. Quadro's core capabilities include fine milling, emulsification and special handling of liquid and solid particulates for laboratories, through the pilot phase to full scale up with production scale processing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Fitzpatrick is a global leader in the design and manufacture of process technologies for the pharmaceutical and chemical sectors. Fitzpatrick designs and manufactures customized size reduction and roll compaction systems to support their customers' product development and manufacturing processes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Microfluidics is a global leader in the design and manufacture of laboratory and production equipment used in the production of micro and nano scale materials for the pharmaceutical, biologics, personal care and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer family of high shear fluid processors for uniform nano-emulsion formation, lipid nanoparticle creation, robust cell disruption and particle size reduction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Matcon is a global leader in creating flexible material processing solutions for high value powders used in the manufacture of foods, pharmaceuticals, batteries, plastics and fine chemicals. Matcon's innovative products consist of the original cone valve powder discharge system and filling, mixing and packaging systems, all of which support its customers' automation and process requirements. These products are critical to its customers' need to maintain clean, reliable and repeatable formulations of prepackaged foods and pharmaceuticals while helping them achieve lean and agile manufacturing.

**FLUID & METERING TECHNOLOGIES SEGMENT**

The FMT segment designs, produces and distributes positive displacement pumps, valves, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services.

The following table summarizes the percentage of total FMT sales generated by each end market served:

![11306](iex-20251231_g3.jpg)

The following discussion describes the reporting units included in the FMT segment:

*Pumps.* Pumps is a leading manufacturer of positive displacement pumps including rotary internal gear, external gear, vane and rotary lobe pumps, custom-engineered original equipment manufacturer pumps, strainers, gear reducers and engineered pump systems. Pumps primarily uses independent distributors to market and sell its products. Pumps is comprised of the following businesses:

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Viking Pump is a global leader in pumping solutions, with products including internal gear, external gear, vane, lobe and circumferential piston pumps, as well as parts, kits and accessories designed to support customers worldwide. With a focus on industrial applications like chemicals, polyurethane foam and asphalt; energy applications like oil transfer and glycol dehydration; and hygienic applications like biopharma, food and beverage, Viking Pump delivers proven liquid transfer pumping solutions for a wide variety of thin to viscous applications. Viking Pump maintains operations in Cedar Falls, Iowa, with locations in Windsor, Canada; Shannon, Ireland and Eastbourne, England.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Warren Rupp manufactures air and electrically-operated double diaphragm pump products (which includes Sandpiper, Versamatic and Cognito products) used for abrasive and semisolid materials as well as for applications where product degradation is a concern. Warren Rupp products primarily serve the chemical, paint, food processing, electronics, construction, utilities, oil and gas, mining and industrial maintenance markets. Warren Rupp maintains primary operations in Mansfield, Ohio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ABEL designs and manufactures highly engineered reciprocating positive displacement pumps used for mine dewatering, back filling, transfer of mine tailings, municipal sledge and wastewater applications in a variety of end markets including mining, power, water and wastewater as well as other general industries. ABEL maintains operations in Büchen, Germany and Mansfield, Ohio and has facilities in Madrid, Spain and Mumbai, India.

*Water.* Water is a leading provider of metering technology, flow monitoring products and underground surveillance services for wastewater markets, as well as alloy and non-metallic gear pumps and peristaltic pumps. Water is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ADS' products and services provide comprehensive integrated solutions that enable industry, municipalities and government agencies to analyze and measure the capacity, quality and integrity of wastewater collection systems, including the maintenance and construction of such systems. ADS maintains operations in Huntsville, Alabama and various other locations in the United States, Canada and Australia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• iPEK, Envirosight and WinCan combined are the leading providers of integrated solutions for managing the complete lifecycle of water infrastructure assets and process workflows. Their products and solutions include sewer crawlers, inspection and monitoring systems and software applications that allow teams to identify, anticipate and correct water system issues, automate and simplify inspection processes, improve infrastructure asset management and support distributed teams and cloud-based collaboration. MyTana and Pipeline Renewal Technologies design and build products used to clean and repair infrastructure in the sewer and drain industry. iPEK maintains operations in Hirschegg, Austria and Sulzberg, Germany. Envirosight and Pipeline Renewal Technologies maintain operations in Randolph, New Jersey and Callery, Pennsylvania. WinCan has development centers in Murten, Switzerland and Krakow, Poland. MyTana maintains operations in St. Paul, Minnesota. All entities have various sales and service outlets across the United States and Europe.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Trebor is a leader in high-purity fluid handling products, including air-operated diaphragm pumps and deionized water-heating systems. Trebor products are used in the manufacturing of semiconductors, disk drives and flat panel displays. Trebor maintains operations in West Jordan, Utah.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pulsafeeder products are used to introduce precise amounts of fluids into processes to manage water quality and chemical composition. Pulsafeeder produces hydraulic and mechanical diaphragm pumps, rotary pumps, peristaltic pumps and controllers, which serve the industrial and municipal water and wastewater treatment, oil and gas, power generation, chemical and hydrocarbon processing and swimming pools markets. Pulsafeeder maintains operations in Rochester, New York and Punta Gorda, Florida.

*Energy.* Energy is a leading supplier of flow meters, small volume provers, electronic registration and control products, rotary vane and turbine pumps, reciprocating piston compressors and terminal automation control systems. Energy is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Advanced Flow Solutions ("AFS") consists of the Company's Corken, Liquid Controls and SAMPI businesses. Corken products consist of positive displacement rotary vane pumps, single and multistage regenerative turbine pumps and small horsepower reciprocating piston compressors in the oil, gas and industrial markets. Products for Liquid Controls and SAMPI consist of positive displacement flow meters as well as electronic registration and control products, including mobile and stationary metering installations for wholesale and retail distribution of petroleum and liquefied petroleum gas, aviation refueling and industrial metering and dispensing of refined liquids and gases. AFS maintains operations in Oklahoma City, Oklahoma and Altopascio, Italy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Toptech supplies terminal automation hardware and software to control and manage inventories as well as transactional data and invoicing to customers in the oil, gas and refined-fuels markets. Toptech maintains operations in Longwood, Florida and Zwijndrecht, Belgium.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Flow Management Devices ("Flow MD") engineers and manufactures small volume provers that ensure custody transfer accuracy in the oil and gas market. Flow MD maintains operations in Phoenix, Arizona.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Agriculture.* Agriculture is a leading supplier of pumps, valves, controllers, fittings and systems used in agricultural and industrial applications. Agriculture consists of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Banjo is a provider of special purpose, severe-duty pumps, valves, fittings and systems used in liquid handling. Its products are used in agricultural and industrial applications. Banjo maintains operations in Crawfordsville, Indiana and has distribution facilities in Didam, the Netherlands and Valinhos, Brazil.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• KZValve is a leading manufacturer of electric valves and controllers used primarily in agricultural applications. KZValve maintains operations in Greenwood, Nebraska.

*Valves.* Valves is a leader in the design, manufacture and sale of specialty valve products for use in the chemical, petro-chemical, energy and sanitary markets as well as a leading producer of fluoroplastic lined corrosion-resistant magnetic drive and mechanical seal pumps, shut-off, control and safety valves for corrosive, hazardous, contaminated, pure and high-purity fluids. Valves is comprised of the following businesses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Richter and Aegis produce superior solutions for demanding and complex pump and valve applications in the process industry as well as specialty chemical processing valves for use in the chemical, petro-chemical, pharmaceutical, energy and battery industries. Richter and Aegis maintain operations in Kempen, Germany; Suzhou, China; Vadodara, India and Geismar, Louisiana.

**FIRE & SAFETY/DIVERSIFIED PRODUCTS SEGMENT**

The FSDP segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems, engineered stainless steel banding and clamping devices, and precision equipment for dispensing, metering and mixing colorants and paints.

The following table summarizes the percentage of total FSDP sales generated by each end market served:

![21357](iex-20251231_g4.jpg)

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following discussion describes the reporting units included in the FSDP segment:

*Fire & Safety.* Fire businesses produce truck-mounted and portable fire pumps, stainless steel and brass valves, monitors, nozzles, foam and compressed air foam systems, pump modules and pump kits, electronic controls and information systems, conventional and networked electrical systems and mechanical components for the fire and specialty vehicle markets. Safety businesses produce hydraulic, battery, gas and electric-operated rescue equipment, hydraulic re-railing equipment, hydraulic tools for industrial applications, recycling cutters, pneumatic lifting and sealing bags for vehicle and aircraft rescue, environmental protection and disaster control and jumping cushions for building rescue for the rescue market. Fire & Safety's customers are original equipment manufacturers as well as public and private fire and rescue organizations. Fire & Safety maintains operations in Ocala, Florida (Class 1 and Hale products); Warwick, England (Godiva products); Wooster and Columbus, Ohio (Akron Brass and Weldon products); Ballendorf, Germany (AWG Fittings products); Shelby, North Carolina (Hurst Jaws of Life® products); Tianjin, China (Dinglee products); Erlangen, Germany (Lukas products) and Zülpich, Germany (Vetter products).

*Dispensing.* Dispensing businesses produce precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world. Dispensing is a global supplier of such equipment focused on the architectural paints segment used in retail and commercial stores, hardware stores, home centers and paint and specialized stores as well as in some industrial settings. Dispensing maintains operations in Sassenheim, the Netherlands; Wheeling, Illinois and Sandani, India as well as multiple sales offices around the world.

*BAND-IT.* BAND-IT is a leading producer of high-quality stainless steel banding, buckles and clamping systems. The BAND-IT brand is highly recognized worldwide. BAND-IT products are used for securing exhaust system heat and sound shields, airbags, industrial hose fittings, traffic signs and signals, electrical cable shielding, identification and bundling and in numerous other industrial and commercial applications. BAND-IT products primarily serve the automotive, aerospace, energy, utility, municipal, cable management and general industrial markets. BAND-IT maintains operations in Denver, Colorado, with additional operations in Staveley, England and Suzhou, China.

**INFORMATION APPLICABLE TO THE COMPANY'S BUSINESS IN GENERAL AND ITS SEGMENTS**

*Competitors*

The Company's businesses participate in highly competitive markets. The Company encounters a wide variety of competitors that vary by product, market and geographic area. Each of the Company's segments has multiple competitors, as no single competitor offers all of the same products or serves all of the same markets as IDEX. The Company's competitors are both U.S. and foreign companies and range in size. IDEX believes that the principal points of competition are product quality, design and engineering capabilities, product development, conformity to customer specifications, quality of post-sale support, timeliness of delivery and effectiveness of the Company's distribution channels.

*Customers*

In 2025, the Company did not have any customers that accounted for more than 3% of net sales. Since the Company serves a wide variety of markets, customer concentrations are not significant.

*International* 

The Company's products and services are available worldwide, with manufacturing, sales, distribution, service and/or administrative facilities located in more than 20 countries. The businesses located outside the U.S. are primarily based in the United Kingdom, Germany, the Netherlands, Canada, Italy, China and India. The Company's geographic diversity allows it to draw on the skills of a global workforce, provides greater stability to its operations, allows the Company to drive economies of scale, provides revenue streams that may help offset economic trends that are specific to individual economies and offers the Company an opportunity to access new markets for products.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following table illustrates sales to customers within and outside the U.S. as a percentage of total sales for total IDEX as well as by segment and by reporting unit for the year ended December 31, 2025:

---

| | | |
|:---|:---|:---|
| | **Domestic** | **International** |
| **HST** | **47%** | **53%** |
| &nbsp;&nbsp;Scientific Fluidics & Optics | 45% | 55% |
| &nbsp;&nbsp;Performance Pneumatic Technologies | 77% | 23% |
| &nbsp;&nbsp;Sealing Solutions | 25% | 75% |
| &nbsp;&nbsp;Material Processing Technologies | 40% | 60% |
| **FMT** | **57%** | **43%** |
| &nbsp;&nbsp;Pumps | 58% | 42% |
| &nbsp;&nbsp;Water | 57% | 43% |
| &nbsp;&nbsp;Energy | 62% | 38% |
| &nbsp;&nbsp;Agriculture | 73% | 27% |
| &nbsp;&nbsp;Valves | 15% | 85% |
| **FSDP** | **50%** | **50%** |
| &nbsp;&nbsp;Fire & Safety | 56% | 44% |
| &nbsp;&nbsp;Dispensing | 27% | 73% |
| &nbsp;&nbsp;BAND-IT | 53% | 47% |
| **IDEX** | **51%** | **49%** |

---

*Shared Services*

The Company has production facilities in Suzhou, China, Vadodara, India and Ahmedabad, India that support multiple business units. IDEX also has personnel in China, India, Dubai, Mexico, Latin America and Singapore that provide sales, marketing, product design, engineering and sourcing support to its business units in those regions, as well as personnel in various locations in South America, Southeast Asia, the Middle East, Korea and Japan to support sales and marketing efforts in those regions.

*Raw Materials*

The Company uses a wide variety of raw materials, which are generally purchased from a large number of independent sources around the world. The Company believes it has an adequate supply of raw materials necessary to meet demand. The Company is exposed to fluctuations in commodity pricing and inflation, including the impact of tariffs, and attempts to control these impacts through increased prices to customers and various other programs with its suppliers.

*Suppliers*

The Company manufactures many of the parts and components used in its products. Substantially all materials, parts and components purchased by the Company are available from a large number of independent sources around the world. The Company believes it has a sufficient number of suppliers necessary to meet demand but continues to actively evaluate its current suppliers and identify alternative sources to manage supply chain constraints, if needed.

*Inventory and Backlog*

The Company is primarily a short cycle business and backlog is not generally considered a significant factor as relatively short delivery periods and rapid inventory turnover are characteristic of most of the Company's products. Even still, the Company regularly and systematically adjusts production schedules and quantities based on the flow of incoming orders. While backlog was elevated in recent years due to global supply chain constraints, which extended lead times, shifted customer order patterns and resulted in increased inventory to support production, customer destocking efforts beginning in 2023 have resulted in orders stabilizing with backlog and lead times returning to more normalized levels in 2025. The Company remains focused on delivering products and services to customers and continues to actively manage inventory levels. Further, the Company has not historically experienced significant order cancellations and does not expect significant order cancellations in the future.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Government Regulations*

Our compliance with federal, state and local laws and regulations, including those related to environmental, international trade, labor and employment, human rights, tax, anti-bribery and competition matters, did not have a material effect upon our capital expenditures, earnings or competitive position during the fiscal year ended December 31, 2025.

*Employees*

At December 31, 2025, the Company had approximately 8,700 employees. Approximately 4% of its employees are covered by various collective bargaining agreements in the U.S. which will expire at various times between now and January 2029. There are four collective bargaining agreements in the U.S. that will expire in 2026, with a new agreement already ratified for one of these agreements. Management believes that the Company has a positive relationship with its employees. The Company historically has been able to renegotiate its collective bargaining agreements satisfactorily, with its last work stoppage occurring in March 1993.

*Human Capital Management*

The Company attributes its success to the valuable contributions of its talented workforce and is committed to fostering a work environment where employees can thrive and grow. Investments in attracting, retaining and developing talent enable the Company to accomplish its strategic goals and deliver innovative customer solutions. The Company's corporate Human Capital strategy is overseen by its Vice President, Talent and Culture. Annually, the Vice President, Talent and Culture presents a talent review to the Company's Board of Directors focused on senior leader team development, the human capital strategy action plan and succession planning for senior management. This process is intended to help ensure that the Company's Board of Directors remains informed and aligned on the Company's human capital management strategies for business continuity and long-term performance.

The Company's workforce advancement strategy is centered around investments in three pillars: enhancing skills across the workforce, leadership development aligned with the Company's leadership methodology and fostering a strong and inclusive culture. The Company's approach to performance management, talent development, talent management and employee engagement is designed to support long-term value creation by providing employees with opportunities to grow and contribute both individually and as part of high-performing teams. The Company prioritizes hiring employees who embrace its team-oriented culture and places emphasis on developing and promoting internal talent, including filling many leadership positions from within its workforce.

Employee engagement is a critical element of fostering a strong and inclusive culture where employees can thrive and have the opportunity to do their best work. Each year, the Company conducts an employee engagement survey and partners with employees to implement improvements based on the results. Additionally, key initiatives like the annual Global Leadership Conference for senior leaders are designed to strengthen leadership capabilities, reinforce learning and development, and support skill and career growth.

In 2025, the Company continued to execute on the strategic roadmap tied to its human capital strategy, including: (1) implementation of local business unit inclusion plans; (2) delivery of quarterly inclusive leadership training and a two-day enterprise-wide inclusion summit to promote leadership skill building for all employees; (3) expansion of the Company's employee resource groups ("ERGs"); and (4) participation in talent networks. All offerings, including participation in ERGs, are open to all employees, regardless of their specific background, identity or experiences.

Additional information regarding the Company's human capital practices is available on the Company's website, under the Sustainability link at https://www.idexcorp.com/about-idex/idex-sustainability/. Information on the Company's website is not incorporated into this Form 10-K.

*Employee Pay and Benefits*

Attracting and retaining talent is critical to the success of the Company's business. The Company offers competitive pay and benefits for employees in the markets in which it operates. Many employees are eligible for performance-based compensation, including short-term performance incentive opportunities. The Company also provides equity-based, long-term incentives to its eligible senior leaders.

The Company's U.S. employees are eligible to participate in a 401(k) retirement plan. The Company's U.S. employees can also purchase the Company's common stock through payroll deductions.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Further, since 2018, the Company has conducted pay equity analyses for U.S. employees to assess whether employees' actual pay is substantially similar to predicted pay based on relevant factors such as role and level. Where appropriate, the Company has provided base pay adjustments for employees who were identified as outliers relative to their predicted pay.

*Workplace Health & Safety*

The Company is committed to providing a workplace that is safe for all of our employees, contractors, business partners and visitors. The commitment to Environmental, Health, and Safety ("EH&S") begins at the corporate and executive level. The program is overseen by the Senior Director, Health & Safety and the Chief Sustainability Officer, both of whom are part of the Legal Department. Each of the Company's businesses employ local EH&S specialists. These individuals and local safety committees, in conjunction with the corporate team, form the basis of the global EH&S program. The Company's corporate EH&S policies are a key part of the global EH&S program. They apply to all of the Company's businesses and each business is expected to comply with policies and all EH&S laws and regulations. In addition to the corporate policies, each business develops and implements its own health and safety policies tailored to the local business.

The Company also encourages employees enrolled in the U.S. Healthcare Benefit Plan to participate in the third-party operated Wellness Program which provides access to annual biometric screenings and health evaluations. The Company offers "wellness credits" that can be earned by employees as well as spouses and partners who take advantage of these early detection services offered or engage in healthy challenges and other activities each year. In addition, a number of the business units organize complementary wellness programs, including walking clubs, health fairs and "lunch and learns" with nutritionists for their employees.

*Worker Rights and Protection*

The Company believes that a respectful workplace is free from unlawful discrimination and harassment, and this involves more than just compliance with the law. The Company strives to create a work environment that is free of inappropriate and unprofessional behavior and consistent with the Company's values – a place where everyone is invited to do their best every day and feel free to report any concerns. The Company has policies, procedures and regular training in place, including, but not limited to a global Code of Business Conduct & Ethics, to protect its workforce and prevent workplace harassment and discrimination. The Company also maintains a global hotline where employees are encouraged (and can choose to remain anonymous) to report any concerns or issues.

*Information about Our Executive Officers* 

Set forth below are the names of the executive officers of the Company, their ages, years of service, the positions held by them and their business experience.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Years of<br>Service** | **Position** |
| Eric D. Ashleman | 58 | 17 | Chief Executive Officer and President |
| Sean M. Gillen | 40 | 0\* | Chief Financial Officer and Senior Vice President |
| Lisa M. Anderson | 49 | 9 | Senior Vice President, General Counsel, Chief Administrative Officer, and Corporate Secretary |
| Tara M. Tereso | 48 | 4 | Group Executive, Health and Science Technologies (HST) |
| William L. Simmons | 54 | 19 | Group Executive, Fluid and Metering Technologies (FMT) and Fire & Safety/Diversified Products (FSDP) |

---

\*Mr. Gillen joined IDEX as Senior Vice President and Chief Financial Officer in January 2026.

Mr. Ashleman has served as President and Chief Executive Officer since December 2020. Prior to that, Mr. Ashleman served as Chief Operating Officer from July 2015 to December 2020. He served as Senior Vice President and Group Executive of the Company's Global Dispensing, FSDP, and HST and Optics business segments from early 2014 through July 2015 and as Vice President and Group Executive of the Company's FSDP segment from 2011 through early 2014. Mr. Ashleman joined IDEX in 2008 as the President of Gast Manufacturing.

Mr. Gillen has served as Senior Vice President and Chief Financial Officer since January 2026. Prior to joining IDEX, Mr. Gillen served as Senior Vice President and Chief Financial Officer at AAR CORP., a provider of aviation services to the

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

aerospace and defense industries, from January 2019 to December 2025. Prior to his time at AAR CORP., Mr. Gillen served as Vice President and Treasurer at USG Corporation, a building materials manufacturing company, after serving in roles of increasing responsibility earlier in his career in investment banking at Goldman Sachs.

Ms. Anderson has served as Senior Vice President, General Counsel and Corporate Secretary since February 2022, and as Chief Administrative Officer since December 2025. Prior to that, Ms. Anderson served as Vice President, Associate General Counsel and Assistant Secretary from December 2017 through February 2022 after joining IDEX as Assistant General Counsel in October 2016. Prior to joining IDEX, Ms. Anderson served in various roles of increasing responsibility at SunCoke Energy, Inc., most recently as Senior Counsel and Deputy Chief Compliance Officer.

Ms. Tereso has served as Group Executive, HST since September 2024. Prior to that, Ms. Tereso served as Group President IDEX Health & Science from September 2023 to September 2024, after serving as President IDEX Health & Science from September 2021 to September 2023. Prior to joining IDEX in 2021, Ms. Tereso served as Vice President & General Manager EFD Division for Nordson Corporation, a precision technology company.

Mr. Simmons has served as Group Executive, FMT, FSDP since February 2026. Prior to that, Mr. Simmons served as Group Executive FSDP from September 2024 through February 2026. He served as Group President IDEX Fire & Safety and Dispensing from September 2023 to September 2024, as Group President IDEX Fire & Safety and BAND-IT from March 2023 to September 2023, and as President of IDEX Fire & Safety from January 2021 to March 2023.

*Public Filings*

Copies of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports are made available free of charge at www.idexcorp.com as soon as reasonably practicable after being filed electronically with the SEC. The Company's reports are also available free of charge on the SEC's website, www.sec.gov. Information on the Company's website is not incorporated into this Form 10-K.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Item 1A. &nbsp;&nbsp;&nbsp;&nbsp;Risk Factors.**

For an enterprise as diverse and complex as the Company, a wide range of factors present risks to the Company and could materially and adversely affect future developments and performance. In addition to the factors affecting specific business operations identified in connection with the description of the Company's operations and the financial results of its operations elsewhere in this report, the most material of these factors are included below. Current global economic events and conditions may amplify many of these risks. These risks are not the only risks that may affect the Company. Additional risks that the Company is not aware of or does not believe are material at the time of this filing may also become important factors that adversely affect the Company's business.

**Risks Related to the Company's Operations**

*The Company's Inability to Continue to Develop New Products Could Limit Sales Growth.*

The Company's ability to continue to grow organically is tied in large part to its ability to continue to develop new products. A failure to continue to develop and deliver new, innovative and competitive products to the market could limit sales growth and negatively impact the Company and its financial condition, results of operations and cash flow.

*The Company's Growth Strategy Includes Acquisitions and Divestitures, and the Company May Not be Able to Make Acquisitions of Suitable Candidates, Integrate Acquisitions Successfully, or Successfully Execute Divestitures.*

The Company's historical growth has included, and the Company's future growth is likely to continue to include, acquisitions. The Company intends to continue to seek acquisition opportunities both to expand into new markets and to enhance its position in existing markets throughout the world. The Company may not be able to successfully identify suitable candidates, negotiate appropriate acquisition terms, obtain financing needed to consummate those acquisitions, complete proposed acquisitions or successfully integrate acquired businesses into its existing operations. In addition, any acquisition, once successfully integrated, may not perform as planned, be accretive to earnings, or otherwise prove beneficial to the Company.

Acquisitions involve numerous risks, including the assumption of unexpected, undisclosed, uninsured or unindemnified liabilities including exposure to litigation, governmental investigations, regulatory exposure or other claims that may be pending or inherited at the time of the acquisition or that may be filed, expanded or commenced thereafter; difficulties in the assimilation of the operations, technologies, services and products of the acquired companies and the diversion of management's attention from other business concerns. In addition, prior acquisitions have resulted in, and future acquisitions could result in, the incurrence of substantial additional indebtedness and other expenses.

The Company may also seek to divest portions of its business that are not deemed to fit with its strategic plan. Divestitures involve additional risks and uncertainties, such as the ability to sell such businesses on satisfactory terms and within the anticipated time frame, or at all. Any failure to realize the expected benefits of any divestiture transaction could negatively impact the Company and its financial condition, results of operations and cash flow. In addition, divestitures of businesses involve a number of risks, including significant costs and expenses, the loss of customer relationships, decrease in revenues and earnings associated with the divested business and the diversion of management's attention from other business concerns. Furthermore, divestitures may also involve continued financial involvement in the divested business, such as through guarantees, indemnities or other financial obligations which could negatively impact the Company and its financial condition, results of operations and cash flow.

*The Markets Served by the Company are Highly Competitive and this Competition Could Reduce Sales and Profit Margins.*

Most of the Company's products are sold in competitive markets. Maintaining and improving a competitive position will require continued investment in manufacturing, engineering, quality standards, marketing, technology, customer service and support and distribution networks. The Company may not be successful in maintaining its competitive position. The Company's competitors may develop products that are superior, may develop methods of more efficiently and effectively providing products and services or may adapt quicker to new technologies or evolving customer requirements. Additionally, the Company's competitors may adopt new technologies and technological advancements, such as using artificial intelligence ("AI") and machine learning to pursue new products and approaches more quickly, successfully and effectively than the Company. The Company may not be able to compete successfully with existing competitors or with new competitors. Pricing pressures may require the Company to adjust the prices of products to stay competitive. Failure to continue competing successfully could reduce sales, profit margins and overall financial performance.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*The Company is Dependent on the Availability of Raw Materials, Parts and Components Used in Its Products and Changes in Supply of, or Price for, Raw Materials, Parts and Components May Materially Adversely Affect the Company.*

While the Company manufactures certain parts and components used in its products, the Company also requires substantial amounts of raw materials and purchases certain parts and components from suppliers. The availability of and prices for raw materials, parts and components may be subject to curtailment or change due to, among other things, suppliers' allocations to other purchasers, interruptions in production by suppliers, including due to geopolitical or civil unrest, unfavorable economic or industry conditions, increased or new tariffs and other trade barriers, labor disruptions, supply chain disruptions, catastrophic weather events and natural disasters, including any that may be caused or exacerbated by global climate change, public health concerns, changes in exchange rates and prevailing price levels. Any change in the supply of, or price for, raw materials or parts and components could materially affect the Company and its financial condition, results of operations and cash flow.

*The Company's Business Operations May Be Materially Adversely Affected by Information Systems Interruptions or Intrusion, Including those Arising From Cybersecurity Attacks or Incidents or Violations of Laws Regulating Privacy and Data Security.*

The Company depends on various internal and third-party information technologies to administer, store, process and transmit electronic information (including sensitive or controlled data such as confidential business information and personal data relating to employees, customers and other business partners) and to support a variety of critical business activities. Our business has an increasing reliance on IT systems and a growing digital footprint as a result of changing technologies, increasing connected devices and digital offerings, and an increase in remote and hybrid workforce populations. Additionally, some of our products contain computer hardware and software and offer the ability to connect to computer networks. Our customers, including government customers, are also requiring cybersecurity protections and mandating cybersecurity standards for our businesses with more frequency. If the Company's systems, technologies, products or services (including those we acquire through business acquisitions), or the systems, technologies, products or services of the Company's customers or third-party hosting services (including third-party data centers and cloud platforms upon which we rely), are damaged or cease to function properly, or if the Company or third-party hosting service systems are subject to deliberate cybersecurity attacks, such as those involving unauthorized access or malicious software, or unintentional cybersecurity incidents, such as those involving systems misconfigurations, misuse or human error and/or other intrusions, the Company, its operating results and financial condition could be materially adversely impacted. These impacts could include production downtimes, operational delays or other detrimental impacts on operations or the ability to provide products and services to customers; the compromise, destruction, corruption or theft of confidential or otherwise protected information, data or intellectual property; security breaches; other manipulation or improper use of the Company's systems or networks; financial losses from fraudulent transactions; financial losses from remedial actions; loss of business or potential liability; adverse media coverage; legal claims or legal proceedings including regulatory investigations, actions, penalties or fines, including those arising from the violation of any applicable data privacy laws; and/or damage to the Company's reputation. While we have experienced, and expect to continue to experience, these types of threats and incidents, based on our analysis at this time, we have not experienced a cybersecurity threat or incident that we believe has or is reasonably likely to materially affect the Company.

As a global organization, we are also subject to data privacy and security laws, regulations and customer-imposed controls in numerous jurisdictions as a result of having access to and processing confidential, personal and/or sensitive data in the course of our business. We are required to comply with increasingly complex laws and regulations enacted to protect business and personal data regarding privacy, data protection and data security in the U.S. and other jurisdictions, including the European Union's General Data Protection Regulation ("GDPR") and the California Consumer Privacy Act ("CCPA") as revised and expanded under the California Privacy Rights Act ("CPRA"), as well as new laws governing digital technologies and cybersecurity and increasingly robust contractual requirements on privacy and security. Litigation, governmental investigations and enforcement actions can be costly and interrupt the regular operations of our business, and data breaches or violations of laws regarding privacy, data protection and data security can result in civil and criminal, monetary and non-monetary penalties and damages to our reputation, any of which may adversely affect our business and financial statements. The interpretation and enforcement of existing and new laws and regulations regarding privacy, data protection and data security are continuously evolving and there is significant uncertainty with respect to how compliance with these laws and regulations may develop and the costs and complexity of future compliance. As cybersecurity threats continue to evolve and as cybersecurity and data protection laws and regulations continue to develop globally, we expect to expend additional resources to continue to develop our compliance programs, strengthen our information security, data protection, disaster recovery and business continuity measures, and investigate and remediate vulnerabilities.

There has been a rise in the number of cyberattacks targeting confidential business information generally and in the manufacturing industry specifically by both state-sponsored and criminal organizations. These may include such things as denial of service attacks, introduction of ransomware or other malicious software programs, and other disruptive problems. In

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

addition, there has been a rise in the number of cyberattacks that depend on human error or manipulation, including phishing attacks or schemes that use social engineering to gain access to systems or perpetuate wire transfer or other frauds. Moreover, the rapid evolution and increased adoption of AI technologies may intensify our cybersecurity risks.

The Company's cybersecurity defenses may be insufficient to fully mitigate cyber risks and losses related to cybersecurity events, any of which may result in a material adverse effect on the Company and its financial condition or results of operations. Moreover, until we have migrated businesses we acquire onto our IT systems or ensured compliance with our information technology and cybersecurity standards, we have in the past and may in the future face additional risks because of the continued use of predecessor IT systems, procedures and cybersecurity risk mitigation measures. Given the unpredictability, nature and scope of cybersecurity attacks and incidents, it is possible that potential vulnerabilities could go undetected for an extended period, and it could take considerable time for the Company to obtain full and reliable information as to the extent, amount and type of information and/or systems compromised. Any imposition of liability, particularly liability that is not covered by insurance or is in excess of our insurance coverage, could materially adversely harm our operating results and financial condition.

*Uncertainties with Respect to the Development, Deployment, and Use of Artificial Intelligence in Our Business and Products May Result in Harm to Our Business and Reputation.*

We are in the initial stages of our phased approach in reviewing AI solutions and capabilities and incorporating AI into our business activities and product and service offerings. As with many innovations, AI presents risks and challenges that could adversely impact our business. The development, adoption, and use of AI technologies are still in their early stages and ineffective or inadequate AI development or deployment practices could result in unintended consequences. For example, AI algorithms may be flawed or may be based on datasets that are biased or insufficient. In addition, any disruption or failure in the AI functionality we have incorporated or may in the future incorporate into our business activities, products or services could adversely impact our business or result in delays or errors in our offerings. The legal and regulatory landscape surrounding AI technologies is rapidly evolving and uncertain, including in the areas of intellectual property, cybersecurity and privacy and data protection. Compliance with new or changing laws, regulations or industry standards relating to AI may impose significant costs and may limit our ability to develop, deploy or use AI technologies. Failure to appropriately respond to this evolving landscape may result in legal liability, regulatory action, or brand and reputational harm.

*Uncertainty Related to Environmental Regulation, Industry Standards, or Other Risks Associated with a Potential Global Transition to a Lower-Carbon Economy, as well as Physical Risks of Climate Change, Could Adversely Impact the Company's Results of Operations and Financial Position.*

Increased public awareness and concern regarding environmental risks, including global climate change and the potential global transition to a lower-carbon economy, may result in more international, regional, federal and/or state requirements or industry standards to reduce or mitigate global warming and other environmental risks. New climate change laws and regulations could require the Company or its suppliers to change their respective manufacturing processes or obtain substitute materials that may cost more or be less available for manufacturing operations. Various jurisdictions in which the Company does business have implemented, or in the future could implement or amend, restrictions on emissions of carbon dioxide or other greenhouse gases, taxation of or caps on the use of carbon-based energy, limitations or restrictions on water use, limitations or restrictions on the production of single-use plastics, regulations on energy management and waste management and other rules and regulations to address climate change and other environmental risks, which may increase the Company's expenses and adversely affect its operating results. Similarly, to the extent any of the foregoing adversely affects the Company's customers and suppliers, it may also adversely affect the Company's financial results.

We also are or may become subject to increasing sustainability-related reporting requirements. For example, the State of California has recently enacted its own legislation requiring extensive climate-related disclosures for companies deemed to be doing business in California, and other states are considering similar laws. We are also subject to the European Union's Corporate Sustainability Reporting Directive. Complying with such laws and regulations, which may continue to evolve, may impose substantial additional costs and require additional resources, including for third-party attestation to enable the capture, analysis and audit of appropriate data. Any actual or alleged failure to comply with laws and regulations around disclosures could result in fines, penalties and civil liabilities and damages to our reputation.

In addition to changes in regulations or industry standards, a failure by the Company to innovate and adapt products to new markets, changing customer preferences for higher-efficiency products, or increasing scrutiny related to sustainability activities and greenhouse gas emissions could limit sales growth and negatively impact the Company and its financial condition, results of operations and cash flow. At the same time, certain governmental representatives and other stakeholders have increasingly expressed or pursued opposing views, legislation and investment expectations around sustainability initiatives, including the

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

enactment or proposal of "anti-ESG" legislation or policies. If our sustainability reporting and practices do not meet the expectations and standards of our stockholders, customers and other stakeholders, our reputation and business activities may be negatively impacted and our appeal to certain investors may be reduced.

The physical risks of climate change are highly uncertain and differ in the geographic regions in which the Company and, in particular, its suppliers and customers operate. These physical risks, including wildfires, rising sea levels, floods and other extreme weather events or natural disasters, may impact the availability and cost of materials, sources and supply of energy, product demand and manufacturing and could increase insurance and other operating costs. Any future increased worldwide regulatory activity relating to climate change could expand the nature, scope and complexity of matters that the Company is required to control, assess and report. If environmental laws or regulations or industry standards are either changed or adopted and impose significant operational restrictions and compliance requirements upon the Company, its suppliers, its customers or its products, or the Company's operations are disrupted due to physical impacts of climate change on the Company, its customers or its suppliers, the Company's business, results of operations and financial condition could be adversely impacted.

*Business Disruptions Due to Catastrophic Weather Events, Natural Disasters and Public Health Threats Could Adversely Affect the Company.*

The Company faces various risks related to the occurrence of catastrophic weather events or significant natural disasters, including earthquakes, wildfires, droughts, fires, power-outages or other catastrophic events, in areas in which we have manufacturing facilities, from which we obtain products or in which our customers operate and conduct business. Severe weather conditions or natural disasters, including any that may be caused or exacerbated by global climate change, may cause physical damage to our properties, closure of one or more of our manufacturing or distribution facilities, lack of an adequate work force in a market, temporary disruption in the supply of inventory, disruption in the transport of products and utilities, delays in the delivery of products to our customers or decreased demand for our products from customers who may be affected by such weather conditions or natural disasters.

Additionally, public health threats may negatively impact the global economy by causing changes in consumer behavior, market downturns, restrictions on business and individual activities and increased volatility. Any widespread public health threats could have a significant impact on the Company's supply chain, such as the Company experienced during the global outbreak of the COVID-19 pandemic.

To the extent that any of the foregoing adversely affect the Company and its financial results, they may also have the effect of heightening many of the other risks described in this <u>[Item 1A](#ibaf335d4459d4d2499897b1ecd08d11c_19)</u>, "Risk Factors" of this annual report, such as those relating to international operations, the Company's ability to develop new products, the Company's ability to execute on its growth strategy of acquisitions, the Company's dependency on raw materials, parts and components, the effects on movements in foreign currency exchange rates on the Company, the effects on the Company that result from declines in commodity prices and the Company's reliance on labor availability to operate and grow the business.

**Risks Related to Economic and Political Conditions**

*A Slowdown in the U.S. or International Economy Could Materially Adversely Affect the Sales and Profitability of the Company's Businesses.*

In 2025, 51% of the Company's sales were derived from customers within the U.S. and 49% were derived from customers outside of the U.S. The Company's largest end markets include industrial, life sciences, energy, water, fire suppression, semiconductor, automotive and aviation, chemical, paint dispensing and food and beverage. A slowdown in the U.S. or global economy and, in particular, any of these specific end markets could materially reduce the Company's sales and profitability.

In addition, the increasing use and development of AI has increased demand for AI-related projects, including data center power solutions and semiconductor applications. The growth and development of this rapidly-evolving industry is difficult to predict. Changes in demand can affect the timing and amounts of customer investments in our products, which could materially affect the Company and its financial condition and results of operations.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Changes to Geopolitical and Economic Conditions in the U.S. and Foreign Countries in Which the Company Operates Could Adversely Affect the Company.*

The Company expects international operations and export sales to continue to be significant for the foreseeable future. The Company's sales from international operations and sales from export are both subject in varying degrees to risks inherent in doing business outside the U.S. These risks include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• possibility of unfavorable circumstances arising from host country laws or regulations and the risks related to required compliance with local laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks of economic instability, including due to inflation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• currency exchange rate fluctuations and restrictions on currency repatriation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential negative consequences from changes to taxation policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• disruption of operations from labor and political disturbances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• withdrawal from or renegotiation of international trade agreements and other restrictions on the trade between the United States and other countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the imposition of and changes in the United States' and other governments' trade regulations, trade wars, increased or new tariffs and other trade barriers, and variability and unpredictability in trade relations, including as a result of geopolitical developments (such as escalating tensions in the Middle East) and relations between the United States and China and the United States and Russia and any changes arising as a result of global leadership changes; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• geopolitical events, including natural disasters, catastrophic weather events, climate change, public health conditions, including epidemics, pandemics and other outbreaks (such as the global outbreak of the COVID-19 pandemic), political instability or other geopolitical events, including civil or political unrest, terrorism, insurrection, global conflicts or war.

Any of these events could have a materially adverse impact on the Company and its operations.

*Significant Movements in Foreign Currency Exchange Rates May Harm the Company's Financial Results.*

The Company is exposed to fluctuations in foreign currency exchange rates arising from its global business operations. Approximately 34% of net sales in 2025 were recorded by subsidiaries with functional currencies other than the U.S. Dollar. Results of these subsidiaries are translated into U.S. Dollars for reporting purposes and the strengthening of the U.S. Dollar could result in unfavorable translation effects. In addition, certain of the Company's businesses transact in a currency other than the business's functional currency, and movements in the transaction currency as related to the functional currency could also result in unfavorable transactional exchange rate effects. Any significant change in the value of the currencies of the countries in which the Company does business against the U.S. Dollar could affect the Company's ability to sell products competitively and control its cost structure, which could have a material adverse effect on results of operations. For additional detail related to this risk, see Part II, <u>[Item 7A](#ibaf335d4459d4d2499897b1ecd08d11c_67)</u>, "Quantitative and Qualitative Disclosures About Market Risk."

*Fluctuations in Interest Rates Could Adversely Affect the Company's Results of Operations and Financial Position.*

The Company's profitability may be adversely affected during any periods of unexpected or rapid increases in interest rates. The Company maintains a Credit Agreement with a revolving credit facility (the "Revolving Facility") in an aggregate principal amount of $800 million, which bears interest at either an alternate base rate or adjusted Term SOFR (or appropriate alternative currency reference rates) plus, in each case, an applicable margin based on the lower of the Company's senior, unsecured, long-term debt rating or the Company's applicable leverage ratio. A significant increase in Term SOFR or the other rates the Company has agreed to use as an alternative to Term SOFR (should Term SOFR become unavailable) under the Credit Agreement, as amended, would significantly increase the Company's cost of borrowings. Further, any changes in regulatory standards or industry practices, such as the discontinuation of the use of Term SOFR and/or the transition to alternative benchmark rates may result in the usage of higher interest rates under the Credit Agreement or Revolving Facility, and the Company's current or future indebtedness may be adversely affected. The Company is also exposed to risks if the U.S. Federal Reserve raises its benchmark interest rate, which may reduce the availability of and increase the cost of obtaining new debt and refinancing existing indebtedness. For additional detail related to this risk, see Part II, <u>[Item 7A](#ibaf335d4459d4d2499897b1ecd08d11c_67)</u>, "Quantitative and Qualitative Disclosures About Market Risk."

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*A Significant or Sustained Decline in Commodity Prices, Including Oil, Could Negatively Impact the Levels of Expenditures by Certain of the Company's Customers.*

Demand for the Company's products depends, in part, on the level of new and planned expenditures by certain of its customers. The level of expenditures by the Company's customers is dependent on, among other factors, general economic conditions, availability of credit, economic conditions within their respective industries and expectations of future market behavior. Volatility in commodity prices, including oil, can negatively affect the level of these activities and can result in postponement of capital spending decisions or the delay or cancellation of existing orders. The ability of the Company's customers to finance capital investment and maintenance may also be affected by the conditions in their industries. Reduced demand for the Company's products could result in the delay or cancellation of existing orders or lead to excess manufacturing capacity, which unfavorably impacts the absorption of fixed manufacturing costs. This reduced demand could have a material adverse effect on the Company and its financial condition and results of operations.

**Risks Related to Legal, Accounting and Regulatory Matters**

*An Unfavorable Outcome of Any Pending Contingencies or Litigation Could Adversely Affect the Company.*

The Company and its subsidiaries are currently involved in pending and threatened legal, regulatory and other proceedings incidental to the operations of their businesses. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Where it is reasonably possible to do so, the Company accrues estimates of the probable costs for the resolution of these matters. These estimates are developed in consultation with outside counsel and are based upon an analysis of potential results and the availability of insurance coverage, assuming a combination of litigation and settlement strategies. It is possible, however, that future operating results for any particular quarter or annual period could be materially affected by changes in assumptions, the continued availability of insurance coverage or the effectiveness of the Company's strategies related to these proceedings. For additional detail related to this risk, see <u>[Item 3](#ibaf335d4459d4d2499897b1ecd08d11c_31)</u>, "Legal Proceedings" and <u>[Note 10](#ibaf335d4459d4d2499897b1ecd08d11c_127)</u>, "Commitments and Contingencies" in Part II, Item 8, "Financial Statements and Supplementary Data."

*Failure to Adequately Protect the Company's Intellectual Property and the Risk of Disputes Involving Intellectual Property Infringement Could Adversely Impact the Company's Competitive Position, Results of Operations, and Financial Condition.* 

The Company owns patents, trademarks, licenses and other forms of intellectual property related to its products and continuously invests in research and development that may result in technological innovations and general intellectual property rights. The Company employs various measures to develop, maintain and protect its intellectual property rights. If these measures are not effective, or if the Company's intellectual property is otherwise infringed, challenged, invalidated or circumvented, the Company may face adverse impacts to its results of operations and/or financial condition. Further, if intellectual property is infringed, challenged, invalidated or circumvented, this could reduce barriers to entry into the Company's existing lines of business and may result in a loss of market share and adversely impact the Company's competitive position. Additionally, the Company has registered intellectual property in multiple countries, and the Company's ability to protect and enforce its intellectual property rights may be limited in foreign countries due to differences in intellectual property protections or proprietary rights laws. If the Company's intellectual property is infringed, challenged, invalidated or circumvented due to these lesser protections, the Company may face adverse impacts to its results of operations, financial condition and/or competitive position.

Litigation may be necessary to enforce the Company's intellectual property rights or to defend against infringement claims by third parties. Any litigation or claims brought by the Company could result in costs and diversion of resources, which could adversely affect the Company's results of operations and/or financial condition. Any intellectual property litigation or claims brought against the Company may lead to litigation expenses, diversion of resources, losses or licensing expenses or the cessation of selling certain products, any of which could adversely affect the Company's results of operations and/or financial condition.

*The Company's Intangible Assets, Including Goodwill, are a Significant Portion of Total Assets and a Write-off of Intangible Assets or Goodwill Would Adversely Impact the Company's Operating Results and Significantly Reduce the Company's Net Worth.*

The Company's total assets includes substantial intangible assets, primarily goodwill and identifiable intangible assets, which primarily result from acquisitions. At December 31, 2025, goodwill and intangible assets totaled $3,414.5 million and

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

$1,247.4 million, respectively. Annually, or when certain events occur that require a more current valuation, the Company assesses whether there has been an impairment in the value of goodwill and identifiable intangible assets. If future operating performance at one or more of the Company's reporting units were to fall significantly below forecasted levels, the Company could be required to reflect, under current applicable accounting rules, a non-cash charge to operating income for an impairment. Any determination requiring the write-off of a significant portion of goodwill or identifiable intangible assets would adversely impact the Company's results of operations and net worth. See <u>[Note 6](#ibaf335d4459d4d2499897b1ecd08d11c_115)</u>, "Goodwill and Intangible Assets" in Part II, Item 8, "Financial Statements and Supplementary Data" for further discussion on goodwill and intangible assets.

*The Company May Face Adverse Effects Resulting from Improper Conduct by Our Employees, Agents or Business Partners.*

While we strive to maintain high standards, the Company cannot guarantee that our internal controls and compliance systems will always protect us from reckless or criminal acts committed by employees, agents or business partners of ours (or businesses that we acquire or partner with) that would violate laws in the U.S. or foreign countries in which the Company operates, including laws governing payment to government officials, bribery, fraud, conflicts of interest, competition, employment practices and workplace behavior, export and import compliance, economic and trade sanctions, money laundering and data privacy.

In particular, recent years have seen a substantial increase in anti-bribery law enforcement activity with more frequent investigations and enforcement proceedings by both the Department of Justice and the SEC, increased enforcement activity by non-U.S. regulators and increases in criminal and civil proceedings brought against companies and individuals. The Company's policies mandate compliance with all anti-bribery laws, including the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act and similar anti-bribery laws in other jurisdictions which generally prohibit companies and their intermediaries from making improper payments for the purpose of obtaining or retaining business. However, the Company operates in certain countries that are recognized as having governmental and commercial corruption. Violations of any of these laws may result in criminal or civil sanctions or penalties, both monetary and non-monetary, increased costs of compliance and/or damage to our reputation, any of which could have a material adverse effect on the Company and its financial condition and results of operations.

**General Risk Factors**

*A Failure to Retain Executive Management and Key Personnel or Recruit Adequate Successors May Adversely Affect the Company's Operations and Implementation of Strategy.*

The Company's future success depends to a significant degree on the skills, experience and efforts of its executive management and other key personnel and their ability to provide the Company with uninterrupted leadership and direction. The loss of the services of any of the executive officers or other key personnel or a failure to provide adequate succession plans for these individuals could have an adverse impact on the Company's operations and implementation of its strategic plan. The availability of highly qualified talent is limited and the competition for talent is robust.

*Challenges with Respect to Labor Availability Could Negatively Impact the Company's Ability to Operate or Grow the Business.*

The Company's success depends in part on the ability of its businesses to proactively attract, motivate and retain a qualified and highly skilled workforce in an intensely competitive labor market. A failure to attract, motivate and retain highly skilled personnel could adversely affect the Company's operating results or its ability to operate or grow the business. Additionally, any labor stoppages or labor disruptions, including due to geopolitical unrest, unfavorable economic or industry conditions, catastrophic weather events, natural disasters or public health threats could adversely affect the Company's operating results or its ability to operate or grow the business.

**Item 1B.&nbsp;&nbsp;&nbsp;&nbsp;Unresolved Staff Comments.**

None.

**Item 1C.&nbsp;&nbsp;&nbsp;&nbsp;Cybersecurity.**

*Risk Management and Strategy.*

The Company's cybersecurity program is designed to be aligned to the Cybersecurity Framework published by the National Institute of Standards and Technology ("NIST CSF"). While we use the NIST CSF as a guide, this does not imply that

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

we meet any particular standards, specifications or requirements. We conduct regular internal and external assessments of our information security and cybersecurity programs, including periodic external audits for company-wide compliance with our program as well as specific business unit alignment, as required, with U.S. federal acquisition regulations and UK Cyber Essentials certifications. An external penetration test is performed annually against the Company's network, in addition to our regular internal vulnerability scans.

The Company's internal Incident Response Policy sets forth specific protocols for cyber or data incident detection, response and recovery. This process includes the assembly of a response team consisting of internal and, as required, external technical and legal experts upon the event of a cyberattack or incident. The Company reviews and updates this process regularly, including by engaging in tabletop exercises to simulate cybersecurity and data breach incidents. The Company maintains global cybersecurity insurance coverage that is reviewed annually for adequacy against operations and information systems.

The Company has implemented a number of measures to mitigate cybersecurity risk in its operations, including annual cybersecurity awareness training for employees, regular internal phishing exercises, technical security controls, maintenance of certain backup and protective systems, physical and system securities measures, and data security protocols. Once fully integrated, all of our businesses have access to a "cyber risk dashboard" that monitors various risk indicators. The cyber risk dashboard is monitored by our business units. The Company's internal auditors periodically review and audit various processes and controls throughout the organization related to cybersecurity readiness.

The Company also has certain processes in place to manage cyber risks associated with third-party service providers which include various technical as well as contractual measures.

For more information on cybersecurity risks and how they affect our business, operating results and financial condition, please refer to <u>[Item 1A](#ibaf335d4459d4d2499897b1ecd08d11c_19)</u>., "Risk Factors – *The Company's Business Operations May Be Materially Adversely Affected by Information Systems Interruptions or Intrusion, Including those Arising From Cybersecurity Attacks or Incidents or Violations of Laws Regulating Privacy and Data Security*." Based on our analysis at this time, we have not identified any risks from a cybersecurity threat or incident that we believe has or is reasonably likely to materially affect the Company.

*Governance, Oversight and Leadership.*

The Company's Board of Directors and the Audit Committee oversee management's efforts to address cybersecurity and information security risks. Senior management provides the Company's Board of Directors updates on the Company's cybersecurity program at least once a year, including as part of the Company's enterprise risk management assessment, and, beginning in 2026, the Audit Committee reviews the cybersecurity program at least three times a year and on an as-needed basis. Such reviews, among other things, include the results of internal and/or external assessments, a review of cybersecurity governance at the management level, and a review of the Company's cybersecurity program and progress toward various initiatives.

The Company also maintains an Executive Cybersecurity Steering Committee (the "Cybersecurity Committee"), made up of key members of senior leadership, to oversee and monitor progress of various cybersecurity initiatives throughout the organization. The Cybersecurity Committee meets quarterly. In addition, the Company asks each business unit to designate an employee as the local Information Security Officer responsible for monitoring the business unit's cyber risk dashboard and coordinating with local leadership to respond to identified risks accordingly. Each local Information Security Officer completes an annual certification process and receives regular updates with respect to the Company's cybersecurity program.

The Chief Information Officer ("CIO"), who reports to the Chief Financial Officer, along with members of the corporate and business unit information technology teams, are generally responsible for developing and managing the Company's cybersecurity programs. Our CIO has over 20 years of experience in various information technology and information security roles, and our information security team is comprised of employees with broad knowledge of cybersecurity issues gained through experience and through training and certifications and includes our Director of Information Security, who has over 20 years of experience leading and managing cybersecurity programs. These individuals, along with other internal and external personnel as needed, monitor the prevention, detection, mitigation and remediation of cybersecurity incidents, and applicable personnel are informed of known cybersecurity incidents to form the appropriate incident response team and respond accordingly.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Properties.** 

Due to the Company's decentralized operating structure and global operations, the Company operates out of a large number of facilities worldwide. As of December 31, 2025, the Company operated approximately 210 plants and office facilities, of which approximately 20% are owned and the remainder are leased. Approximately 110 of the facilities were located outside of the U.S. Principal foreign countries include the U.K., Germany, the Netherlands, Canada, Italy, China and India. The number of facilities by business segment is approximately 90 for HST, 80 for FMT and 25 for FSDP. The remaining facilities relate to the Company's shared service locations as well as 2 leased corporate offices in Illinois. The Company considers its facilities suitable and adequate for the Company's operations and believes it has ample capacity in its plants and equipment to meet demand increases for future growth in the intermediate term, especially given its operational improvement initiatives that usually increase capacity.

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings.**

The Company and its subsidiaries are party to legal proceedings incidental to the operation of their businesses as described in <u>[Note 10](#ibaf335d4459d4d2499897b1ecd08d11c_127)</u> in Part II, Item 8, "Financial Statements and Supplementary Data," and such disclosure is incorporated by reference into this Item 3, "Legal Proceedings."

The Company's threshold for disclosing material environmental legal proceedings involving a government authority where potential monetary sanctions are involved is $1.0 million.

In addition, the Company and seven of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third-party suppliers and were not manufactured by the Company or any of the defendant subsidiaries. To date, the majority of the Company's settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Asbestos-related claims have been filed in jurisdictions throughout the United States and the United Kingdom. Most of the claims resolved to date have been dismissed without payment. The balance of the claims have been settled for various immaterial amounts. Only one case has been tried, resulting in a verdict for the Company's business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company's business, financial position, results of operations or cash flows.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures.**

Not applicable.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**PART II**

**Item 5.**&nbsp;&nbsp;&nbsp;&nbsp;**Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.**

The Company's common stock trades on the New York Stock Exchange under the symbol "IEX". As of February 13, 2026, there were approximately 7,472 stockholders of record of the Company's common stock and there were 74,347,824 shares outstanding.

The Company's payment of dividends in the future will be determined by the Company's Board of Directors and will depend on business conditions, earnings and other factors.

For information pertaining to securities authorized for issuance under equity compensation plans and the related weighted average exercise price, see Part III, <u>[Item 12](#ibaf335d4459d4d2499897b1ecd08d11c_181)</u>, "Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters."

On September 17, 2025, the Company's Board of Directors authorized the repurchase of an additional $635.0 million of the Company's common shares. This approval is in addition to the prior repurchase authorization of the Company's Board of Directors of $500.0 million on March 17, 2020. These authorizations have no expiration date and exclude fees, commissions, excise taxes and other expenses related to such common stock repurchases.

The Company's purchases of common stock during the quarter ended December 31, 2025 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>Period</u>** | **Total Number of Shares Purchased** | **Average Price**<br>**Paid per Share**<sup>(1)</sup> | **Total Number of<br>Shares Purchased as<br>Part of Publicly<br>Announced Plans<br>or Programs** | **Maximum Dollar<br>Value that May Yet<br>be Purchased Under<br>the Plans<br>or Programs** |
| October 1, 2025 to October 31, 2025 |  | $— |  | $999689374 |
| November 1, 2025 to November 30, 2025 | 194251 | 168.03 | 194251 | 967048882 |
| December 1, 2025 to December 31, 2025 | 238029 | 177.96 | 238029 | 924689463 |
| Total | 432280 | $173.50 | 432280 | $924689463 |

---

<sup>(1)</sup> Excludes commissions and the 1% excise tax imposed by the Inflation Reduction Act of 2022.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Performance Graph*

The following table compares total stockholder returns over the last five years to the Standard & Poor's (the "S&P") 500 Index, the S&P Midcap 400 Industrials Sector Index and the Russell 2000 Index assuming the value of the investment in the Company's common stock and each index was $100 on December 31, 2020. Total return values for the Company's common stock, the S&P 500 Index, S&P Midcap 400 Industrials Sector Index and the Russell 2000 Index were calculated on cumulative total return values assuming reinvestment of dividends. The stockholder return shown on the graph below is not necessarily indicative of future performance.

![1861](iex-20251231_g5.jpg)

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **12/20** | **12/21** | **12/22** | **12/23** | **12/24** | **12/25** |
| IDEX Corporation | $100.00 | $119.81 | $117.14 | $112.70 | $110.04 | $94.99 |
| S&P 500 Index | $100.00 | $128.71 | $105.40 | $133.10 | $166.40 | $196.16 |
| S&P Midcap 400 Industrials Sector Index | $100.00 | $128.45 | $113.68 | $149.41 | $169.56 | $191.48 |
| Russell 2000 Index | $100.00 | $114.82 | $91.35 | $106.82 | $119.14 | $134.40 |

---

The information contained in this Performance Graph section shall not be deemed to be "soliciting material" or "filed" with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

**Item 6. [Reserved]**

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion and analysis should be read in conjunction with the Company's Consolidated Financial Statements and related notes in this annual report. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Company's actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under <u>[Item 1A](#ibaf335d4459d4d2499897b1ecd08d11c_19)</u>, "Risk Factors" and under the heading "Cautionary Statement Under the Private Securities Litigation Reform Act" discussed elsewhere in this annual report.*

*This discussion includes certain non-GAAP financial measures that have been defined and reconciled to the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") under the headings "Non-GAAP Disclosures" and "Free Cash Flow." This discussion also includes Operating working capital which has been defined under the heading "Liquidity and Capital Resources." The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.*

**Overview**

IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers' specifications. IDEX's products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX's businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business, as well as by the relationship of the U.S. Dollar to other currencies. Levels of capacity utilization and capital spending in certain markets and overall industrial activity are important factors that influence the demand for IDEX's products.

**2025 Highlights**

(All comparisons are against 2024 unless otherwise noted)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Record reported Net sales of $3,457.5 million increased 6% overall and increased 1% organically\*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported diluted earnings per common share ("EPS") attributable to IDEX of $6.41 decreased 3%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted EPS attributable to IDEX\* of $7.95 increased 1%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating cash flow of $680.4 million increased 2% and was 141% of net income, up from 132%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Free cash flow\* of $616.8 million increased 2% and was 103% of adjusted net income\*, up from 101%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Returned capital to shareholders in the form of $248 million of share repurchases and $213 million of dividends

\*These are non-GAAP measures. See the definitions of these non-GAAP measures and reconciliations to their most directly comparable U.S. GAAP financial measures under the headings "Non-GAAP Disclosures" and "Free Cash Flow."

During 2025, the Company delivered organic sales growth and margin expansion as positive price across all segments more than offset lower volumes in the FMT and FSDP segments. Improved operational results included productivity improvements together with platform optimization savings resulting from restructuring and other cost containment actions taken during 2025. Results were tempered by higher interest expense, the absence of certain tax benefits recognized in 2024 as well as higher amortization on acquisition related intangibles assets. The Company generated strong cash flow and continued to deploy capital, including nearly $250 million of share repurchases during the year.

**2026 Outlook**

Looking ahead, the Company plans to continue strengthening its position in targeted advantaged markets by further integrating its capabilities and advancing its 8020 operating framework. These initiatives are designed to support sustained organic growth while enabling disciplined bolt-on acquisitions. At the same time, the Company remains committed to a balanced capital deployment strategy that includes returning capital to shareholders.

Within the HST segment, the Company anticipates continued growth supported by robust demand across data center, semiconductor, space and defense, and food and beverage and pharmaceutical end markets. By contrast, the industrial and automotive businesses have yet to experience a meaningful recovery in demand. In the FMT segment, the Company expects continued momentum in the Water businesses. However, core industrial markets continue to track flat, and the Company is monitoring softer demand trends across chemical, energy and agricultural applications. For the FSDP segment, near-term headwinds are expected to persist due to ongoing weakness in Fire & Safety markets outside the United States and subdued

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

capital spending in Dispensing. BAND-IT is generally performing in line with the Company's other industrial businesses, trending flat to start the year.

**Results of Operations**

The following is a discussion and analysis of the Company's results of operations for the year ended December 31, 2025 compared with the year ended December 31, 2024. For the discussion related to the consolidated results of operations for the year ended December 31, 2024 compared with the year ended December 31, 2023, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on February 20, 2025.

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Change** |
| **(In millions, except per share amounts)** | **2025** | **2024** | $**% / bps** |
| &nbsp;&nbsp;Domestic sales | $1760.8 | $1618.1 | 9% |
| &nbsp;&nbsp;International sales | 1696.7 | 1650.7 | 3% |
| **Net sales** | **3457.5** | **3268.8** | **6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 1918.7 | 1823.6 | 5% |
| **Gross profit** | **1538.8** | **1445.2** | **6%** |
| ***Gross margin*** | ***44.5*** *%*** | ***44.2*** *%*** | ***30 bps*** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expenses | 818.8 | 758.7 | 8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring expenses and asset impairments | 20.7 | 9.3 | 123% |
| **Operating income** | **699.3** | **677.2** | **3%** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of businesses - net |  | (4.0) | (100%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other expense (income) – net | 2.3 | (2.6) | (188%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense - net | 64.4 | 44.5 | 45% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes | 632.6 | 639.3 | (1%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 150.1 | 134.7 | 11% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Effective tax rate* | *23.7 %* | *21.1 %* | *260 bps* |
| **Net income attributable to IDEX** | $**483.2** | $**505.0** | **(4** **%)** |
| **Diluted earnings per common share attributable to IDEX** | $**6.41** | $**6.64** | **(3** **%)** |

---

***Net Sales***

Net sales increased compared to the prior year as a result of contributions from the acquisition of Mott Corporation and its subsidiaries ("Mott") as well as from organic sales and favorable impacts from foreign currency. Organic sales increased 1% primarily driven by positive price across all segments. Lower volumes in our FMT and FSDP segments were only partly mitigated by higher volumes in our HST segment.

***Gross Profit and Gross Margin***

Gross profit and Gross margin were positively impacted by price/cost and operational productivity improvements, and were negatively impacted by volume deleverage and unfavorable mix. Operational productivity improvements include platform optimization savings resulting from restructuring actions and other cost containment actions taken in 2025, which largely offset increases in other employee-related costs. Gross profit was also positively impacted by acquisitions, net of divestitures.

***Selling, General and Administrative Expenses***

Selling, general and administrative expenses increased primarily due to the $51.0 million impact from acquisitions, net of divestitures, including amortization.

***Restructuring Expenses and Asset Impairments***

Restructuring expenses and asset impairments primarily relate to severance expense for restructuring actions taken during both periods. Severance costs in 2025 were incurred in conjunction with organizational changes, primarily designed to connect scalable groups of businesses, which resulted in a reduction of headcount. Additionally, the Company eliminated certain

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

management layers in select areas. For additional information regarding restructuring expenses and asset impairments, refer to <u>[Note 1](#ibaf335d4459d4d2499897b1ecd08d11c_139)[4](#ibaf335d4459d4d2499897b1ecd08d11c_139)</u>, "Restructuring Expenses and Asset Impairments," in the Notes to Consolidated Financial Statements.

***Gain on Sale of Businesses - Net***

In 2024, the Company completed the sale of Alfa Valvole, Srl ("Alfa Valvole") for proceeds of $45.1 million, net of cash remitted, resulting in a gain on the sale of $4.0 million, net of a release of cumulative foreign currency translation losses of $5.5 million. For additional information, refer to <u>[Note 2](#ibaf335d4459d4d2499897b1ecd08d11c_103)</u>, "Acquisitions and Divestitures," in the Notes to Consolidated Financial Statements.

***Other Expense (Income) – Net***

Other expense (income) – net in both periods primarily reflects the impact of foreign currency transactions.

***Interest Expense - Net***

Interest expense - net increased primarily due to the impact of higher debt outstanding in connection with financing the acquisition of Mott. For additional information, refer to <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings," in the Notes to Consolidated Financial Statements.

***Income Taxes***

The 2025 effective tax rate was 23.7% as compared to the 2024 effective tax rate of 21.1%. The increase in the rate was primarily due to legislation enacted in 2025, which lowered tax benefits from certain foreign sourced income and increased state income taxes. Additionally, the mix of earnings in higher tax rate jurisdictions increased taxes and discrete tax items were less favorable than in the prior year period. For additional information, refer to <u>[Note 12](#ibaf335d4459d4d2499897b1ecd08d11c_133)</u>, "Income Taxes," in the Notes to Consolidated Financial Statements.

The One Big Beautiful Bill Act ("OBBBA") was signed into law on July 4, 2025. Key income tax related provisions of the OBBBA impacting the Company include the repeal of mandatory capitalization of research and development expenditures under Internal Revenue Code Section 174, extension of bonus depreciation, and revisions to international tax regimes. The Company has reflected the tax impacts of the OBBBA legislation and estimates an immaterial impact on the Company's Consolidated Financial Statements. The Company will continue to evaluate the impacts of the OBBBA as more guidance becomes available.

In October 2021, members of the Organization for Economic Co-operation and Development ("OECD") and G20 Inclusive Framework on Base Erosion and Profit Shifting agreed to a two-pillar solution to address the tax challenges associated with the digitalization of the economy. In December 2021, the OECD released the Pillar Two Model Rules ("Pillar Two"), which define the global minimum tax and call for the taxation of large corporations at a minimum rate of 15%. While it is uncertain whether the United States will enact legislation to adopt Pillar Two, certain countries in which we operate have enacted legislation, and other countries are in the process of introducing draft legislation to implement the minimum tax directive. Many aspects of Pillar Two became effective January 1, 2025; however, nearly all of the jurisdictions in which IDEX operates have an effective tax rate above the 15% threshold. Therefore, the Company does not expect a material impact from the Pillar Two income tax rules. We are continuing to monitor legislative developments and evaluate financial results for changes in the expected impact.

**Results of Reportable Business Segments**

The Company has three reportable segments: HST, FMT and FSDP. For a detailed description of the operations within each segment, please refer to Part I, <u>[Item 1](#ibaf335d4459d4d2499897b1ecd08d11c_16)</u>, *"*Business*"* of this Annual Report on Form 10-K.

Management's measurements of segment performance are Net sales, adjusted earnings before interest, income taxes, depreciation and amortization ("Adjusted EBITDA") and Adjusted EBITDA margin.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Health & Science Technologies Segment*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Components of Change** | **Components of Change** | **Components of Change** | **Components of Change** |
| **(In millions)** | **2025** | **2024** | **Change** | **Organic** | **Acq/Div**<sup>(1)</sup> | **Foreign Currency** | **Total** |
| &nbsp;&nbsp;Domestic sales | $695.7 | $573.7 | 21% |  |  |  |  |
| &nbsp;&nbsp;International sales | 799.8 | 724.4 | 10% |  |  |  |  |
| Net sales | $1495.5 | $1298.1 | 15% | 4% | 10% | 1% | 15% |
| Adjusted EBITDA | 397.8 | 346.8 | 15% | 8% | 6% | 1% | 15% |
| Adjusted EBITDA margin | 26.6% | 26.7% | (10) bps | 90 bps | (100) bps | — bps | (10) bps |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Acquisitions included Mott acquired in September 2024 and Micro-LAM, Inc. ("Micro-LAM") acquired in July 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic sales reflected positive price and favorable volumes driven by higher volumes in the Company's data center, semiconductor consumables and space and defense businesses as well as 8020-driven commercial initiatives, partially offset by lower volumes in the Company's semiconductor OEM, industrial and automotive businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA margin decreased slightly, reflecting net productivity improvements, including platform optimization savings and cost containment, favorable price/cost and volume leverage, which largely mitigated the impact of acquisitions, unfavorable mix and higher variable compensation.

*Fluid & Metering Technologies Segment*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Components of Change** | **Components of Change** | **Components of Change** | **Components of Change** |
| **(In millions)** | **2025** | **2024** | **Change** | **Organic** | **Acq/Div**<sup>(1)</sup> | **Foreign Currency** | **Total** |
| &nbsp;&nbsp;Domestic sales | $693.3 | $693.1 | —% |  |  |  |  |
| &nbsp;&nbsp;International sales | 530.7 | 540.1 | (2%) |  |  |  |  |
| Net sales | $1224.0 | $1233.2 | (1%) | —% | (2%) | 1% | (1%) |
| Adjusted EBITDA | 406.8 | 406.3 | —% | —% | (1%) | 1% | —% |
| Adjusted EBITDA margin | 33.2% | 32.9% | 30 bps | 20 bps | 10 bps | — bps | 30 bps |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Divestitures included Alfa Valvole, sold in June 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic sales reflected unfavorable volumes in the Company's chemical, energy, industrial water, agriculture and semiconductor businesses, partially offset by higher volume in the municipal water businesses, which together more than offset the benefit of positive price across the segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA margin increased primarily due to positive price/cost as well as net productivity improvements. These improvements were partially offset by volume deleverage and unfavorable mix. Platform optimization savings and cost containment offset other higher employee-related costs.

*Fire & Safety/Diversified Products Segment*

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Components of Change** | **Components of Change** | **Components of Change** | **Components of Change** |
| **(In millions)** | **2025** | **2024** | **Change** | **Organic** | **Acq/Div** | **Foreign Currency** | **Total** |
| &nbsp;&nbsp;Domestic sales | $371.8 | $354.9 | 5% |  |  |  |  |
| &nbsp;&nbsp;International sales | 373.5 | 389.4 | (4%) |  |  |  |  |
| Net sales | $745.3 | $744.3 | —% | (1%) | —% | 1% | —% |
| Adjusted EBITDA | 213.5 | 214.2 | —% | (1%) | —% | 1% | —% |
| Adjusted EBITDA margin | 28.7% | 28.8% | (10) bps | (10) bps | — bps | — bps | (10) bps |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organic sales reflected positive price, which was more than offset by lower volumes in the Company's Dispensing and Fire & Safety businesses. Volumes in the Company's Dispensing business were impacted by the timing of Dispensing

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

projects in emerging markets and slower equipment replenishment. Strong North America Fire OEM volumes were more than offset by lower Fire & Safety volumes in Asia.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA margin decreased primarily due to volume deleverage and unfavorable mix, mostly offset by price/cost and net productivity improvements, including platform optimization savings and cost containment.

**Liquidity and Capital Resources**

***Liquidity***

Based on management's current expectations and currently available information, the Company believes current cash, cash from operations and cash available under the Revolving Facility will be sufficient to meet its cash requirements, including funding of working capital, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements, share repurchases and quarterly dividend payments to holders of the Company's common stock for the foreseeable future. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. The Company believes that additional borrowings through various financing alternatives remain available, if required.

Select key liquidity metrics at December 31, 2025 are as follows:

---

| | |
|:---|:---|
| **(In millions)** | **December 31, 2025** |
| Working capital | $1067.8 |
| Current ratio | 2.9 to 1 |
| Cash and cash equivalents | $580.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash held outside of the United States | 526.2 |
| Revolving Facility capacity | $800.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Borrowings | 228.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Letters of credit | 2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Revolving Facility availability | $568.6 |

---

***Operating Working Capital***

Operating working capital, calculated as Receivables – net plus Inventories – net minus Trade accounts payable, is used by management as a measurement of operational results as well as the short-term liquidity of the Company. The following table details Operating working capital as of December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(In millions)** | **December 31, 2025** | **December 31, 2024** | **Change** | **Organic Change** |
| Receivables – net | $521.7 | $465.9 | $55.8 | $41.2 |
| Inventories – net | 479.4 | 429.7 | 49.7 | 34.2 |
| Less: Trade accounts payable | 224.7 | 197.8 | 26.9 | 17.0 |
| &nbsp;&nbsp;Operating working capital | $776.4 | $697.8 | $78.6 | $58.4 |

---

Foreign currency translation, slightly offset by the impact of acquisitions, increased Operating working capital by $20.2 million during 2025. Apart from these items, the primary drivers of the change in Operating working capital were higher receivables, driven by price and the timing of shipments, and higher inventories, which increased early in the year to support planned production.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

***Cash Flow Summary***

The following table is derived from the Consolidated Statements of Cash Flows:

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| **(In millions)** | **2025** | **2024** | **Change** |
| Net cash flows provided by (used in): |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $680.4 | $668.1 | $12.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investing activities | (137.6) | (1006.5) | 868.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing activities | (632.6) | 465.9 | (1098.5) |

---

*Operating Activities*

Operating cash flows increased $12.3 million in 2025 primarily due to improved operational results, lower cash payments for taxes and timing of customer deposits and project deliveries impacting the prior year period. These increases were partly offset by higher working capital as discussed under the heading "Operating Working Capital" above, higher interest payments primarily as a result of the issuance of the 4.950% Senior Notes (as defined in <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings," in the Notes to Consolidated Financial Statements) during the third quarter of 2024 to fund the acquisition of Mott as well as higher severance payments made in conjunction with the organizational changes during 2025.

*Investing Activities*

Cash used in investing activities decreased $868.9 million in 2025 as compared to the prior year period driven by $863.2 million of lower net spending on business acquisitions, net of divestitures, in the current year period, primarily due to the acquisition of Mott and the sale of Alfa Valvole during the prior year period. See further details on the Company's acquisition activity in <u>[Note 2](#ibaf335d4459d4d2499897b1ecd08d11c_103)</u>, "Acquisitions and Divestitures," in the Notes to Consolidated Financial Statements.

*Financing Activities*

Financing cash flows decreased $1,098.5 million in 2025 to $632.6 million of cash used in financing activities from $465.9 million of cash provided by financing activities. The prior year period included $774.3 million of net proceeds in connection with the financing of the Mott acquisition. The current year period included $247.8 million of share repurchases, $51.8 million of higher net payments on debt, lower proceeds from stock option exercises, net of shares withheld for taxes, which decreased $17.2 million, and $7.3 million of higher dividends paid to shareholders, as compared to the prior year period.

***Free Cash Flow***

The Company believes free cash flow, a non-GAAP measure, is an important measure of performance because it provides a measurement of cash generated from operations that is available for payment obligations such as operating cash requirements, planned capital expenditures, interest and principal payments on all borrowings, pension and postretirement funding requirements and quarterly dividend payments to holders of the Company's common stock as well as for funding acquisitions and share repurchases. Free cash flow is calculated as cash flows provided by operating activities less capital expenditures. Free cash flow conversion, also a non-GAAP measure, is calculated as free cash flow divided by adjusted net income attributable to IDEX.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following table reconciles cash flows provided by operating activities to free cash flow:

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| **(In millions)** | **2025** | **2024** |
| Cash flows provided by operating activities | $680.4 | $668.1 |
| Less: capital expenditures | 63.6 | 65.1 |
| Free cash flow | $616.8 | $603.0 |
| Reported net income attributable to IDEX | $483.2 | $505.0 |
| Adjusted net income attributable to IDEX\* | 599.5 | 598.5 |
| Operating cash flow as a percent of net income | 141% | 132% |
| Free cash flow conversion | 103% | 101% |

---

\*This is a non-GAAP measure. See the definition of this non-GAAP measure and reconciliation to its most directly comparable U.S. GAAP financial measure under the heading "Non-GAAP Disclosures."

***Cash Requirements***

*Subsequent Borrowings Activity*

Subsequent to December 31, 2025, the Company had net borrowings on the Revolving Facility of $58.2 million.

*Subsequent Share Repurchases*

Subsequent to December 31, 2025, the Company repurchased 0.2 million shares at a cost of $38.1 million.

*Contractual Obligations*

The Company's cash requirements under contractual obligations include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Borrowings and related interest - See <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings," in the Notes to Consolidated Financial Statements for further detail of the Company's debt and timing of expected future principal payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Rental payments for leases - See <u>[Note 9](#ibaf335d4459d4d2499897b1ecd08d11c_124)</u>, "Leases," in the Notes to Consolidated Financial Statements for further detail of our obligations and the timing of expected future payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Purchase obligations - The Company enters into purchase orders with vendors and other parties in the ordinary course of business. As of December 31, 2025, the Company's purchase obligations, consisting primarily of inventory commitments, totaled approximately $326.2 million, of which $290.1 million is expected to be settled during 2026 and the remainder thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pension and post-retirement medical benefit plans - See <u>[Note 17](#ibaf335d4459d4d2499897b1ecd08d11c_148)</u>, "Retirement Benefits," in the Notes to Consolidated Financial Statements for further detail of our obligations and the timing of expected future payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Contingent consideration - In connection with the acquisition of Micro-LAM, the Company entered into an earnout agreement and may be required to pay contingent cash consideration upon the achievement of certain financial performance targets. See <u>[Note 8](#ibaf335d4459d4d2499897b1ecd08d11c_121)</u>, "Fair Value Measurements," in the Notes to Consolidated Financial Statements for further detail of our contingent consideration obligations.

*Capital Expenditures*

Capital expenditures generally include machinery and equipment that support growth and improved productivity, tooling, business system technology, replacement of equipment and investments in new facilities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures. Cash flows from operations were more than adequate to fund capital expenditures of $63.6 million and $65.1 million in 2025 and 2024, respectively.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Share Repurchases*

On September 17, 2025, the Company's Board of Directors authorized the repurchase of an additional $635.0 million of the Company's common shares. This approval is in addition to the prior repurchase authorization of the Company's Board of Directors of $500.0 million on March 17, 2020. In 2025, the Company repurchased 1.4 million shares at a cost of $252.4 million (including estimated excise taxes of $2.4 million, which will be paid in 2026), of which $2.2 million was settled in January 2026. There were no share repurchases in 2024. As of December 31, 2025, the amount of share repurchase authorization remaining was $924.7 million, excluding fees, commissions, excise taxes and other expenses related to such common stock repurchases. For additional information regarding the Company's share repurchase program, refer to <u>[Note 11](#ibaf335d4459d4d2499897b1ecd08d11c_130)</u>, "Share Repurchases," in the Notes to Consolidated Financial Statements and <u>[Item 5](#ibaf335d4459d4d2499897b1ecd08d11c_40)</u> "Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities."

*Dividends* 

The Company increased its quarterly cash dividend by 3% from $0.69 per common share in 2024 to $0.71 per common share in 2025. Total dividend payments to common shareholders were $212.6 million in 2025 compared with $205.3 million in 2024.

***Covenants***

The key financial covenants that the Company is required to maintain in connection with the Revolving Facility and the 5.13% Senior Notes are a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1. At December 31, 2025, the Company was in compliance with both of these financial covenants, as the Company's interest coverage ratio was 13.13 to 1 for covenant calculation purposes and the leverage ratio was 1.96 to 1. There are no financial covenants relating to the 2.625% Senior Notes, the 3.00% Senior Notes or the 4.950% Senior Notes (each as defined in <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings" in the Notes to Consolidated Financial Statements); however, all are subject to cross-acceleration provisions. For a discussion of the Company's Revolving Facility and Senior Notes as well as the associated covenants, refer to <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings," in the Notes to Consolidated Financial Statements.

***Credit Ratings***

The Company's credit ratings, which were independently developed by the following credit agencies, are detailed below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• S&P Global Ratings reaffirmed the Company's corporate credit rating of BBB (stable outlook) in September 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Moody's Investors Service affirmed the Company's corporate credit rating of Baa2 (stable outlook) in August 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Fitch Ratings reaffirmed the Company's corporate credit rating of BBB+ (stable outlook) in September 2025.

***Off-Balance Sheet Arrangements***

The Company had $21.4 million of letters of credit as of December 31, 2025, primarily issued as security for insurance and other performance obligations. Of the $21.4 million of letters of credit, only $2.6 million reduced the Company's borrowing capacity under the Revolving Facility as of December 31, 2025.

Except as disclosed above, the Company has no off-balance sheet arrangements that currently have or are reasonably likely to have a material effect on the Company's consolidated financial condition, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources.

**Critical Accounting Estimates**

The Company believes that the application of the following accounting policy, which is important to its financial position and results of operations, requires significant judgments and estimates on the part of management. For a summary of the Company's accounting policies, including the accounting policy discussed below, see <u>[Note 1](#ibaf335d4459d4d2499897b1ecd08d11c_100)</u>, "Significant Accounting Policies," in the Notes to Consolidated Financial Statements.

*Goodwill and indefinite-lived intangible assets* — Goodwill and other intangible assets with indefinite lives, which consists solely of trade names, are not amortized; rather they are tested for impairment at least annually, or more frequently if events or circumstances indicate that the asset may be impaired. The Company follows the guidance prescribed in Accounting Standards

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Codification ("ASC") 350, *Goodwill and Other Intangible Assets*, to test goodwill and indefinite-lived intangible assets for impairment. In assessing goodwill for impairment, the Company determines the fair value of each reporting unit utilizing an income approach (discounted cash flows) weighted 50% and a market approach (consisting of a comparable public company multiples methodology) weighted 50%. To determine the reasonableness of the calculated fair values, the Company reviews the assumptions to ensure that neither the income approach nor the market approach yielded significantly different valuations. Key assumptions and estimates used in the goodwill impairment assessment are described below. Based on the results of the Company's annual impairment test at October 31, 2025, all reporting units had fair values substantially in excess of their carrying values.

The key assumptions are updated every year for each reporting unit for the income and market approaches used to determine the fair value. Various assumptions are utilized including forecasted operating results, annual operating plans, strategic plans, economic projections, anticipated future cash flows, the weighted average cost of capital, market data and market multiples. The assumptions that have the most significant effect on the fair value calculations are the weighted average cost of capital, market multiples, forecasted cash flows and terminal growth rates. The following assumption ranges were utilized by the Company in 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **<u>Assumptions</u>** | **2025<br>Range** | **2024<br>Range** |
| Weighted average cost of capital | 9.25% to 10.5% | 9.25% to 9.75% |
| Market multiples | 11.0x to 17.0x | 12.0x to 19.0x |
| Terminal growth rates | 3.0% to 3.5% | 3.0% to 3.5% |

---

In assessing trade names for impairment, the Company uses the relief-from-royalty method, a form of the income approach, to determine the fair value of its trade names. The relief-from-royalty method is dependent on a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates. Based on the results of the Company's annual impairment test at October 31, 2025, the trade names had fair values in excess of their carrying values.

The Company's acquisitions have generally included significant goodwill components and the Company expects to continue to make acquisitions. At December 31, 2025, goodwill and other indefinite-lived intangible assets totaled $3,505.4 million, or 51%, of the Company's total assets.

See <u>[Note 6](#ibaf335d4459d4d2499897b1ecd08d11c_115)</u>, "Goodwill and Intangible Assets," in the Notes to Consolidated Financial Statements for further discussion on goodwill and indefinite-lived intangible assets.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Non-GAAP Disclosures**

Set forth below are reconciliations of Organic sales, Adjusted gross profit, Adjusted gross margin, Adjusted net income attributable to IDEX, Adjusted diluted EPS attributable to IDEX, Consolidated Adjusted earnings before interest, income taxes, depreciation and amortization ("Adjusted EBITDA") and Consolidated Adjusted EBITDA margin to their respective most directly comparable U.S. GAAP measure. Management uses these metrics to measure performance of the Company since they exclude items that are not reflective of ongoing operations, as identified in the reconciliations below. Management also supplements its U.S. GAAP financial statements with adjusted information to provide investors with greater insight, transparency and a more comprehensive understanding of the information used by management in its financial and operational decision making.

Management uses Adjusted EBITDA as its measure of segment performance, and believes it is a useful indicator of the strength and performance of the Company and its segments' ongoing business operations, as well as a way for investors to evaluate and compare operating performance and value companies within the Company's industry. Management believes that Adjusted EBITDA margin is useful for the same reason as Adjusted EBITDA. The definition of Adjusted EBITDA used here may differ from that used by other companies.

This report also references free cash flow and free cash flow conversion. These non-GAAP measures are discussed and reconciled to their most directly comparable U.S. GAAP measure in the section above titled "Free Cash Flow."

The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures prepared in accordance with U.S. GAAP. Due to rounding, numbers presented throughout this and other documents may not add up or recalculate precisely. The financial results prepared in accordance with U.S. GAAP and the reconciliations from these results should be carefully evaluated.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | **1. Reconciliations of the Change in Net Sales to Organic Sales** | | |
| | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** |
|  | **HST** | **FMT** | **FSDP** | **IDEX** | **HST** | **FMT** | **FSDP** | **IDEX** |
| Change in net sales | 15% | (1%) | —% | 6% | (1%) | (1%) | 4% | —% |
| Less: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Net impact from acquisitions/divestitures<sup>(1)</sup> | 10% | (2%) | —% | 4% | 6% | (1%) | —% | 2% |
| &nbsp;&nbsp;Impact from foreign currency<sup>(2)</sup> | 1% | 1% | 1% | 1% | —% | —% | —% | —% |
| Change in organic sales | 4% | —% | (1%) | 1% | (7%) | —% | 4% | (2%) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Represents the sales from acquired or divested businesses during the first 12 months of ownership or prior to divestiture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales, and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period.

---

| | | |
|:---|:---|:---|
| **2. Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (in millions)** | **2. Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (in millions)** | **2. Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (in millions)** |
| | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2025** | **2024** |
| Gross profit | $1538.8 | $1445.2 |
| &nbsp;&nbsp;Fair value inventory step-up charges | 0.6 | 9.6 |
| Adjusted gross profit | $1539.4 | $1454.8 |
| Net sales | $3457.5 | $3268.8 |
| Gross margin | 44.5% | 44.2% |
| Adjusted gross margin | 44.5% | 44.5% |

---

---

| | | |
|:---|:---|:---|
| **3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)** | **3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)** | **3. Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts)** |
| | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2025** | **2024** |
| Reported net income attributable to IDEX | $483.2 | $505.0 |
| &nbsp;&nbsp;Fair value inventory step-up charges | 0.6 | 9.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on fair value inventory step-up charges | (0.1) | (2.0) |
| &nbsp;&nbsp;Restructuring expenses and asset impairments<sup>(1)</sup> | 20.4 | 9.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on restructuring expenses and asset impairments | (5.1) | (2.2) |
| &nbsp;&nbsp;Gain on sale of businesses - net |  | (4.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on gain on sale of businesses - net |  |  |
| &nbsp;&nbsp;Loss on sale of assets | 1.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on loss on sale of assets<sup>(2)</sup> | 0.5 |  |
| &nbsp;&nbsp;Acquisition-related intangible asset amortization | 130.7 | 107.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on acquisition-related intangible asset amortization | (31.8) | (24.3) |
| Adjusted net income attributable to IDEX | $599.5 | $598.5 |
| Reported diluted EPS attributable to IDEX | $6.41 | $6.64 |
| &nbsp;&nbsp;Fair value inventory step-up charges | 0.01 | 0.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on fair value inventory step-up charges |  | (0.02) |
| &nbsp;&nbsp;Restructuring expenses and asset impairments<sup>(1)</sup> | 0.27 | 0.12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on restructuring expenses and asset impairments | (0.07) | (0.03) |
| &nbsp;&nbsp;Gain on sale of businesses - net |  | (0.05) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on gain on sale of businesses - net |  |  |
| &nbsp;&nbsp;Loss on sale of assets | 0.02 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on loss on sale of assets<sup>(2)</sup> | 0.01 |  |
| &nbsp;&nbsp;Acquisition-related intangible asset amortization | 1.72 | 1.41 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact on acquisition-related intangible asset amortization | (0.42) | (0.31) |
| Adjusted diluted EPS attributable to IDEX | $7.95 | $7.89 |
| Diluted weighted average shares outstanding | 75.3 | 75.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> This adjustment represents the amount of Restructuring expenses and asset impairments attributable to IDEX. Restructuring expenses and asset impairments of $20.7 million on the Consolidated Statements of Income during 2025

included charges of $0.6 million recognized by the Company's joint venture, $0.3 million of which was attributable to noncontrolling interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> The loss on sale of assets generated tax expense due to the characterization of the underlying assets sold for tax purposes.

---

| | | |
|:---|:---|:---|
| **4. Reconciliations of Net Income to Adjusted EBITDA (in millions)** | **4. Reconciliations of Net Income to Adjusted EBITDA (in millions)** | **4. Reconciliations of Net Income to Adjusted EBITDA (in millions)** |
| | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2025** | **2024** |
| Reported net income | $482.5 | $504.6 |
| &nbsp;&nbsp;Provision for income taxes | 150.1 | 134.7 |
| &nbsp;&nbsp;Interest expense – net | 64.4 | 44.5 |
| &nbsp;&nbsp;Gain on sale of businesses - net |  | (4.0) |
| &nbsp;&nbsp;Depreciation | 75.8 | 68.5 |
| &nbsp;&nbsp;Amortization | 130.7 | 107.1 |
| &nbsp;&nbsp;Fair value inventory step-up charges | 0.6 | 9.6 |
| &nbsp;&nbsp;Restructuring expenses and asset impairments | 20.7 | 9.3 |
| &nbsp;&nbsp;Loss on sale of assets | 1.1 |  |
| Adjusted EBITDA | $925.9 | $874.3 |
| Adjusted EBITDA Components |  |  |
| &nbsp;&nbsp;HST | $397.8 | $346.8 |
| &nbsp;&nbsp;FMT | 406.8 | 406.3 |
| &nbsp;&nbsp;FSDP | 213.5 | 214.2 |
| &nbsp;&nbsp;Corporate and other | (92.2) | (93.0) |
| Total Adjusted EBITDA | $925.9 | $874.3 |
| Net sales | $3457.5 | $3268.8 |
| Net income margin | 14.0% | 15.4% |
| Adjusted EBITDA margin | 26.8% | 26.7% |

---

**Item 7A.** &nbsp;&nbsp;&nbsp;&nbsp;**Quantitative and Qualitative Disclosures About Market Risk.**

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates as well as inflationary factors.

***Foreign Currency Exchange Rates***

The Company is exposed to foreign currency risks that arise from its global business operations. Approximately 34% of net sales in 2025 were recorded by subsidiaries with functional currencies other than the U.S. Dollar. Changes in foreign currency exchange rates affect the Company's results of operations, financial position and cash flows when these subsidiaries' results are translated into U.S. Dollars, the Company's functional reporting currency. The strengthening of the U.S. Dollar could result in unfavorable translation effects as the results of foreign operations are translated into U.S. Dollars.

Changes in foreign currency exchange rates also affect transaction gains and losses associated with transactions denominated in currencies other than a subsidiary's functional currency. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The foreign currency transaction losses

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

(gains) for the years ended December 31, 2025, 2024 and 2023 were $5.6 million, $(1.0) million and $7.3 million, respectively, and are reported within Other expense (income) – net on the Consolidated Statements of Income.

***Interest Rate Fluctuations***

The Company has interest rate exposure due to $228.8 million of the $1,829.8 million debt outstanding at December 31, 2025 bearing floating rate debt. The Company's Revolving Facility bears interest at either an alternate base rate or adjusted Term SOFR (or appropriate alternative currency reference rates) plus, in each case, an applicable margin based on the lower of the Company's senior, unsecured, long-term debt rating or the Company's applicable leverage ratio. At December 31, 2025, there was $228.8 million outstanding under the Revolving Facility with an interest rate of 3.32%. A hypothetical 1% change in the interest rate would cause the interest expense on the Company's floating rate debt to change by approximately $2.3 million per year.

***Inflation Risk***

We source a wide variety of materials and components from a network of global suppliers. While materials are typically available from numerous suppliers, they are subject to price fluctuations, including the impact of new or increased tariffs on imports, which could have a negative impact on our results. We seek to minimize the effects of inflation and changing prices through price increases to maintain reasonable gross margins.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Item 8.** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Financial Statements and Supplementary Data.**

**MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America, and as defined in Exchange Act Rule 13a-15(f).

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting.

Management has used the framework set forth in the report entitled "Internal Control — Integrated Framework" (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission to assess the effectiveness of the Company's internal control over financial reporting. Management excluded Micro-LAM, Inc. from its assessment of internal controls over financial reporting as the acquisition occurred in 2025 (see <u>[Note 2](#ibaf335d4459d4d2499897b1ecd08d11c_103)</u>, "Acquisitions and Divestitures," in the Notes to Consolidated Financial Statements for further detail). This exclusion is in accordance with the general guidance from the Staff of the Securities and Exchange Commission that an assessment of a recently acquired business may be omitted from the scope of management's assessment of internal control over financial reporting for one year following the acquisition. The total assets (excluding goodwill and intangible assets) and net sales of the current year acquisition represented approximately 1.1 percent and 0.4 percent, respectively, of the Consolidated Financial Statements amounts as of and for the year ended December 31, 2025. Based on that assessment, management has concluded that the Company's internal control over financial reporting was effective as of December 31, 2025.

The effectiveness of the Company's internal control over financial reporting as of December 31, 2025, has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report which appears herein.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

To the shareholders and the Board of Directors of IDEX Corporation

**Opinion on Internal Control over Financial Reporting**

We have audited the internal control over financial reporting of IDEX Corporation and subsidiaries (the "Company") as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by COSO.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2025, of the Company and our report dated February 19, 2026, expressed an unqualified opinion on those financial statements.

As described in Management's Report on Internal Control over Financial Reporting, management excluded Micro-LAM, Inc. from its assessment of internal control over financial reporting as this acquisition occurred in the twelve months ended December 31, 2025. The combined total assets (excluding goodwill and intangible assets) and net sales of this acquisition represented approximately 1.1 percent and 0.4 percent, respectively, of the consolidated financial statement amounts as of and for the year ended December 31, 2025. Accordingly, our audit did not include the internal control over financial reporting at this acquired company.

**Basis for Opinion** 

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying *Management's Report on Internal Control Over Financial Reporting*. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

**Definition and Limitations of Internal Control over Financial Reporting**

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;DELOITTE & TOUCHE LLP |
| Chicago, Illinois |
| February 19, 2026 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

To the shareholders and the Board of Directors of IDEX Corporation

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of IDEX Corporation and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of income, comprehensive income, equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 19, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

***Revenue*** *—* ***Disaggregation of Revenue*** *—* ***Refer to <u>[Note 5](#ibaf335d4459d4d2499897b1ecd08d11c_112)</u> to the financial statements***

*Critical Audit Matter Description*

The Company is a highly diversified business with a wide range of products and services that are offered in various markets throughout the world. The Company's business activities are carried out by numerous individual business units, which offer a unique set of products and include niche markets within specific geographic areas.

We identified revenue as a critical audit matter given the disaggregated nature of the Company's operations and business units generating revenue. This required extensive audit effort due to the volume of the underlying transactions and distinctiveness of each individual business unit. High levels of auditor judgment were necessary to determine the nature, timing, and extent of audit procedures and the level of disaggregation within the Company at which to perform such procedures, especially given limited market data for certain products or geographic areas.

*How the Critical Audit Matter Was Addressed in the Audit*

Our audit procedures related to the Company's revenue transactions included the following, among others:

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We tested internal controls within the relevant revenue business processes, including controls over revenue recognition and controls over the review of significant revenue transactions and operating results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For revenue transactions not subject to detail transaction testing, we aggregated the revenue transactions at the reporting unit level and performed substantive analytical procedures. We developed independent expectations of revenue based on data derived from published industry indices and market and customer trends and compared our independent expectations to the revenue recorded by management.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For a sample of revenue transactions, we performed detail transaction testing by agreeing the amounts recorded to source documents and determined that revenue was recognized appropriately.

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;DELOITTE & TOUCHE LLP |
| Chicago, Illinois |
| February 19, 2026 |

---

We have served as the Company's auditor since 1987.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**CONSOLIDATED STATEMENTS OF INCOME**

**(In millions, except per share amounts)** 

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net sales | $3457.5 | $3268.8 | $3273.9 |
| Cost of sales | 1918.7 | 1823.6 | 1827.0 |
| Gross profit | 1538.8 | 1445.2 | 1446.9 |
| Selling, general and administrative expenses | 818.8 | 758.7 | 703.5 |
| Restructuring expenses and asset impairments | 20.7 | 9.3 | 10.9 |
| Operating income | 699.3 | 677.2 | 732.5 |
| Gain on sale of businesses – net |  | (4.0) | (84.7) |
| Other expense (income) – net | 2.3 | (2.6) | 5.2 |
| Interest expense – net | 64.4 | 44.5 | 51.7 |
| Income before income taxes | 632.6 | 639.3 | 760.3 |
| Provision for income taxes | 150.1 | 134.7 | 164.7 |
| Net income | 482.5 | 504.6 | 595.6 |
| Net loss attributable to noncontrolling interest | 0.7 | 0.4 | 0.5 |
| Net income attributable to IDEX | $483.2 | $505.0 | $596.1 |
| *Earnings per common share:* |  |  |  |
| Basic earnings per common share attributable to IDEX | $6.41 | $6.66 | $7.87 |
| Diluted earnings per common share attributable to IDEX | $6.41 | $6.64 | $7.85 |
| *Share data:* |  |  |  |
| Basic weighted average common shares outstanding | 75.3 | 75.7 | 75.6 |
| Diluted weighted average common shares outstanding | 75.3 | 75.9 | 75.9 |

---

See Notes to Consolidated Financial Statements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(In millions)**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Net income | $482.5 | $504.6 | $595.6 |
| **Other comprehensive income (loss):** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pension and other postretirement adjustments, net of tax | 2.2 | 3.1 | (7.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cumulative translation adjustment | 186.3 | (88.2) | 87.8 |
| &nbsp;&nbsp;&nbsp;Other comprehensive income (loss), net of tax | 188.5 | (85.1) | 80.4 |
| **Comprehensive income** | 671.0 | 419.5 | 676.0 |
| Comprehensive loss attributable to noncontrolling interest | 0.7 | 0.4 | 0.5 |
| **Comprehensive income attributable to IDEX** | $671.7 | $419.9 | $676.5 |

---

See Notes to Consolidated Financial Statements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**CONSOLIDATED BALANCE SHEETS**

**(In millions, except per share amounts)** 

---

| | | |
|:---|:---|:---|
| | **As of December 31,** | **As of December 31,** |
| | **2025** | **2024** |
| **ASSETS** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $580.0 | $620.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables – net | 521.7 | 465.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories – net | 479.4 | 429.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 62.1 | 76.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1643.2 | 1592.7 |
| Property, plant and equipment – net | 468.0 | 460.4 |
| Goodwill | 3414.5 | 3251.7 |
| Intangible assets – net | 1247.4 | 1284.8 |
| Other noncurrent assets | 153.9 | 155.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $6927.0 | $6745.3 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | $224.7 | $197.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 297.0 | 278.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term borrowings | 0.7 | 100.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividends payable | 53.0 | 52.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 575.4 | 629.7 |
| Long-term borrowings – net | 1820.1 | 1859.5 |
| Deferred income taxes | 303.0 | 267.2 |
| Other noncurrent liabilities | 202.3 | 194.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 2900.8 | 2951.2 |
| Commitments and contingencies (<u>[Note 10](#ibaf335d4459d4d2499897b1ecd08d11c_127)</u>) |  |  |
| Shareholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized: 5.0 million shares, $0.01 per share par value; Issued: None |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized: 150.0 million shares, $0.01 per share par value |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued: 90.1 million shares at both December 31, 2025 and 2024 | 0.9 | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock at cost: 15.5 million shares at December 31, 2025 and 14.2 million shares at December 31, 2024 | (1423.2) | (1170.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 892.1 | 864.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 4500.1 | 4230.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 57.6 | (130.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total shareholders' equity | 4027.5 | 3794.7 |
| Noncontrolling interest | (1.3) | (0.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 4026.2 | 3794.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $6927.0 | $6745.3 |

---

See Notes to Consolidated Financial Statements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**CONSOLIDATED STATEMENTS OF EQUITY**

**(In millions, except per share amounts)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock Shares** | **Common Stock and Additional Paid-In Capital** | **Treasury Stock Shares** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Total Shareholders' Equity** | **Noncontrolling <br>Interest** | **Total Equity** |
| **Balance, December 31, 2022** | 90.1 | $818.1 | 14.5 | $(1184.3) | $(126.2) | $3531.7 | $3039.3 | $0.3 | $3039.6 |
| Net income (loss) |  |  |  |  |  | 596.1 | 596.1 | (0.5) | 595.6 |
| Other comprehensive income, net of tax of $2.3 |  |  |  |  | 80.4 |  | 80.4 |  | 80.4 |
| Net issuance of shares of treasury stock (net of tax of $2.8) |  |  | (0.3) | 21.5 |  |  | 21.5 |  | 21.5 |
| Repurchases of common stock |  |  | 0.1 | (24.2) |  |  | (24.2) |  | (24.2) |
| Share-based compensation |  | 21.8 |  |  |  |  | 21.8 |  | 21.8 |
| Cash dividends declared - $2.56 per common share |  |  |  |  |  | (193.5) | (193.5) |  | (193.5) |
| **Balance, December 31, 2023** | 90.1 | $839.9 | 14.3 | $(1187.0) | $(45.8) | $3934.3 | $3541.4 | $(0.2) | $3541.2 |
| Net income (loss) |  |  |  |  |  | 505.0 | 505.0 | (0.4) | 504.6 |
| Other comprehensive loss, net of tax of $(0.7) |  |  |  |  | (85.1) |  | (85.1) |  | (85.1) |
| Net issuance of shares of treasury stock (net of tax of $2.7) |  |  | (0.1) | 16.7 |  |  | 16.7 |  | 16.7 |
| Share-based compensation |  | 25.8 |  |  |  |  | 25.8 |  | 25.8 |
| Cash dividends declared - $2.76 per common share |  |  |  |  |  | (209.1) | (209.1) |  | (209.1) |
| **Balance, December 31, 2024** | 90.1 | $865.7 | 14.2 | $(1170.3) | $(130.9) | $4230.2 | $3794.7 | $(0.6) | $3794.1 |
| Net income (loss) |  |  |  |  |  | 483.2 | 483.2 | (0.7) | 482.5 |
| Other comprehensive income, net of tax of $(1.2) |  |  |  |  | 188.5 |  | 188.5 |  | 188.5 |
| Net issuance of shares of treasury stock (net of tax of $4.2) |  |  | (0.1) | (0.5) |  |  | (0.5) |  | (0.5) |
| Repurchases of common stock (including excise tax of $2.4 million) |  |  | 1.4 | (252.4) |  |  | (252.4) |  | (252.4) |
| Share-based compensation |  | 27.3 |  |  |  |  | 27.3 |  | 27.3 |
| Cash dividends declared - $2.84 per common share |  |  |  |  |  | (213.3) | (213.3) |  | (213.3) |
| **Balance, December 31, 2025** | 90.1 | $893.0 | 15.5 | $(1423.2) | $57.6 | $4500.1 | $4027.5 | $(1.3) | $4026.2 |

---

See Notes to Consolidated Financial Statements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In millions)**

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Cash flows from operating activities |  |  |  |
| Net income | $482.5 | $504.6 | $595.6 |
| Adjustments to reconcile net income to net cash flows provided by operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of businesses – net |  | (4.0) | (84.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairments | 0.7 | 0.1 | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Credit loss on note receivable from collaborative partner |  |  | 7.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 75.8 | 68.5 | 57.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 130.7 | 107.1 | 94.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 27.3 | 25.8 | 21.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 12.8 | (19.4) | (14.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in (net of the effect from acquisitions/divestitures and foreign currency translation): |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables – net | (41.2) | (16.9) | 20.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories – net | (34.2) | 17.6 | 66.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 1.6 | (0.1) | (6.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | 15.2 | 8.9 | (25.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 2.7 | (17.9) | 12.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 1.8 | (8.6) | (34.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other – net | 4.7 | 2.4 | 5.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows provided by operating activities | 680.4 | 668.1 | 716.7 |
| Cash flows from investing activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (63.6) | (65.1) | (89.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition of businesses, net of cash acquired | (76.2) | (984.5) | (311.8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of businesses, net of cash remitted |  | 45.1 | 118.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of marketable securities |  |  | (29.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of marketable securities |  | 4.5 | 24.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other – net | 2.2 | (6.5) | 3.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows used in investing activities | (137.6) | (1006.5) | (283.8) |
| Cash flows from financing activities |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Borrowings under revolving credit facilities | 252.0 | 279.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments under revolving credit facilities | (322.9) | (69.1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of long-term borrowings |  | 496.7 | 100.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of long-term borrowings | (100.0) | (50.0) | (250.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash dividends paid to shareholders | (212.6) | (205.3) | (190.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;(Payments) proceeds from share issuances, net of shares withheld for taxes | (0.5) | 16.7 | 21.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of common stock | (247.8) |  | (24.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other – net | (0.8) | (2.4) | (1.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash flows (used in) provided by financing activities | (632.6) | 465.9 | (344.7) |
| Effect of exchange rate changes on cash and cash equivalents | 36.8 | (22.9) | 15.9 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (53.0) | 104.6 | 104.1 |
| Cash and cash equivalents and restricted cash at beginning of year<sup>(1)</sup> | 638.9 | 534.3 | 430.2 |
| Cash and cash equivalents and restricted cash at end of year<sup>(1)</sup> | $585.9 | $638.9 | $534.3 |
| **Supplemental cash flow information** |  |  |  |
| Cash paid for: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest | $72.2 | $47.4 | $50.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes - net | 134.6 | 171.4 | 199.5 |

---

<sup>(1)</sup> Includes $5.9 million and $18.1 million of restricted cash at December 31, 2025 and December 31, 2024. respectively. At December 31, 2025, $3.0 million of the restricted cash has been included in Other current assets and $2.9 million has been included in Other noncurrent assets in the Consolidated Balance Sheets. At December 31, 2024, $18.1 million was included in Other current assets in the Consolidated Balance Sheets. There was no restricted cash as of December 31, 2023 or December 31, 2022.

See Notes to Consolidated Financial Statements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**IDEX CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(In millions, except per share amounts)**

**1. Significant Accounting Policies**

*Business*

IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers' specifications. IDEX's products are sold in niche markets across a wide range of industries throughout the world. The Company operates through three reportable segments: Health & Science Technologies ("HST"), Fluid & Metering Technologies ("FMT") and Fire & Safety/Diversified Products ("FSDP").

*Consolidation and Basis of Presentation*

The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Consolidated Financial Statements include the Company and its subsidiaries. All intercompany transactions and accounts have been eliminated.

*Use of Estimates*

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are revenue recognition, sales returns and allowances, allowance for credit losses, inventory valuation, recoverability of long-lived assets, valuation of goodwill and intangible assets, income taxes, product warranties, contingencies and litigation, insurance-related items, defined benefit retirement plans and purchase accounting related to acquisitions.

*Revenue Recognition*

The Company accounts for a contract with a customer when it has approval from both parties, the rights and payment terms are identified, the contract has commercial substance and collectability of the consideration is probable. The Company determines the appropriate revenue recognition by analyzing the terms and conditions of the contract. Revenue, or Net sales, is recognized when control of the products or services is transferred to a customer at an amount that reflects the consideration the Company expects to be entitled to in exchange for transferring the products or providing the services. Control is transferred to customers when performance obligations within a contract are satisfied. A performance obligation is a promise to transfer a distinct product or service to a customer.

The majority of the Company's contracts have a single performance obligation which represents, in most cases, the product being sold to the customer. Some contracts include multiple performance obligations such as a product and related installation, extended warranty, engineering, software and/or maintenance services.

For contracts that require complex design, manufacturing and installation activities, certain performance obligations may not be separately identifiable and, therefore, not distinct. As a result, the entire contract is accounted for as a single performance obligation. For contracts that include distinct products or services that are substantially the same and have the same pattern of transfer to the customer over time, they are recognized as a series of distinct products or services. For product sales, each product sold to a customer generally represents a distinct performance obligation. For contracts with multiple performance obligations, the Company allocates the total transaction price to each performance obligation in an amount based on the relative standalone selling prices of the promised products or services underlying each performance obligation. When available, the observable standalone sales are used in the allocation of the total transaction price, but in certain cases, the Company may be required to estimate the standalone selling price using the expected cost plus margin approach, under which it forecasts the expected costs of satisfying a performance obligation and then adds an appropriate margin for the distinct product or service.

The Company's performance obligations are satisfied at either a point in time or over time as work progresses. For performance obligations satisfied at a point in time, revenue is recognized when control transfers to the customer, typically upon shipment. For performance obligations in which the Company transfers control of a product or service over time, revenue

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

is recognized over time as work is performed. Typically, this results when the Company performs services over time or the Company creates a product with no alternative use and has an enforceable right to payment for its performance to date.

When accounting for over-time contracts, the Company generally uses a cost input measure to determine the extent of progress towards completion of the performance obligation. The Company believes this measure of progress best depicts the transfer of control to the customer which occurs as the Company incurs costs on its contracts. Incurred cost represents work performed, which corresponds with the transfer of control to the customer. Contract costs include labor, material and overhead. Revenue is recognized based on the relationship between actual costs incurred to date for each contract and the total estimated costs for such contract at completion of the performance obligation.

As a significant change in one or more of these estimates could affect the profitability of the Company's contracts, the Company reviews and updates its estimates regularly. Due to uncertainties inherent in the estimation process, it is reasonably possible that completion costs, including those arising from contract penalty provisions and final contract settlements, will be revised. Such revisions to costs and income are recognized in the period in which the revisions are determined as a cumulative catch-up adjustment. The impact of the adjustment on profit recorded to date on a contract is recognized in the period the adjustment is identified. Revenue and profit in future periods of contract performance are recognized using the adjusted estimate. If at any time the estimate of contract profitability indicates an anticipated loss on the contract, the Company recognizes provisions for estimated losses on incomplete contracts in the period in which such losses are determined.

The Company records allowances for discounts and product returns at the time of sale as a reduction of revenue as such allowances can be reliably estimated based on historical experience and known trends. The Company also offers product warranties (primarily assurance-type) and accrues its estimated exposure for warranty claims at the time of sale based upon the length of the warranty period, warranty costs incurred and any other related information known to the Company.

*Contract Assets and Liabilities*

The timing of billings and cash collections can result in customer receivables, billings in excess of revenue recognized, advance payments or deposits. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables - net on the Consolidated Balance Sheets. Amounts are billed in accordance with contractual terms or as work progresses. Unbilled amounts arise when the timing of billing differs from the timing of revenue recognized, such as when contract provisions require specific milestones to be met before a customer can be billed. Unbilled amounts primarily relate to performance obligations satisfied over time when the cost-to-cost method is utilized and the revenue recognized exceeds the amount billed to the customer as there is not yet a right to invoice in accordance with contractual terms. Unbilled amounts are recorded as a contract asset when the revenue associated with the contract is recognized prior to billing and derecognized when billed in accordance with the terms of the contract.

Contract liabilities include advance payments, deposits and billings in excess of revenue recognized and are included in deferred revenue which is classified as current or noncurrent based on the timing of when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Consolidated Balance Sheets. Advance payments, deposits and billings in excess of revenue represent contract liabilities and are recorded when customers remit contractual cash payments in advance of satisfaction of performance obligations under contractual arrangements, including those with performance obligations satisfied over time. The Company generally receives advance payments from customers related to maintenance services which are recognized ratably over the service term. The Company also receives deposits from customers on certain orders which the Company recognizes as revenue at a point in time. Contract liabilities are derecognized when revenue is recognized.

*Shipping and Handling Costs*

Shipping and handling costs are included in Cost of sales and are recognized as a period expense during the period in which they are incurred.

*Advertising Costs*

Advertising costs of $16.3 million, $16.9 million and $15.9 million for 2025, 2024 and 2023, respectively, are expensed as incurred within Selling, general and administrative expenses.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Cash and Cash Equivalents*

The Company considers all highly liquid instruments purchased with an original maturity of 3 months or less to be cash and cash equivalents.

*Marketable Securities*

From time to time, the Company may hold investments in marketable securities, which are recorded in Other current assets in the Consolidated Balance Sheets. These investments are recorded at fair value, with gains and losses, dividends and interest income included in Other expense (income) – net in the Consolidated Statements of Income.

*Accounts Receivable and Allowance for Credit Losses*

Accounts receivable are recorded at face amount less an allowance for credit losses including bad debts as well as other estimated returns and allowances. The allowance for bad debt is an estimate based on historical collection experience, current and future economic and market conditions and a review of the current status of each customer's trade accounts receivable. Management evaluates the aging of the accounts receivable balances and the financial condition of its customers and all other forward-looking information that is reasonably available to estimate the amount of accounts receivable that may not be collected in the future and records the appropriate provision. Reserves for returns and other allowances and adjustments, which are provided for in the same period the related sales are recorded and reduce net sales, are estimated using historical experience as well as specific customer circumstances when known.

*Inventories*

The Company states inventories at the lower of cost or net realizable value. Cost, which includes material, labor and overhead, is determined on a first in, first out basis. The Company makes adjustments to reduce the cost of inventory to its net realizable value, if required, for estimated excess, obsolete, zero usage or impaired balances. Factors influencing these adjustments include changes in market demand, product life cycle and engineering changes.

*Impairment of Long-Lived Assets*

A long-lived asset is reviewed for impairment if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below its carrying value, as measured by comparing its net book value to the projected undiscounted future cash flows generated by its use. The Company groups and evaluates these long-lived assets for impairment at the lowest level at which individual cash flows can be identified. A long-lived asset impairment exists when the carrying value of the asset group exceeds its fair value. The amount and timing of the impairment charge for an asset group requires the estimation of future cash flows, which are then discounted to determine the fair value of the asset group. An impaired asset group is recorded at its estimated fair value. Refer to <u>[Note 14](#ibaf335d4459d4d2499897b1ecd08d11c_139)</u>, "Restructuring Expenses and Asset Impairments," for further discussion on impairment of long-lived assets.

*Goodwill and Indefinite-Lived Intangible Assets*

The Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually, or more frequently if events occur or circumstances change that would indicate an asset may be impaired. The Company evaluates the recoverability of these assets as of October 31 based on the estimated fair value of each reporting unit and the indefinite-lived intangible assets. See <u>[Note 6](#ibaf335d4459d4d2499897b1ecd08d11c_115)</u>, "Goodwill and Intangible Assets," for further discussion on goodwill and indefinite-lived intangible assets.

*Borrowing Expenses*

Expenses incurred in securing and issuing debt are capitalized and amortized over the life of the related borrowing and the related amortization is included in Interest expense - net in the Consolidated Statements of Income. Debt issuance costs related to senior notes and term loans are included as a reduction of the carrying amount of the related borrowing. Debt issuance costs related to securing the Company's Revolving Facility are included in Other noncurrent assets in the Consolidated Balance Sheets.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Earnings per Common Share*

Diluted earnings per common share ("EPS") attributable to IDEX is computed by dividing Net income attributable to IDEX by the weighted average number of common shares outstanding (basic) plus common stock equivalents outstanding (diluted) during the year. Common stock equivalents consist of restricted stock, performance share units and stock options, which have been included in the calculation of weighted average common shares outstanding using the treasury stock method.

Outstanding unvested share-based payment awards that contain rights to non-forfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has both participating and non-participating securities. Dividend rights for restricted stock awards issued under the IDEX Corporation 2024 Incentive Award Plan (the "2024 Incentive Award Plan") are subject to the same vesting requirements as the underlying restricted stock awards, and therefore these awards are considered non-participating securities. Dividend rights for restricted stock awards issued prior to the adoption of the 2024 Incentive Award Plan are non-forfeitable and are not subject to the same vesting requirements as the underlying restricted stock awards. As such, these awards have been determined to be participating securities. Accordingly, Diluted EPS attributable to IDEX was computed using the two-class method.

Basic weighted average common shares outstanding reconciles to diluted weighted average common shares outstanding as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Basic weighted average common shares outstanding | 75.3 | 75.7 | 75.6 |
| Dilutive effect of restricted stock, performance share units and stock options |  | 0.2 | 0.3 |
| Diluted weighted average common shares outstanding | 75.3 | 75.9 | 75.9 |

---

Share-based payment awards that were not included in the computation of Diluted EPS attributable to IDEX because the effect of their inclusion would have been antidilutive were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Antidilutive shares not included in Diluted EPS attributable to IDEX | 0.8 | 0.4 | 0.2 |

---

*Share-Based Compensation*

The Company expenses the fair value of the awards granted under its share-based compensation plan. That cost is recognized in the Consolidated Financial Statements over the requisite service period of the grants. See <u>[Note 15](#ibaf335d4459d4d2499897b1ecd08d11c_142)</u>, "Share-Based Compensation," for further discussion on share-based compensation.

*Depreciation and Amortization*

Property and equipment are stated at historical cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over each asset's estimated useful life. Property and equipment are generally depreciated over the following estimated useful lives:

---

| | |
|:---|:---|
| Land improvements | 8 to 12 years |
| Buildings and improvements | 8 to 30 years |
| Machinery, equipment and other | 3 to 12 years |
| Office and transportation equipment | 2 to 10 years |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Certain identifiable intangible assets are amortized over their estimated useful lives using the straight-line method. The estimated useful lives used in the computation of amortization of identifiable intangible assets are generally as follows:

---

| | |
|:---|:---|
| Trade names | 15 to 20 years |
| Customer relationships | 5 to 20 years |
| Technology | 5 to 20 years |
| Software | 5 years |

---

*Research and Development Expenditures*

Costs associated with engineering activities, including research and development, are expensed in the period incurred and are included in Cost of sales.

Total engineering expenses, which include research and development as well as application and support engineering, were $122.3 million, $111.2 million and $107.5 million in 2025, 2024 and 2023, respectively. Research and development expenses, which include costs associated with developing new products and major improvements to existing products, were $70.0 million, $67.4 million and $68.4 million in 2025, 2024 and 2023, respectively.

*Foreign Currency Translation and Transaction*

The functional currency of substantially all operations outside the United States is the respective local currency. Accordingly, those foreign currency balance sheet accounts have been translated using the exchange rates in effect as of the balance sheet date and the income statement amounts have been translated using the average monthly exchange rates for the year. Translation adjustments from year to year have been reported in Accumulated other comprehensive income (loss) in the Consolidated Balance Sheets. Foreign currency transaction gains and losses from transactions denominated in a currency other than the functional currency of the subsidiary involved are reported within Other expense (income) – net in the Consolidated Statements of Income. Net transaction loss (gain) for the years ended December 31, 2025, 2024 and 2023 was $5.6 million, $(1.0) million and $7.3 million, respectively.

*Income Taxes*

Income tax expense includes U.S., state, local and international income taxes. Deferred tax assets and liabilities are recognized for the tax consequences of temporary differences between the financial reporting and tax bases of existing assets and liabilities and for loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recognizes the tax benefit of uncertain income tax positions only if those positions are more likely than not to be sustained upon examination. Judgment is required in evaluating tax positions and determining income tax provisions. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits in income tax expense. See <u>[Note 12](#ibaf335d4459d4d2499897b1ecd08d11c_133)</u>, "Income Taxes," for further discussion on income taxes.

*Concentration of Credit Risk*

The Company is not dependent on a single customer as its largest customer accounted for less than 3% of net sales for all years presented.

*Recently Adopted Accounting Standards*

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, *Improvements to Income Tax Disclosures*, which requires public entities, on an annual basis, to disclose standard categories in the tax rate reconciliation, additional information for reconciling items that meet a quantitative threshold and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Adoption of this ASU should be applied prospectively, but may be applied retrospectively to all prior periods presented in the financial statements. The Company adopted this standard on a prospective basis during the year ended December 31, 2025. The adoption of this standard did not have a material impact on the Company's Consolidated Financial Statements, but resulted in incremental income tax disclosures. See <u>[Note 1](#ibaf335d4459d4d2499897b1ecd08d11c_133)[2](#ibaf335d4459d4d2499897b1ecd08d11c_133)</u>, "Income Taxes," for further detail.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

*Recently Issued Accounting Standards*

In November 2024, the FASB issued ASU 2024-03, *Disaggregation of Income Statement Expenses*, which requires public entities to disclose, within the footnotes to the financial statements, disaggregated information about certain income statement expense captions, including disclosure of amounts for purchases of inventory, employee compensation, depreciation and intangible asset amortization, included in each relevant expense caption. ASU 2024-03 is effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Adoption of this ASU should be applied prospectively, but may be applied retrospectively to all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company's financial statement disclosures and expects the standard will increase disclosures in the Company's annual and interim reporting when adopted.

In December 2025, the FASB issued ASU 2025-10, *Accounting for Government Grants Received by Business Entities*, which establishes authoritative guidance on the accounting for government grants to business entities. ASU 2025-10 is effective for annual and interim periods beginning after December 15, 2028. Adoption of this ASU may be applied using a modified prospective, modified retrospective or retrospective approach. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company's financial statement disclosures, but does not expect the impact to be material.

**2. Acquisitions and Divestitures**

All of the Company's acquisitions of businesses have been accounted for under ASC 805, *Business Combinations*. Accordingly, the assets and liabilities of the acquired companies, after adjustments to reflect the fair values assigned to the assets and liabilities, have been included in the Company's Consolidated Balance Sheets from their respective dates of acquisition. The results of operations of businesses acquired have been included in the Company's Consolidated Statements of Income since their respective dates of acquisition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on the Company's Consolidated Financial Statements individually or in the aggregate.

The Company makes a preliminary allocation of the purchase price for each acquisition as of the acquisition date based on its understanding of the fair value of the acquired assets and assumed liabilities. These nonrecurring fair value measurements are classified as Level 3 in the fair value hierarchy. As the Company continues to obtain additional information, primarily related to the valuations of these assets and liabilities, and continues to integrate the newly acquired business, the Company will refine the estimates of fair value and more accurately allocate the purchase price through the completion of the measurement period, which is not to exceed one year from the date of acquisition. Only items that existed as of the acquisition date are considered for subsequent adjustment to the purchase price allocation. Goodwill recognized reflects the strategic fit, revenue and earnings growth potential of the acquired business and its synergies with existing IDEX businesses.

*2025 Acquisitions*

*Micro-LAM, Inc.*

On July 29, 2025, the Company acquired Micro-LAM, Inc. ("Micro-LAM") in a stock acquisition. Micro-LAM is an advanced optics manufacturer of laser-assisted machining, ultra-precision diamond tools and custom optics that is complementary to the Company's Optics Technologies solutions. Headquartered in Portage, Michigan, Micro-LAM operates in the Company's Scientific Fluidics & Optics reporting unit within the Company's HST segment. Micro-LAM was acquired for cash consideration of $80.4 million, net of cash acquired of $0.3 million, plus a potential earnout of up to $12.0 million of additional cash consideration based upon the achievement of certain financial performance targets over a two-year period. Total consideration of $81.6 million includes the fair value of the potential earnout as of the acquisition date of $1.2 million. For additional discussion of the earnout valuation, refer to <u>[Note](#ibaf335d4459d4d2499897b1ecd08d11c_121)[8](#ibaf335d4459d4d2499897b1ecd08d11c_121)</u>, "Fair Value Measurements." The acquisition was funded using additional borrowings under the Company's Revolving Facility (as defined in <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings"). Goodwill and intangible assets recognized as part of this transaction were $37.0 million and $44.8 million, respectively. The goodwill is not deductible for tax purposes.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

As of December 31, 2025, the preliminary allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

---

| | |
|:---|:---|
| | **Total** |
| Current assets, net of cash acquired | $7.5 |
| Property, plant and equipment | 8.1 |
| Goodwill | 37.0 |
| Intangible assets | 44.8 |
| Other noncurrent assets | 2.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | 100.3 |
| Current liabilities | (6.2) |
| Deferred income taxes | (9.9) |
| Other noncurrent liabilities | (2.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net assets acquired<sup>(1)</sup> | $81.6 |

---

<sup>(1)</sup> During the fourth quarter of 2025, the Company finalized the purchase price of Micro-LAM, resulting in a reduction to the purchase price of $0.3 million.

The acquired intangible assets and weighted average amortization periods are as follows:

---

| | | |
|:---|:---|:---|
| | **Total** | **Weighted Average Life (in years)** |
| Trade names | $5.3 | 15 |
| Customer relationships | 21.1 | 11 |
| Technology | 18.4 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired intangible assets | $44.8 |  |

---

*2024 Acquisitions*

*Mott Corporation* 

On September 5, 2024, the Company acquired Mott Corporation and its subsidiaries ("Mott") in a stock acquisition. Mott is a leading microfiltration business specializing in the design, customization and manufacturing of sintered porous metal components and engineered solutions used in fluidic applications. Headquartered in Farmington, Connecticut, Mott operates in the Scientific Fluidics & Optics reporting unit within the Company's HST segment. Mott was acquired for cash consideration of $982.0 million, net of cash acquired of $3.1 million. The purchase price was funded using a combination of cash on hand of $207.7 million, borrowings under the Company's Revolving Facility of $279.3 million and net proceeds of $495.0 million from the issuance of the Company's 4.950% Senior Notes (as defined in <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings"). Goodwill and intangible assets recognized as part of this transaction were $488.6 million and $412.8 million, respectively. Of the total goodwill balance recognized, $439.0 million is deductible for tax purposes.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

---

| | |
|:---|:---|
| | **Total** |
| Current assets, net of cash acquired | $82.3 |
| Property, plant and equipment | 51.5 |
| Goodwill | 488.6 |
| Intangible assets | 412.8 |
| Other noncurrent assets | 15.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | 1050.2 |
| Current liabilities | (50.7) |
| Deferred income taxes | (4.6) |
| Other noncurrent liabilities | (12.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net assets acquired<sup>(1)</sup> | $982.0 |

---

<sup>(1)</sup> During the first quarter of 2025, the Company finalized the purchase price of Mott, resulting in a reduction to the purchase price of $4.2 million. Funds were received by the Company in the first quarter of 2025.

The acquired intangible assets and weighted average amortization periods are as follows:

---

| | | |
|:---|:---|:---|
| | **Total** | **Weighted Average Life (in years)** |
| Trade names | $42.0 | 15 |
| Customer relationships | 269.0 | 14 |
| Technology | 101.8 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired intangible assets | $412.8 |  |

---

*2023 Acquisitions*

*Iridian Spectral Technologies*

On May 19, 2023, the Company acquired Iridian Spectral Technologies ("Iridian") in a stock acquisition. Iridian is a global leader in designing and manufacturing thin-film, multi-layer optical filters serving the laser communications, telecommunications and life sciences markets and expands the Company's array of optical technology offerings. Headquartered in Ottawa, Canada, Iridian operates in the Company's Scientific Fluidics & Optics reporting unit within the HST segment. Iridian was acquired for cash consideration of $109.8 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $54.2 million and $44.1 million, respectively. The goodwill is not deductible for tax purposes.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

---

| | |
|:---|:---|
| | **Total** |
| Current assets, net of cash acquired | $10.6 |
| Property, plant and equipment | 19.4 |
| Goodwill | 54.2 |
| Intangible assets | 44.1 |
| Other noncurrent assets | 5.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | 133.7 |
| Current liabilities | (1.2) |
| Deferred income taxes | (17.8) |
| Other noncurrent liabilities | (4.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net assets acquired | $109.8 |

---

The acquired intangible assets and weighted average amortization periods are as follows:

---

| | | |
|:---|:---|:---|
| | **Total** | **Weighted Average Life (in years)** |
| Trade names | $5.2 | 15 |
| Customer relationships | 27.8 | 12 |
| Technology | 11.1 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired intangible assets | $44.1 |  |

---

*STC Material Solutions*

On December 14, 2023, the Company acquired STC Material Solutions ("STC") in a stock acquisition. STC specializes in the design and manufacturing of technical ceramics and hermetic sealing products for critical applications in the semiconductor, space and defense, industrial technology, medical technology and energy markets. Headquartered in St. Albans, Vermont, with additional operations in Santa Ana, California, STC operates in the Company's Scientific Fluidics & Optics reporting unit within the HST segment. STC was acquired for cash consideration of $200.4 million. The entire purchase price was funded with cash on hand. Goodwill and intangible assets recognized as part of this transaction were $104.3 million and $92.3 million, respectively. The goodwill is not deductible for tax purposes.

The final allocation of the purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at the acquisition date, is as follows:

---

| | |
|:---|:---|
| | **Total** |
| Current assets, net of cash acquired | $16.7 |
| Property, plant and equipment | 12.1 |
| Goodwill | 104.3 |
| Intangible assets | 92.3 |
| Other noncurrent assets | 3.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets acquired | 228.4 |
| Current liabilities | (5.5) |
| Deferred income taxes | (19.8) |
| Other noncurrent liabilities | (2.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net assets acquired<sup>(1)</sup> | $200.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> During the first quarter of 2024, the Company finalized the purchase price of STC, resulting in a reduction to the purchase price of $1.6 million.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The acquired intangible assets and weighted average amortization periods are as follows:

---

| | | |
|:---|:---|:---|
| | **Total** | **Weighted Average Life (in years)** |
| Trade names | $9.3 | 15 |
| Customer relationships | 63.0 | 15 |
| Technology | 20.0 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired intangible assets | $92.3 |  |

---

*Acquisition-Related Costs*

The Company incurred acquisition costs related to completed, pending and potential transactions, including those that ultimately were not completed. These costs were recorded in Selling, general and administrative expenses in the Company's Consolidated Statements of Income. The Company also incurred fair value inventory step-up charges associated with completed acquisitions. These costs were recorded in Cost of sales in the Company's Consolidated Statements of Income. A summary of the acquisition costs and the fair value inventory step-up charges recorded in the years ended December 31, 2025, 2024 and 2023 are presented in the following table:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Acquisition costs | $4.6 | $10.4 | $7.3 |
| Fair value inventory step-up charges | 0.6 | 9.6 | 1.6 |

---

*Divestitures*

The Company periodically reviews its businesses relative to its core business. As such, from time to time, the Company may sell various businesses or assets for a variety of reasons. Any resulting gain or loss recognized due to divestitures is recorded within Gain on sale of businesses - net in the Consolidated Statements of Income. The divestitures did not represent a strategic shift that had a major effect on operations and financial results and, therefore, did not qualify for presentation as discontinued operations.

On June 3, 2024, the Company completed the sale of Alfa Valvole, Srl ("Alfa Valvole") for proceeds of $45.1 million, net of cash remitted, resulting in a gain on the sale of $4.0 million, net of a release of cumulative foreign currency translation losses of $5.5 million. There was no income tax impact associated with this transaction in the Consolidated Statements of Income due to the participation exemption of its consolidated group. The results of Alfa Valvole were reported in the Valves reporting unit within the FMT segment through the date of disposition.

On December 29, 2023, the Company completed the sale of Novotema, SpA ("Novotema") for proceeds of $8.3 million, net of cash remitted, resulting in a loss on the sale of $9.1 million. There was no income tax impact associated with this transaction in the Consolidated Statements of Income due to the participation exemption of its consolidated group. The results of Novotema were reported in the Sealing Solutions reporting unit within the HST segment through the date of disposition.

On August 3, 2023, the Company completed the sale of Micropump, Inc. ("Micropump") for proceeds of $110.3 million, net of cash remitted, resulting in a pre-tax gain on the sale of $93.8 million. The divestiture resulted in $22.7 million of income tax expense in the Consolidated Statements of Income during the year ended December 31, 2023. Micropump was its own reporting unit and its results were reported within the HST segment through the date of disposition.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**3. Collaborative Investments**

On May 12, 2020, a subsidiary of IDEX entered into a joint venture agreement with a third party to form a limited liability company (the "Joint Venture") that manufactures and sells high performance elastomer seals for the oil and gas industry to customers within the Kingdom of Saudi Arabia as well as exports these high performance elastomer seals outside of the Kingdom of Saudi Arabia. The Joint Venture maintains operations in Dammam, Saudi Arabia and operates in the Company's Sealing Solutions reporting unit within the HST segment. The Company has contributed $0.7 million for 55% of the share capital while the third-party partner has contributed $0.6 million for 45% of the share capital. The Joint Venture has been selling since July 2022. Since IDEX controls the entity, IDEX has consolidated the Joint Venture and recorded a Noncontrolling interest in its Consolidated Financial Statements.

During 2021 and 2022, a subsidiary of IDEX funded a total of $7.2 million in promissory notes as an investment in a start-up company that provides communication technology to improve individual performance and team coordination for firefighters' responses, which aligns with IDEX's FSDP segment's strategic plan. On a quarterly basis, the Company evaluated whether an allowance for credit losses was required for these promissory notes and measured the allowance using the current expected credit loss model. During the second quarter of 2023, IDEX determined that its investment may no longer be recoverable. As a result, IDEX recorded a credit loss of $7.7 million in Other expense (income) – net in the Consolidated Statements of Income and a reserve in Other noncurrent assets on the Consolidated Balance Sheets for the full amount of the principal and accrued interest outstanding. During the fourth quarter of 2023, IDEX converted the promissory notes to equity, resulting in a cost method investment with zero value.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**4. Balance Sheet Components**

---

| | | |
|:---|:---|:---|
| | **December 31,** | **December 31,** |
| | **2025** | **2024** |
| RECEIVABLES - NET |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Customers | $511.9 | $461 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 19.2 | 14.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 531.1 | 475.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: allowance for credit losses | 9.4 | 9.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables - net | $521.7 | $465.9 |
| INVENTORIES - NET |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Raw materials and components parts | $316.1 | $285.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Work in process | 47.7 | 34.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finished goods | 115.6 | 109.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories - net | $479.4 | $429.7 |
| PROPERTY, PLANT AND EQUIPMENT - NET |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Land and improvements | $31.6 | $30 |
| &nbsp;&nbsp;&nbsp;&nbsp;Buildings and improvements | 287.5 | 268.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Machinery, equipment and other | 657.3 | 607.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Office and transportation equipment | 107.9 | 108.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Construction in progress | 38.0 | 34.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 1122.3 | 1050.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: accumulated depreciation and amortization | 654.3 | 589.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment - net | $468.0 | $460.4 |
| ACCRUED EXPENSES |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payroll and related items | $112.2 | $105 |
| &nbsp;&nbsp;&nbsp;&nbsp;Management incentive compensation | 19.1 | 14.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 14.0 | 10.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Warranty | 14.4 | 13.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | 45.8 | 50.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease liability | 27.8 | 26.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring | 3.0 | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 11.7 | 12.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 49.0 | 45.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | $297.0 | $278.7 |

---

**5. Revenue**

*Disaggregation of Revenue*

The Company has a comprehensive offering of products, including technologies, built to customers' specifications that are sold in niche markets throughout the world. The Company disaggregates revenue from contracts with customers by reporting unit and geographical region for each segment as the Company believes it best depicts how the amount, nature, timing and uncertainty of its revenue and cash flows are affected by economic factors. Revenue, presented as Net sales on the Consolidated Statements of Income, was attributed to geographical region based on the location of the customer. The following tables present revenue disaggregated by reporting unit and geographical region.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Revenue by reporting unit for the years ended December 31, 2025, 2024 and 2023 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **For the Year Ended December 31,** | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Scientific Fluidics & Optics | $859.3 | $706.1 | $681.5 |
| Performance Pneumatic Technologies | 259.2 | 237.4 | 250.0 |
| Sealing Solutions | 249.6 | 232.4 | 242.3 |
| Material Processing Technologies | 127.4 | 122.2 | 120.7 |
| Micropump<sup>(1)</sup> |  |  | 21.9 |
| Intersegment elimination | (4.8) | (4.1) | (2.9) |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | 1490.7 | 1294.0 | 1313.5 |
| Pumps | 426.6 | 408.3 | 402.9 |
| Water | 351.8 | 347.8 | 345.8 |
| Energy | 205.2 | 207.6 | 209.3 |
| Agriculture | 143.3 | 146.4 | 159.6 |
| Valves | 97.1 | 123.1 | 129.5 |
| Intersegment elimination | (1.5) | (1.4) | (2.9) |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 1222.5 | 1231.8 | 1244.2 |
| Fire & Safety | 478.4 | 467.2 | 431.9 |
| Dispensing | 147.2 | 161.3 | 167.5 |
| BAND-IT | 119.7 | 115.8 | 119.4 |
| Intersegment elimination | (1.0) | (1.3) | (2.6) |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 744.3 | 743.0 | 716.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net sales | $3457.5 | $3268.8 | $3273.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Revenue from Micropump (sold on August 3, 2023) has been included in the Company's Consolidated Statements of Income through the date of disposition. See <u>[Note 2](#ibaf335d4459d4d2499897b1ecd08d11c_103)</u>, "Acquisitions and Divestitures," for further detail.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Revenue by geographical region for the years ended December 31, 2025, 2024 and 2023 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** |
| | **HST** | **FMT** | **FSDP** | **IDEX** |
| U.S. | $695.7 | $693.3 | $371.8 | $1760.8 |
| North America, excluding U.S. | 24.7 | 73.0 | 32.0 | 129.7 |
| Europe | 448.4 | 202.6 | 195.2 | 846.2 |
| Asia | 292.3 | 158.1 | 112.6 | 563.0 |
| Other<sup>(1)</sup> | 34.4 | 97.0 | 33.7 | 165.1 |
| Intersegment elimination | (4.8) | (1.5) | (1.0) | (7.3) |
| &nbsp;&nbsp;&nbsp;Net sales | $1490.7 | $1222.5 | $744.3 | $3457.5 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** |
| | **HST** | **FMT** | **FSDP** | **IDEX** |
| U.S. | $573.7 | $693.1 | $354.9 | $1621.7 |
| North America, excluding U.S. | 29.9 | 68.3 | 34.2 | 132.4 |
| Europe | 408.0 | 210.1 | 178.4 | 796.5 |
| Asia | 261.4 | 169.7 | 139.9 | 571.0 |
| Other<sup>(1)</sup> | 25.1 | 92.0 | 36.9 | 154.0 |
| Intersegment elimination | (4.1) | (1.4) | (1.3) | (6.8) |
| &nbsp;&nbsp;&nbsp;Net sales | $1294.0 | $1231.8 | $743.0 | $3268.8 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** |
| | **HST** | **FMT** | **FSDP** | **IDEX** |
| U.S. | $575.5 | $695.7 | $371.9 | $1643.1 |
| North America, excluding U.S. | 22.6 | 70.3 | 33.4 | 126.3 |
| Europe | 439.9 | 213.8 | 166.7 | 820.4 |
| Asia | 249.4 | 177.6 | 108.5 | 535.5 |
| Other<sup>(1)</sup> | 29.0 | 89.7 | 38.3 | 157.0 |
| Intersegment elimination | (2.9) | (2.9) | (2.6) | (8.4) |
| &nbsp;&nbsp;&nbsp;Net sales | $1313.5 | $1244.2 | $716.2 | $3273.9 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Other includes: South America, Middle East, Australia and Africa.

*Performance Obligations*

The Company's performance obligations are satisfied either at a point in time or over time as work progresses. Revenue from products and services transferred to customers at a point in time comprised approximately 95% of the Company's revenue and over time comprised approximately 5% of the Company's revenue in all years presented.

*Contract Assets and Liabilities*

The timing of billings and cash collections can result in customer receivables, billings in excess of revenue recognized, advance payments or deposits. Customer receivables include both amounts billed and currently due from customers as well as unbilled amounts (contract assets) and are included in Receivables – net on the Consolidated Balance Sheets.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The composition of customer receivables was as follows:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| Billed receivables | $477.1 | $443.2 |
| Unbilled receivables | 34.8 | 17.8 |
| &nbsp;&nbsp;&nbsp;Total customer receivables | $511.9 | $461.0 |

---

Billings in excess of revenue recognized, advance payments and deposits represent contract liabilities and are included in deferred revenue which is classified as current or noncurrent based on when the Company expects to recognize the revenue. The current portion is included in Accrued expenses and the noncurrent portion is included in Other noncurrent liabilities on the Consolidated Balance Sheets.

The composition of deferred revenue was as follows:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| Deferred revenue - current | $45.8 | $50.7 |
| Deferred revenue - noncurrent | 22.0 | 13.2 |
| &nbsp;&nbsp;&nbsp;Total deferred revenue | $67.8 | $63.9 |

---

**6. Goodwill and Intangible Assets**

The changes in the carrying amount of goodwill for 2025 and 2024, by reportable business segment, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **HST** | **FMT** | **FSDP** | **Total** |
| Goodwill | $1834.5 | $805.7 | $398.7 | $3038.9 |
| &nbsp;&nbsp;&nbsp;Accumulated goodwill impairment losses | (149.8) | (20.7) | (30.1) | (200.6) |
| Balance at January 1, 2024 | 1684.7 | 785.0 | 368.6 | 2838.3 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation | (43.4) | (8.9) | (8.1) | (60.4) |
| &nbsp;&nbsp;&nbsp;Acquisitions | 483.6 |  |  | 483.6 |
| &nbsp;&nbsp;&nbsp;Measurement period adjustments | 1.8 |  |  | 1.8 |
| &nbsp;&nbsp;&nbsp;Divestitures |  | (11.6) |  | (11.6) |
| Balance at December 31, 2024 | 2126.7 | 764.5 | 360.5 | 3251.7 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation | 88.0 | 16.5 | 16.3 | 120.8 |
| &nbsp;&nbsp;&nbsp;Acquisitions | 37.0 |  |  | 37.0 |
| &nbsp;&nbsp;&nbsp;Measurement period adjustments | 5.0 |  |  | 5.0 |
| Balance at December 31, 2025 | $2256.7 | $781.0 | $376.8 | $3414.5 |

---

Goodwill represents the purchase price in excess of the net amount assigned to the assets acquired and liabilities assumed and was tested for impairment at each of the Company's reporting units as determined in accordance with ASC 350 as of October 31, 2025, the Company's annual impairment test date, with no impairment noted. In assessing the fair value of the reporting units, the Company considers both the market approach and the income approach. Under the market approach, the fair value of the reporting unit is determined by the respective trailing 12 month earnings before interest, income taxes, depreciation and amortization ("EBITDA") and the forward looking 2026 EBITDA (50% each), based on multiples of comparable public companies. The market approach is dependent on a number of significant management assumptions including forecasted EBITDA and selected market multiples. Under the income approach, the fair value of the reporting unit is determined based on the present value of estimated future cash flows. The income approach is dependent on a number of significant management assumptions including estimates of operating results, capital expenditures, net working capital requirements, long-term growth rates and discount rates. Weighting was equally attributed to both the market and the income approaches (50% each) in arriving at the fair value of the reporting units. In 2025 and 2024, there were no events or circumstances that would have required an interim impairment test.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at December 31, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2025** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
| | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net** | **Gross<br>Carrying<br>Amount** | **Accumulated<br>Amortization** | **Net** |
| Amortized intangible assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Trade names | 209.7 | (71.4) | 138.3 | 201.4 | (60.0) | 141.4 |
| &nbsp;&nbsp;&nbsp;Customer relationships | 1148.4 | (380.9) | 767.5 | 1078.8 | (278.7) | 800.1 |
| &nbsp;&nbsp;Technology<sup>(1)</sup> | 344.3 | (102.3) | 242.0 | 327.9 | (87.1) | 240.8 |
| &nbsp;&nbsp;&nbsp;Software | 16.0 | (7.3) | 8.7 | 15.2 | (3.6) | 11.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total amortized intangible assets | 1718.4 | (561.9) | 1156.5 | 1623.3 | (429.4) | 1193.9 |
| Indefinite-lived intangible assets: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Banjo trade name | 62.1 |  | 62.1 | 62.1 |  | 62.1 |
| &nbsp;&nbsp;&nbsp;Akron Brass trade name | 28.8 |  | 28.8 | 28.8 |  | 28.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total intangible assets | $1809.3 | $(561.9) | $1247.4 | $1714.2 | $(429.4) | $1284.8 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) In the third quarter of 2025, the Company revised its classification of intangible assets to combine patents and unpatented technology into a single category. This change was made to better reflect the integrated nature of the Company's intellectual property portfolio. The gross carrying amount and accumulated amortization for patents as of December 31, 2024 of $2.5 million and $2.0 million, respectively, have been reclassified to conform to the current period presentation. The change had no impact on total intangible assets or amortization expense.

The Banjo and Akron Brass trade names are indefinite-lived intangible assets that were also tested for impairment as of October 31, 2025, with no impairments noted. These indefinite-lived intangible assets are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the assets might be impaired. The Company uses the relief-from-royalty method, a form of the income approach, to determine the fair value of these trade names. The relief-from-royalty method is dependent on a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates. In 2025 and 2024, there were no events or circumstances that would have required an interim impairment test.

Amortization of intangible assets was $130.7 million, $107.1 million and $94.9 million in 2025, 2024 and 2023, respectively. Based on the intangible asset balances as of December 31, 2025, expected amortization expense for the years 2026 through 2030 is as follows:

---

| | |
|:---|:---|
| | **Estimated Amortization** |
| 2026 | $133.5 |
| 2027 | 128.7 |
| 2028 | 125.9 |
| 2029 | 115.7 |
| 2030 | 106.5 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**7. Borrowings**

Borrowings at December 31, 2025 and 2024 consisted of the following:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| 3.37% Senior Notes, due June 2025 (the "3.37% Senior Notes") | $— | $100 |
| 5.13% Senior Notes, due June 2028 (the "5.13% Senior Notes") | 100.0 | 100.0 |
| 4.950% Senior Notes, due September 2029 (the "4.950% Senior Notes") | 500.0 | 500.0 |
| 3.00% Senior Notes, due May 2030 (the "3.00% Senior Notes") | 500.0 | 500.0 |
| 2.625% Senior Notes, due June 2031 (the "2.625% Senior Notes") | 500.0 | 500.0 |
| $800.0 million Revolving Facility, due November 2027 (the "Revolving Facility") | 228.8 | 269.8 |
| Other borrowings | 1.0 | 1.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total borrowings | 1829.8 | 1971.3 |
| Less: current portion | 0.7 | 100.7 |
| Less: unamortized debt issuance costs and discount on debt | 9.0 | 11.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term borrowings | $1820.1 | $1859.5 |

---

*Revolving Facility and Term Facility*

On November 1, 2022, the Company entered into an amended and restated credit agreement (as amended and restated, the "Credit Agreement") along with certain of its subsidiaries, as borrowers (the "Borrowers"), Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, and other agents party thereto. The Credit Agreement consists of a revolving credit facility in an aggregate principal amount of $800 million and a term credit facility available to the Company in an aggregate principal amount of $200 million (the "Term Facility"), both of which have a final maturity date of November 1, 2027. The maturity date of the Revolving Facility may be extended under certain conditions for an additional one-year term. Up to $100 million of the Revolving Facility is available for the issuance of letters of credit. Additionally, up to $50 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.

Proceeds of the Revolving Facility are available for use by the Borrowers for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries and financing of acquisitions. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments pursuant to such increases may not exceed $400 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement. During 2025, the Company drew down an aggregate amount of $252.0 million under the Revolving Facility. A portion of these funds as well as cash on hand were used to repay the 3.37% Senior Notes upon their maturity in June 2025. Additionally, these funds were used to finance the Company's acquisition of Micro-LAM and to finance share repurchases. The Company repaid $322.9 million under the Revolving Facility during 2025.

Borrowings under the Credit Agreement bear interest, at either an alternate base rate or Term SOFR (or appropriate alternative currency reference rates) plus, in each case, an applicable margin. Such applicable margin is based on the better of the Company's senior, unsecured, long-term debt rating or the Company's applicable leverage ratio and can range from 0.00% to 1.275%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of Term SOFR loans, on the last day of the applicable interest period selected, or every three months from the effective date of such interest period for interest periods exceeding three months. The weighted-average interest rate for borrowings outstanding under the Revolving Facility was 3.55% and 4.46% for the years ended December 31, 2025 and 2024, respectively. The weighted-average interest rate for borrowings outstanding under the Term Facility was 6.54% for the year ended December 31, 2024. There were no borrowings outstanding under the Term Facility during the year ended December 31, 2025.

The Credit Agreement requires payment to the lenders of a facility fee based upon the amount of the lenders' commitments under the credit facility from time to time, equal to the applicable interest rate times the actual daily amount of the Revolving Facility. Voluntary prepayments of any loans and voluntary reductions of the unutilized portion of the commitments under the credit facility are permissible without penalty, subject to break funding payments and minimum notice and minimum reduction amount requirements.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The Credit Agreement gives the Company the option to enter into a future environmental, social and governance amendment by which pricing may be adjusted pursuant to the Company's performance measured against certain key performance indicators agreed by the Company and BofA Securities, Inc., as sustainability coordinator.

At December 31, 2025, there was $228.8 million outstanding under the Revolving Facility and $2.6 million of outstanding letters of credit, resulting in a net available borrowing capacity under the Revolving Facility of approximately $568.6 million. Subsequent to December 31, 2025, the Company had net borrowings on the Revolving Facility of $58.2 million.

*Senior Notes*

At December 31, 2025, the Company has $1.6 billion in senior notes outstanding at various interest rates detailed in the table above (the "Senior Notes"). Interest is payable semi-annually in arrears during the second and fourth quarters of the year for all the Senior Notes except for the 4.950% Senior Notes, which is payable semi-annually in arrears during the first and third quarters of the year. The Senior Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company's other unsecured, unsubordinated debt. Subject to the terms of the respective indenture, the Company may redeem all or a portion of the Senior Notes at any time prior to maturity at the redemption prices set forth in each indenture governing the respective Senior Notes. The terms of the Senior Notes also require the Company to make an offer to repurchase the respective notes upon a change of control event at a defined price (both of which are defined within each indenture governing the respective Senior Notes).

*Covenants*

There are two key financial covenants that the Company is required to maintain in connection with the Credit Agreement and the Senior Notes, excluding the 4.950% Senior Notes, the 3.00% Senior Notes and the 2.625% Senior Notes which have no financial covenants. Those two covenants include a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.50 to 1, which is the ratio of the Company's consolidated total debt to its consolidated EBITDA, as defined within the Credit Agreement, both of which are tested quarterly and in the case of the leverage ratio, there is an option to increase the ratio to 4.00 for 12 months in connection with certain acquisitions. While there are no financial covenants relating to the 4.950% Senior Notes, the 3.00% Senior Notes and the 2.625% Senior Notes, they are subject to cross-acceleration provisions.

Total borrowings at December 31, 2025 have scheduled maturities as follows:

---

| | |
|:---|:---|
| **Maturity of Borrowings** | |
| 2026 | $0.7 |
| 2027 | 229.1 |
| 2028 | 100.0 |
| 2029 | 500.0 |
| 2030 | 500.0 |
| Thereafter | 500.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total borrowings | $1829.8 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**8. Fair Value Measurements**

ASC 820, *Fair Value Measurements and Disclosures,* defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

The following table summarizes the basis used to measure the Company's financial assets (liabilities) at fair value on a recurring basis in the balance sheets at December 31, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets |  |  |  |  |
| &nbsp;&nbsp;Trading securities - mutual funds held in nonqualified SERP<sup>(1)</sup> | $10.8 | $— | $— | $10.8 |
| Liabilities |  |  |  |  |
| &nbsp;&nbsp;Contingent consideration<sup>(2)</sup> | $— | $— | $1.2 | $1.2 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets |  |  |  |  |
| &nbsp;&nbsp;Trading securities - mutual funds held in nonqualified SERP<sup>(1)</sup> | $10.6 | $— | $— | $10.6 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> The Supplemental Executive Retirement Plan ("SERP") investment assets are offset by a SERP liability which represents the Company's obligation to distribute SERP funds to participants. The SERP investment assets and liability are included in Other noncurrent assets and Other noncurrent liabilities, respectively, on the Company's Consolidated Balance Sheets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> In connection with the acquisition of Micro-LAM, the Company entered into an earnout agreement that may require it to make future cash consideration payments of up to $12.0 million based upon the achievement of certain financial performance targets from January 1, 2026 to December 31, 2027. As of December 31, 2025, $1.2 million of contingent consideration related to the Micro-LAM acquisition is included in Other noncurrent liabilities on the Company's Consolidated Balance Sheets and was derived using a Monte Carlo simulation model which utilizes inputs including discount rates, volatility rates, and estimated probability of achieving projected revenue and profitability targets. This fair value measurement of contingent consideration is categorized within Level 3 of the fair value hierarchy, as the measurement amount is based primarily on significant inputs that are not observable in the market. The fair value of the contingent consideration is re-measured at each reporting period, and the change in fair value is recognized within Selling, general and administrative expenses in the Company's Consolidated Statements of Income. There was no change in the fair value measurement of contingent consideration during 2025.

There were no transfers of assets or liabilities between Level 1, Level 2 and Level 3 in 2025 or 2024.

The carrying values of the Company's other financial instruments (i.e., cash and cash equivalents, accounts receivable, accounts payable and accrued expenses) approximate fair value because of the short-term nature of these instruments.

Certain non-financial assets, primarily property, plant and equipment, goodwill and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets. See <u>[Note](#ibaf335d4459d4d2499897b1ecd08d11c_115)[6](#ibaf335d4459d4d2499897b1ecd08d11c_115)</u>, "Goodwill and Intangible Assets," for additional information about these assets.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following table provides the fair value of the outstanding indebtedness described in <u>[Note 7](#ibaf335d4459d4d2499897b1ecd08d11c_118)</u>, "Borrowings," which is based on quoted market prices and current market rates for debt with similar credit risk and maturity, as well as the carrying value. These fair value measurements are classified as Level 2 within the fair value hierarchy since they are determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to the Company's rating.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** |
| | **Fair Value** | **Carrying Amount** | **Fair Value** | **Carrying Amount** |
| Total Borrowings, less unaccreted debt discount | $1773.9 | $1828.8 | $1855.0 | $1970.1 |

---

**9. Leases**

The Company has commitments under operating leases for certain office facilities, warehouses, manufacturing plants, equipment (which includes both office and plant equipment) and vehicles used in its operations. Leases with an initial term of 12 months or less are not recorded on the balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company's finance leases are immaterial.

Certain leases include one or more options to renew. The exercise of lease renewal options is at the Company's sole discretion. The Company does not include renewal periods in any of the leases' terms until the renewal is executed as they are generally not reasonably certain of being exercised. The Company does not have any material purchase options.

Certain of the Company's lease agreements contain provisions for future rent increases or have rental payments that are adjusted periodically for inflation or based on usage. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The Company does not have any significant leases that have not yet commenced.

Supplemental balance sheet information related to leases as of December 31, 2025 and 2024 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Balance Sheet Caption** | **December 31, 2025** | **December 31, 2024** |
| **Right-of-Use ("ROU") Assets:** | | | |
| &nbsp;&nbsp;&nbsp;Building ROU assets - net | Other noncurrent assets | $109.5 | $114.4 |
| &nbsp;&nbsp;&nbsp;Equipment ROU assets - net | Other noncurrent assets | 10.2 | 10.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total ROU assets - net |  | $119.7 | $125.2 |
| **Lease Liabilities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Current lease liabilities | Accrued expenses | $27.8 | $26.1 |
| &nbsp;&nbsp;&nbsp;Noncurrent lease liabilities | Other noncurrent liabilities | 94.1 | 101.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities |  | $121.9 | $127.7 |

---

The components of lease cost for the years ended December 31, 2025, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Fixed lease cost<sup>(1)</sup> | $36.6 | $34.7 | $33.0 |
| Variable lease cost | 4.2 | 3.1 | 2.7 |
| &nbsp;&nbsp;&nbsp;Total lease expense | $40.8 | $37.8 | $35.7 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Includes short-term leases, which are immaterial.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Supplemental cash flow information related to leases for the years ended December 31, 2025, 2024 and 2023 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Cash paid for amounts included in the measurement of lease liabilities | $33.1 | $34.6 | $33.6 |
| Right-of-use assets obtained in exchange for new lease liabilities | 17.4 | 19.1 | 29.0 |

---

Other supplemental information related to leases as of December 31, 2025 and 2024 was as follows:

---

| | | |
|:---|:---|:---|
| **Lease Term and Discount Rate** | **December 31, 2025** | **December 31, 2024** |
| Weighted-average remaining lease term (years): |  |  |
| &nbsp;&nbsp;&nbsp;Building and equipment | 5.71 | 6.40 |
| &nbsp;&nbsp;&nbsp;Vehicles | 2.64 | 2.69 |
| Weighted-average discount rate: |  |  |
| &nbsp;&nbsp;&nbsp;Building and equipment | 4.19% | 4.07% |
| &nbsp;&nbsp;&nbsp;Vehicles | 4.47% | 4.35% |

---

The Company uses its incremental borrowing rate to determine the present value of the lease payments.

Total lease liabilities at December 31, 2025 have scheduled maturities as follows:

---

| | |
|:---|:---|
| **Maturity of Lease Liabilities** | |
| 2026 | $29.1 |
| 2027 | 27.7 |
| 2028 | 23.2 |
| 2029 | 17.7 |
| 2030 | 12.2 |
| Thereafter | 27.3 |
| &nbsp;&nbsp;&nbsp;Total lease payments | 137.2 |
| Less: Imputed interest | (15.3) |
| &nbsp;&nbsp;&nbsp;Present value of lease liabilities | $121.9 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**10. Commitments and Contingencies**

Warranty costs are provided for at the time of sale. The warranty provision is based on historical costs and adjusted for specific known claims. A rollforward of the warranty reserve is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Beginning balance, January 1 | $13.6 | $9.1 | $8.1 |
| &nbsp;&nbsp;&nbsp;Provision for warranties | 8.2 | 5.1 | 5.8 |
| &nbsp;&nbsp;&nbsp;Claim settlements | (13.8) | (4.1) | (4.7) |
| &nbsp;&nbsp;Acquisitions and divestitures | 6.2 | 3.6 | (0.1) |
| &nbsp;&nbsp;Other adjustments, including foreign currency translation | 0.2 | (0.1) |  |
| Ending balance, December 31 | $14.4 | $13.6 | $9.1 |

---

The Company and certain of its subsidiaries are involved in pending and threatened legal, regulatory and other proceedings incidental to the operations of their businesses. These proceedings may pertain to matters such as product liability or contract disputes, and may also involve governmental inquiries, inspections, audits or investigations relating to issues such as tax matters, intellectual property, environmental, health and safety issues, governmental regulations, employment and other matters. Although the results of such legal proceedings cannot be predicted with certainty, the Company believes that the ultimate disposition of these matters will not have a material adverse effect, individually or in the aggregate, on the Company's business, financial condition, results of operations or cash flows.

**11. Share Repurchases**

On September 17, 2025, the Company's Board of Directors authorized the repurchase of an additional $635.0 million of the Company's common shares. This approval is in addition to the prior repurchase authorization of the Company's Board of Directors of $500.0 million on March 17, 2020. These authorizations have no expiration date. During 2025, the Company repurchased a total of 1.4 million shares at a cost of $252.4 million (which includes estimated excise taxes of $2.4 million which will be paid in 2026), of which $2.2 million was settled in January 2026. There were no share repurchases during 2024. During 2023, the Company repurchased a total of 0.1 million shares at a cost of $24.2 million. As of December 31, 2025, the amount of share repurchase authorization remaining was $924.7 million, excluding fees, commissions, excise taxes and other expenses related to such common stock repurchases. Subsequent to December 31, 2025, the Company repurchased 0.2 million shares at a cost of $38.1 million.

**12. Income Taxes**

Pretax income for 2025, 2024 and 2023 was taxed in the following jurisdictions:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| U.S. | $375.5 | $377.9 | $534.1 |
| Foreign | 257.1 | 261.4 | 226.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $632.6 | $639.3 | $760.3 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The provision (benefit) for income taxes for 2025, 2024 and 2023 was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| Current |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. | $47.4 | $69.0 | $103.8 |
| &nbsp;&nbsp;&nbsp;State and local | 10.9 | 11.6 | 13.7 |
| &nbsp;&nbsp;&nbsp;Foreign | 79.0 | 73.5 | 61.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current | 137.3 | 154.1 | 179.4 |
| Deferred |  |  |  |
| &nbsp;&nbsp;&nbsp;U.S. | 26.1 | (2.6) | (11.1) |
| &nbsp;&nbsp;&nbsp;State and local | 1.9 | (2.1) | 1.7 |
| &nbsp;&nbsp;&nbsp;Foreign | (15.2) | (14.7) | (5.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred | 12.8 | (19.4) | (14.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total provision for income taxes | $150.1 | $134.7 | $164.7 |

---

Deferred tax assets (liabilities) at December 31, 2025 and 2024 were:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| Allowances and accruals | $23.7 | $21.7 |
| Employee and retiree benefit plans | 19.8 | 19.4 |
| Inventories | 17.3 | 13.9 |
| Foreign tax credit and other carryforwards | 30.4 | 20.8 |
| Lease liabilities | 27.8 | 26.4 |
| Right of use assets | (26.7) | (25.1) |
| Depreciation and amortization | (353.8) | (311.6) |
| Taxes on undistributed foreign earnings | (17.4) | (14.9) |
| Other | 0.8 | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross deferred tax liabilities | (278.1) | (248.4) |
| Valuation allowance | (23.7) | (17.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax liabilities, net of valuation allowances | $(301.8) | $(265.7) |

---

The deferred tax assets and liabilities recognized in the Company's Consolidated Balance Sheets as of December 31, 2025 and 2024 were:

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| Noncurrent deferred tax asset - Other noncurrent assets | $1.2 | $1.5 |
| Noncurrent deferred tax liabilities - Deferred income taxes | (303.0) | (267.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net deferred tax liabilities | $(301.8) | $(265.7) |

---

The Company had prepaid income taxes, recorded within Other current assets on the Consolidated Balance Sheets, of $20.2 million and $18.3 million as of December 31, 2025 and 2024, respectively.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

As further described in <u>[Note](#ibaf335d4459d4d2499897b1ecd08d11c_100)[1](#ibaf335d4459d4d2499897b1ecd08d11c_100)</u>, "Significant Accounting Policies," the Company has elected to prospectively adopt the guidance in ASU 2023-09, *Improvements to Income Tax Disclosures*. The following table shows the principal reasons for the difference between the effective income tax rate and the statutory federal income tax rate for the year ended December 31, 2025 in accordance with ASU 2023-09:

---

| | | |
|:---|:---|:---|
| | **2025** | **2025** |
| U.S. Federal statutory tax rate | $132.8 | *21.0 %* |
| State and local income taxes, net of federal income tax effect<sup>(1)</sup> | 10.1 | *1.6 %* |
| Foreign tax effects | 11.0 | *1.7 %* |
| Effect of cross-border tax laws | 2.6 | *0.4 %* |
| Tax credits |  |  |
| &nbsp;&nbsp;Foreign tax credit<sup>(2)</sup> | (10.4) | *(1.6 %)* |
| &nbsp;&nbsp;Other | (3.8) | *(0.6 %)* |
| Changes in valuation allowances<sup>(2)</sup> | 4.5 | *0.7 %* |
| Nontaxable or nondeductible items | 3.4 | *0.5 %* |
| Changes in unrecognized tax benefits | 0.4 | *0.1 %* |
| Other adjustments | (0.5) | *(0.1 %)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Total provision for income taxes | $150.1 | *23.7 %* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> The states that contribute to the majority (greater than 50%) of the tax effect in this category include California, Florida and Illinois.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> During 2025, the Company recorded an additional deferred tax asset for a foreign tax credit carryforward of $4.4 million with a full valuation allowance.

The following table is a reconciliation of the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2024 and 2023 in accordance with U.S. GAAP prior to the adoption of ASU 2023-09:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2024** | **2024** | **2023** | **2023** |
| Pretax income | $639.3 |  | $760.3 |  |
| Provision for income taxes: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Computed amount at statutory rate of 21% | $134.2 | *21.0 %* | $159.7 | *21.0 %* |
| &nbsp;&nbsp;&nbsp;State and local income tax, net of federal tax benefit | 7.3 | *1.1 %* | 12.6 | *1.7 %* |
| &nbsp;&nbsp;&nbsp;Taxes on non-U.S. earnings, net of foreign tax credits | 6.3 | *1.0 %* | 10.8 | *1.4 %* |
| &nbsp;&nbsp;&nbsp;Foreign-Derived Intangible Income Deduction | (9.7) | *(1.5 %)* | (11.3) | *(1.5 %)* |
| &nbsp;&nbsp;&nbsp;Share-based payments | (0.7) | *(0.1 %)* | (2.0) | *(0.3 %)* |
| &nbsp;&nbsp;&nbsp;Other | (2.7) | *(0.4 %)* | (5.1) | *(0.6 %)* |
| &nbsp;&nbsp;&nbsp;&nbsp;Total provision for income taxes | $134.7 | *21.1 %* | $164.7 | *21.7 %* |

---

The Company has $90.2 million and $73.4 million of permanently reinvested earnings of non-U.S. subsidiaries as of December 31, 2025 and 2024, respectively. No deferred U.S. income taxes have been provided on the $90.2 million of earnings that are considered to be permanently reinvested. The Company does not expect these earnings to incur U.S. taxes when ultimately repatriated other than potentially U.S. federal, state and local taxes on foreign exchange gains or losses recognized on the distribution of such earnings. Such distributions could also be subject to additional foreign withholding and foreign income taxes. The amount of unrecognized deferred income tax liabilities on currently permanently reinvested earnings is estimated to be $13.5 million and $11.0 million as of December 31, 2025 and 2024, respectively.

During the years ended December 31, 2025, 2024 and 2023, the Company repatriated $79.8 million, $483.8 million and $134.1 million of foreign earnings, respectively. These actual distributions resulted in no incremental income tax expense other than tax impacts on foreign exchange gains or losses.

As of December 31, 2025, the Company had an unrecognized tax benefit of $0.3 million, resulting from a gross increase for tax positions of prior years. The Company did not have any significant unrecognized tax benefits in 2024 and 2023. The Company recognizes interest and penalties related to uncertain tax positions within Provision for income taxes in the

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Consolidated Statements of Income. As of December 31, 2025, the Company accrued interest and penalties of less than $0.2 million related to uncertain tax positions.

As of December 31, 2025, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate if recognized is $0.3 million. The tax years 2020-2025 remain open to examination by major taxing jurisdictions.

As of December 31, 2025, the Company has deferred tax assets on U.S., non-U.S. and U.S. state net operating loss carryforwards of $2.5 million, $1.0 million and $0.9 million, respectively. The majority of the balance of net operating losses across jurisdictions, most of which relates to acquisitions, is available to be carried forward indefinitely. The deferred tax assets on the non-U.S. net operating losses have a valuation allowance of $0.9 million. There is no valuation allowance on the U.S. and U.S. state net operating loss carryforward as it is more likely than not that the net operating losses will be realized.

As of December 31, 2025, the Company has deferred tax assets on non-U.S. capital loss carryforwards of $3.8 million with a full valuation allowance. The non-U.S. capital loss can be carried forward indefinitely.

As of December 31, 2025, the Company has deferred tax assets on non-U.S. disallowed interest expense carryforwards of $3.5 million. The non-U.S. disallowed interest expense carryforwards are available to be carried forward indefinitely. A valuation allowance of $0.7 million has been recorded to recognize only the portion of the deferred tax asset that is more likely than not to be realized.

As of December 31, 2025, the Company has deferred tax assets on foreign tax credit carryforwards for U.S. federal tax purposes of approximately $17.9 million with a full valuation allowance. The U.S. federal foreign tax credit carryforward will expire between 2029 and 2035.

Disclosed below is a summary of income taxes paid by jurisdiction for the year ended December 31, 2025, in accordance with ASU 2023-09:

---

| | |
|:---|:---|
| | **2025** |
| Federal | $46.8 |
| State | 11.1 |
| Foreign |  |
| &nbsp;&nbsp;China | 8.5 |
| &nbsp;&nbsp;Germany | 23.7 |
| &nbsp;&nbsp;India | 6.9 |
| &nbsp;&nbsp;Netherlands | 12.7 |
| &nbsp;&nbsp;All other foreign | 24.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid, net of amounts refunded | $134.6 |

---

For the years ended December 31, 2024 and 2023, the Company paid income taxes, net of refunds, of $171.4 million and $199.5 million, respectively.

**13. Business Segments and Geographic Information**

IDEX has three operating business segments, which are the same as our reportable business segments: HST, FMT and FSDP. The Company has determined its segments based on how financial information is reviewed by the chief operating decision maker ("CODM") to analyze financial performance, make decisions and allocate resources.

The Company's CODM is the Chief Executive Officer. The Company's CODM evaluates the performance of the segments and allocates resources to them based on Adjusted EBITDA. Segment Adjusted EBITDA includes intersegment revenues as well as charges allocating certain corporate overhead costs. Intersegment sales are contracted with terms equivalent to those of an arm's-length transaction. Adjusted EBITDA is the Company's measure of segment performance.

For all segments, the CODM uses Adjusted EBITDA in the annual budgeting and forecasting process. The CODM considers Adjusted EBITDA budget and forecast-to-actual variances when making decisions about the allocation of operating and capital resources to each segment. Adjusted EBITDA is also used in determining the compensation of certain employees.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The HST segment designs, produces and distributes a wide range of precision fluidics, positive displacement pumps, powder and liquid processing technologies, drying systems, micro-precision components, pneumatic components and sealing solutions, high performance molded and extruded sealing components, custom mechanical and shaft seals, engineered hygienic mixers and valves, biocompatible medical devices and implantables, air compressors and blowers, optical components and coatings, ultra-precision diamond tools, laboratory and commercial equipment and precision photonic solutions, technical ceramics and hermetic sealing products and porous material structures and flow control solutions. HST primarily serves a variety of end markets, including life sciences, industrial, semiconductor, energy, space and defense and food and beverage.

The FMT segment designs, produces and distributes positive displacement pumps, valves, small volume provers, flow meters, injectors and other fluid-handling pump modules and systems and provides flow monitoring and other services. FMT primarily serves the industrial, water, energy, chemical and agriculture markets.

The FSDP segment designs, produces and distributes firefighting pumps, valves and controls, rescue tools, lifting bags and other components and systems, engineered stainless steel banding and clamping devices and precision equipment for dispensing, metering and mixing colorants and paints. FSDP primarily serves the fire suppression, paint dispensing, rescue tools, automotive and aviation and industrial markets.

Financial information for the Company's reportable business segments is presented below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** | **For the Year Ended December 31, 2025** |
| | **HST** | **FMT** | **FSDP** | **Total Segments** | **Eliminations** | **IDEX** |
| NET SALES |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;External customers | $1490.7 | $1222.5 | $744.3 | $3457.5 | $— | $3457.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment sales | 4.8 | 1.5 | 1.0 | 7.3 | (7.3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net sales | 1495.5 | 1224.0 | 745.3 | 3464.8 | (7.3) | 3457.5 |
| Adjusted segment cost of sales<sup>(1)</sup> | (885.5) | (622.8) | (417.1) | (1925.4) | 7.3 | (1918.1) |
| Other segment expenses<sup>(2)</sup> | (212.2) | (194.4) | (114.7) | (521.3) |  |  |
| Segment Adjusted EBITDA | 397.8 | 406.8 | 213.5 | 1018.1 |  |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** | **For the Year Ended December 31, 2024** |
| | **HST** | **FMT** | **FSDP** | **Total Segments** | **Eliminations** | **IDEX** |
| NET SALES |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;External customers | $1294.0 | $1231.8 | $743.0 | $3268.8 | $— | $3268.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment sales | 4.1 | 1.4 | 1.3 | 6.8 | (6.8) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net sales | 1298.1 | 1233.2 | 744.3 | 3275.6 | (6.8) | 3268.8 |
| Adjusted segment cost of sales<sup>(1)</sup> | (769.5) | (639.4) | (411.9) | (1820.8) | 6.8 | (1814.0) |
| Other segment expenses<sup>(2)</sup> | (181.8) | (187.5) | (118.2) | (487.5) |  |  |
| Segment Adjusted EBITDA | 346.8 | 406.3 | 214.2 | 967.3 |  |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** | **For the Year Ended December 31, 2023** |
| | **HST** | **FMT** | **FSDP** | **Total Segments** | **Eliminations** | **IDEX** |
| NET SALES |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;External customers | $1313.5 | $1244.2 | $716.2 | $3273.9 | $— | $3273.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intersegment sales | 2.9 | 2.9 | 2.6 | 8.4 | (8.4) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Net sales | 1316.4 | 1247.1 | 718.8 | 3282.3 | (8.4) | 3273.9 |
| Adjusted segment cost of sales<sup>(1)</sup> | (783.1) | (650.1) | (400.6) | (1833.8) | 8.4 | (1825.4) |
| Other segment expenses<sup>(2)</sup> | (173.8) | (180.9) | (109.6) | (464.3) |  |  |
| Segment Adjusted EBITDA | 359.5 | 416.1 | 208.6 | 984.2 |  |  |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Adjusted segment cost of sales represents Cost of sales excluding fair value inventory step-up charges. There were step-up charges of $0.6 million, $9.6 million, and $1.6 million recorded during the years ended December 31, 2025, 2024 and 2023, respectively. All step-up charges were recorded within the HST segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> Other segment expenses consists primarily of selling, general and administrative expenses.

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| ADJUSTED EBITDA |  |  |  |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | $397.8 | $346.8 | $359.5 |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 406.8 | 406.3 | 416.1 |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 213.5 | 214.2 | 208.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Segment Adjusted EBITDA | 1018.1 | 967.3 | 984.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate and other<sup>(1)</sup> | (92.2) | (93.0) | (84.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense - net | (64.4) | (44.5) | (51.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | (75.8) | (68.5) | (57.2) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | (130.7) | (107.1) | (94.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value inventory step-up charges | (0.6) | (9.6) | (1.6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring expenses and asset impairments | (20.7) | (9.3) | (10.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of businesses - net |  | 4.0 | 84.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on sale of assets | (1.1) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credit loss on note receivable from collaborative partner<sup>(2)</sup> |  |  | (7.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes | $632.6 | $639.3 | $760.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Corporate expenses that can be identified with a segment have been included in determining segment results. The remainder is included in Corporate and other.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> Represents a reserve recorded on an investment with a collaborative partner in Other expense (income) – net during 2023. During the fourth quarter of 2023, the Company converted the promissory note receivable from the collaborative partner to equity, resulting in a cost method investment with zero value. See <u>[Note 3](#ibaf335d4459d4d2499897b1ecd08d11c_106)</u>, "Collaborative Investments," for further detail.

---

| | | | |
|:---|:---|:---|:---|
| | **2025** | **2024** | **2023** |
| DEPRECIATION |  |  |  |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | $47.9 | $41.2 | $33.2 |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 17.9 | 17.3 | 14.1 |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 9.2 | 9.0 | 8.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Segments | 75.0 | 67.5 | 56.2 |
| &nbsp;&nbsp;&nbsp;Corporate and other | 0.8 | 1.0 | 1.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total depreciation | $75.8 | $68.5 | $57.2 |
| AMORTIZATION OF INTANGIBLE ASSETS |  |  |  |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | $103.7 | $79.7 | $65.8 |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 21.6 | 21.1 | 22.7 |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 5.4 | 6.3 | 6.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total amortization | $130.7 | $107.1 | $94.9 |
| CAPITAL EXPENDITURES |  |  |  |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | $32.9 | $40.1 | $55.1 |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 21.3 | 14.8 | 24.2 |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 8.9 | 10.2 | 9.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Segments | 63.1 | 65.1 | 89.0 |
| &nbsp;&nbsp;&nbsp;Corporate and other | 0.5 |  | 0.9 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total capital expenditures | $63.6 | $65.1 | $89.9 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| ASSETS |  |  |
| &nbsp;&nbsp;&nbsp;Health & Science Technologies | $4301.1 | $4142.6 |
| &nbsp;&nbsp;&nbsp;Fluid & Metering Technologies | 1694.4 | 1609.4 |
| &nbsp;&nbsp;&nbsp;Fire & Safety/Diversified Products | 825.2 | 794.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Segments | 6820.7 | 6546.1 |
| &nbsp;&nbsp;&nbsp;Corporate and other | 106.3 | 199.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $6927.0 | $6745.3 |

---

Information about the Company's long-lived assets in different geographical regions as of December 31, 2025 and 2024 is shown below.

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| LONG-LIVED ASSETS — PROPERTY, PLANT AND EQUIPMENT |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. | $273.6 | $271.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;North America, excluding U.S. | 19.2 | 20.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Netherlands | 50.2 | 51.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe, excluding Netherlands | 83.6 | 71.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asia | 41.1 | 44.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other<sup>(1)</sup> | 0.3 | 0.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-lived assets - net | $468.0 | $460.4 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Other includes: South America, Middle East, Australia and Africa.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**14. Restructuring Expenses and Asset Impairments**

Restructuring expenses generally represent expenses incurred by the Company to facilitate long-term sustainable growth through cost reduction actions, consisting of employee reductions, facility rationalization and contract termination costs. These costs include severance costs, exit costs and asset impairments and are included in Restructuring expenses and asset impairments in the Consolidated Statements of Income. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs, employer tax liabilities and related legal costs, while exit costs primarily consist of lease exit and contract termination costs.

*2025 Initiative*

In January 2025, the Company initiated restructuring actions designed with the focus of connecting scalable groups of businesses, which resulted in a reduction of headcount. Additionally, the Company eliminated certain management layers in select areas. These changes are expected to enable the Company to self-fund more growth resources, increase sourcing productivity, improve agility and speed of decision making and position the Company closer to the customer for maximum impact. These actions, which have primarily resulted in recognizing severance costs related to employee reductions, have been substantially completed during 2025.

Pre-tax Restructuring expenses and asset impairments by segment for the 2025 initiative were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Severance Costs** | **Exit Costs** | **Asset Impairments** | **Total** |
| Health & Science Technologies | $11.8 | $0.1 | $0.6 | $12.5 |
| Fluid & Metering Technologies | 4.9 |  | 0.1 | 5.0 |
| Fire & Safety/Diversified Products | 2.4 |  |  | 2.4 |
| Corporate/Other | 0.8 |  |  | 0.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total restructuring costs and asset impairments | $19.9 | $0.1 | $0.7 | $20.7 |

---

*2024 Initiatives*

During the year ended December 31, 2024, the Company incurred severance costs related to employee reductions in conjunction with cost mitigation efforts as a result of market conditions, all of which were substantially completed during 2024.

Pre-tax Restructuring expenses and asset impairments by segment for the 2024 initiative were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Severance Costs** | **Exit Costs** | **Asset Impairments** | **Total** |
| Health & Science Technologies | $5.8 | $— | $0.1 | $5.9 |
| Fluid & Metering Technologies | 2.4 |  |  | 2.4 |
| Fire & Safety/Diversified Products | 0.5 |  |  | 0.5 |
| Corporate/Other | 0.5 |  |  | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total restructuring costs and asset impairments | $9.2 | $— | $0.1 | $9.3 |

---

*2023 Initiatives*

During the year ended December 31, 2023, the Company incurred severance costs related to employee reductions in conjunction with cost mitigation efforts as a result of market conditions, which were substantially completed during 2023, as well as contract termination costs and asset impairments.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

Pre-tax Restructuring expenses and asset impairments by segment for the 2023 initiative were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Severance Costs** | **Exit Costs** | **Asset Impairments** | **Total** |
| Health & Science Technologies | $6.4 | $0.2 | $— | $6.6 |
| Fluid & Metering Technologies | 1.5 | 0.6 | 0.8 | 2.9 |
| Fire & Safety/Diversified Products | 0.7 | 0.2 |  | 0.9 |
| Corporate/Other | 0.5 |  |  | 0.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total restructuring costs and asset impairments | $9.1 | $1.0 | $0.8 | $10.9 |

---

Restructuring accruals reflected in Accrued expenses in the Company's Consolidated Balance Sheets are as follows:

---

| | |
|:---|:---|
| | **Restructuring<br>Initiatives** |
| Balance at January 1, 2024 | $2.1 |
| &nbsp;&nbsp;Restructuring expenses<sup>(1)</sup> | 9.2 |
| &nbsp;&nbsp;&nbsp;Payments, utilization and other | (10.4) |
| Balance at December 31, 2024 | 0.9 |
| &nbsp;&nbsp;Restructuring expenses<sup>(2)</sup> | 19.9 |
| &nbsp;&nbsp;&nbsp;Payments, utilization and other | (17.8) |
| Balance at December 31, 2025 | $3.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Excludes $0.1 million of asset impairments related to property, plant and equipment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> Excludes $0.7 million of asset impairments related to property, plant and equipment and $0.1 million of exit costs.

**15. Share-Based Compensation**

The Company maintains a share-based compensation plan for executives, non-employee directors and certain key employees that authorize the granting of restricted stock, performance share units and stock options and other types of awards consistent with the purpose of the plan. A total of 9.9 million shares of the Company's common stock have been authorized for issuance under the Company's share-based compensation plan. As of December 31, 2025, 9.4 million shares of the Company's common stock were available for future issuance.

The Company typically grants equity awards annually at its regularly scheduled first quarter meeting of the Company's Board of Directors based on the recommendation from the Compensation Committee of the Company's Board of Directors.

*Stock Options*

Stock options granted under the Company's plan are generally non-qualified and are granted with an exercise price equal to the market price of the Company's common stock on the date of grant. The fair value of each option grant in the periods presented was estimated on the date of the grant using the Black Scholes valuation model. Stock options generally vest ratably over four years, with vesting beginning one year from the date of grant, and generally expire 10 years from the date of grant.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The service period for certain retiree eligible participants is accelerated. The assumptions used in determining the fair value of the stock options granted during December 31, 2025, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Weighted average fair value of grants | $46.74 | $63.61 | $59.77 |
| Dividend yield | 1.41% | 1.09% | 1.09% |
| Volatility | 23.06% | 26.66% | 27.14% |
| Risk-free interest rate | 4.28% | 4.31% | 4.15% |
| Expected life (in years) | 4.70 | 4.60 | 4.50 |

---

The assumptions were determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company estimated volatility using its historical share price performance over the expected life of the option.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company uses historical data to estimate the expected life of the option based on IDEX's own exercise and cancellation history adjusted for current vesting schedules.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The risk-free interest rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option. The Company presents the spot rate used in the Black Scholes valuation model.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The expected dividend yield is based on the Company's current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

A summary of the Company's stock option activity as of December 31, 2025, and changes during the year ended December 31, 2025, are presented in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Shares** | **Weighted<br>Average Exercise Price** | **Weighted-Average<br>Remaining<br>Contractual Term<br>(years)** | **Aggregate<br>Intrinsic<br>Value** |
| **<u>Stock Options</u>** | | | | |
| Outstanding at January 1, 2025 | 998856 | $191.96 | 6.63 | $24.9 |
| Granted | 82470 | 196.07 |  |  |
| Exercised | (28408) | 128.86 |  |  |
| Forfeited | (98717) | 212.92 |  |  |
| Outstanding at December 31, 2025 | 954201 | $192.03 | 5.82 | $8.9 |
| Vested and expected to vest at December 31, 2025 | 942815 | $191.69 | 5.79 | $8.9 |
| Exercisable at December 31, 2025 | 671427 | $181.50 | 4.95 | $8.9 |

---

The intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company's common stock as of the end of the period and the grant price. The total intrinsic value of options exercised in 2025, 2024 and 2023 was $1.8 million, $9.6 million and $14.9 million, respectively. In 2025, 2024 and 2023, cash received from options exercised was $3.7 million, $19.4 million and $26.3 million, respectively, while the actual tax benefit realized for the tax deductions from stock options exercised totaled $0.4 million, $2.0 million and $3.1 million, respectively.

As of December 31, 2025, there was $4.5 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.1 years.

*Restricted Stock*

Restricted stock awards generally cliff vest after three years for employees and generally cliff vest after one year for non-employee directors. The service period for certain retiree eligible participants is accelerated. Unvested restricted stock granted after the adoption of the 2024 Incentive Award Plan earn dividend equivalents for the award period, which will be paid to participants upon vesting of the underlying awards. Unvested restricted stock granted prior to the adoption of the 2024 Incentive Award Plan earn and are paid dividends on a current basis. The sale of the shares is restricted prior to the date of vesting. The fair value of restricted stock is equal to the market price of the Company's common stock at the date of the grant. A summary of the Company's restricted stock activity as of December 31, 2025, and changes during the year ended December 31, 2025, are presented in the following table:

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

---

| | | |
|:---|:---|:---|
| **<u>Restricted Stock</u>** | **Shares** | **Weighted-Average<br>Grant Date Fair<br>Value** |
| Unvested at January 1, 2025 | 175991 | $201.27 |
| Granted | 106875 | 191.13 |
| Vested | (64072) | 190.37 |
| Forfeited | (27972) | 205.42 |
| Unvested at December 31, 2025 | 190822 | $198.64 |

---

As of December 31, 2025, there was $14.9 million of total unrecognized compensation cost related to restricted stock that is expected to be recognized over a weighted-average period of 0.9 years.

*Cash-Settled Restricted Stock*

The Company also maintains a cash-settled share-based compensation plan for certain employees. Cash-settled restricted stock awards generally cliff vest after three years. The service period for certain retiree eligible participants is accelerated. Cash-settled restricted stock awards are recorded at fair value on a quarterly basis using the market price of the Company's common stock on the last day of the quarter. At December 31, 2025 and 2024, the Company had accrued $3.6 million and $4.0 million, respectively, for cash-settled restricted stock in Accrued expenses in the Consolidated Balance Sheets and had accrued $2.4 million in both periods for cash-settled restricted stock in Other noncurrent liabilities in the Consolidated Balance Sheets. These recurring fair value measurements are classified as Level 1 in the fair value hierarchy. Dividend equivalents are earned throughout the award period and paid upon vesting for certain cash-settled restricted stock awards granted after the adoption of the 2024 Incentive Award Plan. Dividend equivalents are paid on a current basis on certain cash-settled restricted stock awards granted prior to the adoption of the 2024 Incentive Award Plan. A summary of the Company's unvested cash-settled restricted stock activity as of December 31, 2025, and changes during the year ended December 31, 2025, are presented in the following table:

---

| | | |
|:---|:---|:---|
| **<u>Cash-Settled Restricted Stock</u>** | **Shares** | **Weighted-Average<br>Fair Value** |
| Unvested at January 1, 2025 | 55395 | $209.29 |
| Granted | 32090 | 195.10 |
| Vested | (19131) | 186.52 |
| Forfeited | (6062) | 177.94 |
| Unvested at December 31, 2025 | 62292 | $177.94 |

---

As of December 31, 2025, there was $3.9 million of total unrecognized compensation cost related to cash-settled restricted stock that is expected to be recognized over a weighted-average period of 1.0 year.

*Performance Share Units*

The Company grants performance share units to selected key employees. Performance share unit awards represent rights to receive shares of the Company's common stock and will vest between 0% to 250% of the target share unit amount. Performance share units are expected to be made annually and are paid out at the end of a three-year period following the date of grant, based on the Company's performance, as described below. Performance share units granted in 2025 are earned over a three-year performance period based on an internal income growth metric (a performance condition), weighted 25%, and the total shareholder return of the Company's common stock in relation to the total shareholder return of companies in the S&P 500 Index (a market condition), weighted 75%. Performance share unit awards granted prior to 2025 are earned solely based on the Company's total shareholder return ranking in relation to the total shareholder return of companies in the S&P 500 Index over a three-year period following the date of grant. A target payout of 100% of the market condition portion of the award is earned if total shareholder return is equal to the 50th percentile of the peer group. Performance share units earn dividend equivalents for the award period, which will be paid to participants with the award payout at the end of the period based on the actual number of performance share units that are earned. Payments made at the end of the award period will be in the form of stock for performance share units and will be in cash for dividend equivalents.

The fair value of the performance condition portion of the 2025 awards is equal to the market price of the Company's common stock at the date of the grant, and the amount of expense recognized over the vesting period is subject to adjustment based on the expected attainment of the performance condition. The fair value of the market condition portion of the 2025

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

awards and all awards granted prior to 2025 is determined using a Monte Carlo simulation model, and the amount of expense recognized over the vesting period is not subject to change based on future market conditions.

The assumptions used in the Monte Carlo simulation model to determine the fair value of the market condition portion of the performance share units granted during December 31, 2025, 2024 and 2023 were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Weighted average fair value of grants | $232.44 | $349.59 | $308.18 |
| Dividend yield | —% | —% | —% |
| Volatility | 22.93% | 22.23% | 27.00% |
| Risk-free interest rate | 4.23% | 4.45% | 4.37% |
| Expected life (in years) | 2.94 | 2.94 | 2.94 |

---

The assumptions used in the Monte Carlo simulation model were determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company estimated volatility using its historical share price performance over the remaining performance period as of the grant date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Company uses a Monte Carlo simulation model that uses an expected life commensurate with the performance period. As a result, the expected life of the performance share units was assumed to be the period from the grant date to the end of the performance period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant with a term commensurate with the remaining performance period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total shareholder return is determined assuming that dividends are reinvested in the issuing entity over the performance period, which is mathematically equivalent to utilizing a 0% dividend yield.

A summary of the Company's performance share unit activity as of December 31, 2025, and changes during the year ended December 31, 2025, are presented in the following table:

---

| | | |
|:---|:---|:---|
| **<u>Performance Share Units</u>** | **Shares** | **Weighted-Average<br>Grant Date Fair<br>Value** |
| Unvested at January 1, 2025 | 72825 | $299.87 |
| Granted | 43360 | 216.98 |
| Vested | (15530) | 234.23 |
| Forfeited | (22450) | 264.20 |
| Unvested at December 31, 2025 | 78205 | $267.78 |

---

The performance period for the 2022 grants ended as of January 31, 2025. The 2022 grants achieved a 65% payout factor and the Company issued 15,530 shares of the Company's common stock in February 2025 for awards that vested in 2025. The performance period for the 2023 grants ended as of January 31, 2026. The 2023 grants achieved a 0% payout factor, and as such, the Company did not issue any shares of the Company's stock for awards that vested in 2026.

As of December 31, 2025, there was $2.4 million of total unrecognized compensation cost related to performance share units that is expected to be recognized over a weighted-average period of 1.0 year.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Summary of Share-Based Compensation Expense**

The Company's policy is to recognize compensation cost on a straight-line basis, assuming forfeitures, over the requisite service period for the entire award. Classification of share-based compensation cost within the Consolidated Statements of Income is consistent with the classification of cash compensation for the same employees. Total compensation cost related to all share-based awards was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Stock options expense | $6.1 | $9.8 | $9.9 |
| Restricted stock expense | 15.2 | 8.3 | 5.7 |
| Cash-settled restricted stock expense | 3.2 | 3.4 | 3.4 |
| Performance share units expense | 6.0 | 7.7 | 6.0 |
| Total pre-tax share-based compensation expense<sup>(1)</sup> | 30.5 | 29.2 | 25.0 |
| Income tax benefit | (4.1) | (3.2) | (2.7) |
| Total share-based compensation expense, net of income taxes | $26.4 | $26.0 | $22.3 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Pre-tax compensation cost is recognized in the Company's Consolidated Statements of Income depending on the functional area of the underlying employees, as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Years Ended December 31,** | **Years Ended December 31,** | **Years Ended December 31,** |
| | **2025** | **2024** | **2023** |
| Cost of sales | $1.9 | $1.6 | $1.4 |
| Selling, general and administrative expenses | 29.2 | 27.6 | 23.6 |
| Restructuring expenses and asset impairments<sup>(2)</sup> | (0.6) |  |  |
| Total pre-tax share-based compensation expense | $30.5 | $29.2 | $25.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> During the year ended December 31, 2025, a benefit of $0.6 million was recognized in Restructuring expenses and asset impairments in the Company's Consolidated Statements of Income related to forfeitures of share-based compensation awards resulting from previously announced restructuring actions initiated during the first quarter of 2025.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**16. Accumulated Other Comprehensive Income (Loss)**

The components of Accumulated other comprehensive income (loss) for the years ended December 31, 2025, 2024 and 2023 are as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Cumulative Translation Adjustment** | **Pension and Other Postretirement Adjustments** | **Accumulated Other Comprehensive Income (Loss)** |
| Balance, January 1, 2023<sup>(1)</sup> | $(137.1) | $10.9 | $(126.2) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassification adjustments | 87.8 | (8.2) | 79.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain reclassified from Accumulated other comprehensive loss<sup>(2)(3)</sup> |  | (1.5) | (1.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact |  | 2.3 | 2.3 |
| Net other comprehensive income (loss)<sup>(1)</sup> | 87.8 | (7.4) | 80.4 |
| Balance, December 31, 2023<sup>(1)</sup> | $(49.3) | $3.5 | $(45.8) |
| &nbsp;&nbsp;Other comprehensive (loss) income before reclassification adjustments | (93.7) | 4.8 | (88.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain reclassified from Accumulated other comprehensive loss<sup>(2)(3)</sup> |  | (1.0) | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss reclassified related to divestitures<sup>(4)</sup> | 5.5 |  | 5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact |  | (0.7) | (0.7) |
| Net other comprehensive (loss) income<sup>(1)</sup> | (88.2) | 3.1 | (85.1) |
| Balance, December 31, 2024<sup>(1)</sup> | $(137.5) | $6.6 | $(130.9) |
| &nbsp;&nbsp;Other comprehensive income before reclassification adjustments | 186.3 | 4.3 | 190.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain reclassified from Accumulated other comprehensive loss<sup>(2)(3)</sup> |  | (0.9) | (0.9) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax impact |  | (1.2) | (1.2) |
| Net other comprehensive income<sup>(1)</sup> | 186.3 | 2.2 | 188.5 |
| Balance, December 31, 2025<sup>(1)</sup> | $48.8 | $8.8 | $57.6 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Amounts are presented net of tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(2)</sup> Included in the computation of net periodic cost (benefit). See <u>[Note 17](#ibaf335d4459d4d2499897b1ecd08d11c_148)</u>, "Retirement Benefits."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(3)</sup> Included in Other expense (income) – net in the Consolidated Statements of Income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(4)</sup> In conjunction with the divestiture of Alfa Valvole during the second quarter of 2024, the Company released

associated cumulative foreign currency translation losses and included the release as part of the gain on sale of business.

**17. Retirement Benefits**

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans as well as other post-retirement plans for its employees. The Company uses a measurement date of December 31 for its defined benefit pension plans and post-retirement medical plans. The Company employs the measurement date provisions of ASC 715, *Compensation-Retirement Benefits*, which require the measurement date of plan assets and liabilities to coincide with the sponsor's year end.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The following table provides a reconciliation of the changes in the benefit obligation and fair value of plan assets over the periods described below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Other Benefits** | **Other Benefits** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2024** |
| | **U.S.** | **Non-U.S.** | **U.S.** | **Non-U.S.** | | |
| CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION | CHANGE IN BENEFIT OBLIGATION |
| Obligation at January 1 | $8.3 | $84.6 | $8.9 | $88.5 | $16.8 | $17.2 |
| Service cost | 0.1 | 1.5 | 0.1 | 1.5 | 0.4 | 0.5 |
| Interest cost | 0.4 | 2.5 | 0.4 | 2.6 | 0.8 | 0.8 |
| Benefits paid | (0.6) | (2.9) | (0.8) | (2.2) | (0.8) | (0.8) |
| Actuarial (gain) loss | 0.3 | (5.4) | (0.3) | 0.3 | 0.3 | (0.7) |
| Currency translation |  | 10.4 |  | (5.3) | 0.2 | (0.2) |
| Settlements |  | (4.8) |  | (2.5) |  |  |
| Curtailments |  | (0.4) |  |  |  |  |
| Acquisition/Divestiture |  |  |  | 0.9 |  |  |
| Participant contributions |  | 0.9 |  | 0.9 |  |  |
| Other |  |  |  | (0.1) | (0.1) |  |
| Obligation at December 31 | $8.5 | $86.4 | $8.3 | $84.6 | $17.6 | $16.8 |
| CHANGE IN PLAN ASSETS |  |  |  |  |  |  |
| Fair value of plan assets at January 1 | $4.1 | $45.1 | $4.3 | $41.7 | $— | $— |
| Actual return on plan assets | (0.1) | 0.9 | 0.2 | 6.2 |  |  |
| Employer contributions | 0.6 | 3.8 | 0.4 | 3.4 | 0.8 | 0.8 |
| Benefits paid | (0.6) | (2.9) | (0.8) | (2.2) | (0.8) | (0.8) |
| Currency translation |  | 5.3 |  | (2.3) |  |  |
| Settlements |  | (4.8) |  | (2.5) |  |  |
| Participant contributions |  | 0.9 |  | 0.9 |  |  |
| Other |  | 0.1 |  | (0.1) |  |  |
| Fair value of plan assets at December 31 | $4.0 | $48.4 | $4.1 | $45.1 | $— | $— |
| Funded status at December 31 | $(4.5) | $(38.0) | $(4.2) | $(39.5) | $(17.6) | $(16.8) |
| COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS | COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS |
| Other noncurrent assets | $— | $3.8 | $— | $2.1 | $— | $— |
| Accrued expenses | (0.8) | (2.1) | (0.7) | (1.8) | (1.0) | (1.1) |
| Other noncurrent liabilities | (3.7) | (39.7) | (3.5) | (39.8) | (16.6) | (15.7) |
| Net asset (liability) at December 31 | $(4.5) | $(38.0) | $(4.2) | $(39.5) | $(17.6) | $(16.8) |

---

The pension benefits actuarial gain in 2025 was primarily driven by the increase in discount rates from 2024 to 2025 for the non-U.S. pension schemes, partially offset by lower than expected asset returns.

The other benefits actuarial loss in 2025 was primarily driven by the decrease in discount rates from 2024 to 2025 and losses from the updated health care trend and claim cost assumptions, partially offset by gains from updated participant data for the U.S. plans.

The accumulated benefit obligation for all defined benefit pension plans was $91.6 million and $89.4 million at December 31, 2025 and 2024, respectively.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

The weighted average assumptions used in the measurement of the Company's benefit obligation at December 31, 2025 and 2024 were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Other Benefits** | **Other Benefits** |
| | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Discount rate | 5.09% | 5.41% | 3.38% | 2.91% | 5.16% | 5.40% |
| Rate of compensation increase | N/A | N/A | 2.33% | 2.38% | N/A | N/A |
| Cash balance interest credit rate | N/A | N/A | 1.31% | 1.25% | N/A | N/A |

---

The pretax amounts recognized in Accumulated other comprehensive income (loss) on the Consolidated Balance Sheets as of December 31, 2025 and 2024 were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Other Benefits** | **Other Benefits** |
| | **2025** | **2025** | **2024** | **2024** | **2025** | **2024** |
| | **U.S.** | **Non-U.S.** | **U.S.** | **Non-U.S.** | | |
| Prior service cost (credit) | $0.1 | $(0.2) | $0.1 | $(0.3) | $(0.3) | $(0.2) |
| Net loss (gain) | 2.6 | (6.6) | 2.3 | (1.8) | (7.3) | (8.4) |
| Total | $2.7 | $(6.8) | $2.4 | $(2.1) | $(7.6) | $(8.6) |

---

The components of the net periodic cost (benefit) for the plans in 2025, 2024 and 2023 are as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** | **Pension Benefits** |
| | **2025** | **2025** | **2024** | **2024** | **2023** | **2023** |
| | **U.S.** | **Non-U.S.** | **U.S.** | **Non-U.S.** | **U.S.** | **Non-U.S.** |
| Service cost | $0.1 | $1.5 | $0.1 | $1.5 | $0.1 | $1.2 |
| Interest cost | 0.4 | 2.5 | 0.4 | 2.6 | 0.4 | 2.8 |
| Expected return on plan assets | (0.2) | (1.9) | (0.3) | (1.8) | (0.2) | (1.6) |
| Settlement gain recognized |  | (0.1) |  | (0.3) |  | (0.1) |
| Curtailment gain recognized |  | (0.4) |  |  |  |  |
| Net amortization | 0.3 | (0.3) | 0.3 | (0.1) | 0.1 | (0.6) |
| Net periodic cost | $0.6 | $1.3 | $0.5 | $1.9 | $0.4 | $1.7 |

---

---

| | | | |
|:---|:---|:---|:---|
| | **Other Benefits** | **Other Benefits** | **Other Benefits** |
| | **2025** | **2024** | **2023** |
| Service cost | $0.4 | $0.5 | $0.4 |
| Interest cost | 0.8 | 0.8 | 0.8 |
| Net amortization | (0.8) | (0.9) | (0.9) |
| Net periodic cost | $0.4 | $0.4 | $0.3 |

---

The Company recognizes the service cost component in both Cost of sales and Selling, general and administrative expenses in the Consolidated Statements of Income depending on the functional area of the underlying employees. All other components of net periodic cost (benefit) are recorded in Other expense (income) – net in the Consolidated Statements of Income.

The assumptions used in determining the net periodic cost (benefit) were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| | **2025** | **2024** | **2023** | **2025** | **2024** | **2023** |
| Discount rate | 5.41% | 4.93% | 5.17% | 2.91% | 3.01% | 3.75% |
| Expected return on plan assets | 4.15% | 5.40% | 4.65% | 4.13% | 4.37% | 4.17% |
| Rate of compensation increase | N/A | N/A | N/A | 2.38% | 2.55% | 2.44% |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

---

| | | | |
|:---|:---|:---|:---|
| | **Other Benefits** | **Other Benefits** | **Other Benefits** |
| | **2025** | **2024** | **2023** |
| Discount rate | 5.40% | 4.90% | 5.21% |
| Expected return on plan assets | N/A | N/A | N/A |
| Rate of compensation increase | N/A | N/A | N/A |

---

The pretax change recognized in Accumulated other comprehensive income (loss) on the Consolidated Balance Sheet in 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Pension Benefits** | **Pension Benefits** | **Other<br>Benefits** |
| | **U.S.** | **Non-U.S.** | |
| Net gain in current year | $(0.6) | $4.4 | $(0.3) |
| Prior service credit |  |  | 0.1 |
| Amortization of prior service credit |  | (0.1) |  |
| Amortization of net loss (gain) | 0.3 | (0.2) | (0.8) |
| Settlement gain recognized |  | (0.1) |  |
| Exchange rate effect on amounts in other comprehensive income |  | 0.7 |  |
| Total | $(0.3) | $4.7 | $(1.0) |

---

The discount rates for the Company's plans are derived by matching the plan's cash flows to a yield curve that provides the equivalent yields on zero-coupon bonds for each maturity. The discount rate selected is the rate that produces the same present value of cash flows.

In selecting the expected rate of return on plan assets, the Company considers the historical returns and expected returns on plan assets. The expected returns are evaluated using asset return class, variance and correlation assumptions based on the plan's target asset allocation and current market conditions.

Prior service costs are amortized on a straight-line basis over the average remaining service period of active participants. Gains and losses in excess of 10% of the greater of the benefit obligation or the market value of assets are amortized over the average remaining service period of active participants.

A 7.87% weighted average annual rate of increase in the per capita cost of covered health care benefits was assumed for measurement of the pension obligation as of December 31, 2025 and measurement of the following year's expense. The rate was assumed to decrease gradually each year to a rate of 4.00% for 2050 and remain at that level thereafter.

Costs of defined contribution plans were $17.8 million, $17.4 million and $16.8 million for 2025, 2024 and 2023, respectively.

The Company, through its subsidiaries, participates in a multi-employer pension plan covering approximately 216 participants under U.S. collective bargaining agreements. None of these plans are considered individually significant to the Company as contributions to these plans totaled $1.0 million, $1.0 million, and $0.9 million for 2025, 2024 and 2023, respectively.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

***Plan Assets***

The Company's pension plan weighted average asset allocations at December 31, 2025 and 2024, by asset category, were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **U.S. Plans** | **U.S. Plans** | **Non-U.S. Plans** | **Non-U.S. Plans** |
| | **2025** | **2024** | **2025** | **2024** |
| Equity securities | 9% | 9% | 1% | 1% |
| Fixed income securities | 83% | 79% | 29% | 25% |
| Cash/Commingled Funds/Other<sup>(1)</sup> | 8% | 12% | 70% | 74% |
| Total | 100% | 100% | 100% | 100% |

---

The basis used to measure the defined benefit plans' assets at fair value at December 31, 2025 and 2024 is summarized as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** |
| | **Outstanding<br>Balances** | **Level 1** | **Level 2** | **Level 3** |
| **As of December 31, 2025** | | | | |
| Equity |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Large Cap | $0.2 | $0.2 | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Small / Mid Cap |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 0.8 | 0.8 |  |  |
| Fixed Income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Intermediate | 2.2 |  | 2.2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Long Term | 3.1 |  | 3.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. High Yield | 1.0 |  | 1.0 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 10.8 | 0.2 | 10.6 |  |
| Other Commingled Funds<sup>(1)</sup> | 31.5 |  |  | 31.5 |
| Cash and Equivalents | 0.8 | 0.8 |  |  |
| Other | 2.0 |  | 2.0 |  |
|  | $52.4 | $2.0 | $18.9 | $31.5 |

---

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Other commingled funds represent pooled institutional investments in non-U.S. plans.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** | **Basis of Fair Value Measurement** |
| | **Outstanding<br>Balances** | **Level 1** | **Level 2** | **Level 3** |
| **As of December 31, 2024** | | | | |
| Equity |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Large Cap | $0.2 | $0.2 | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Small / Mid Cap |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 0.8 | 0.8 |  |  |
| Fixed Income |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Intermediate | 2.5 |  | 2.5 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. Long Term | 3.1 |  | 3.1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. High Yield | 0.7 |  | 0.7 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;International | 8.2 | 0.2 | 8.0 |  |
| Other Commingled Funds<sup>(1)</sup> | 30.0 |  |  | 30.0 |
| Cash and Equivalents | 2.1 | 2.1 |  |  |
| Other | 1.7 |  | 1.7 |  |
|  | $49.3 | $3.3 | $16.0 | $30.0 |

---

&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup>Other commingled funds represent pooled institutional investments in non-U.S. plans.

Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the net asset value ("NAV") provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund minus its liabilities. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry-recognized vendors.

***Investment Policies and Strategies***

The investment objective of the U.S. plan, consistent with prudent standards for preservation of capital and maintenance of liquidity, is to earn the highest possible total rate of return consistent with the plan's tolerance for risk. The general asset allocation guidelines for plan assets are that "equities" will constitute 10% and "fixed income" obligations, including cash, will constitute 90% of the market value of total fund assets.

The investment objective of the UK plan, consistent with prudent standards for preservation of capital and maintenance of liquidity, is to earn a target return of a reasonable margin above UK Gilts. The general asset allocation guidelines for plan assets are that "fixed income" obligations, including cash, will constitute 100% of the market value of total fund assets.

The term "equities" includes common stock, while the term "fixed income" includes obligations with contractual payments and a specific maturity date. Diversification of assets is employed to ensure that adverse performance of one security or security class does not have an undue detrimental impact on the portfolio as a whole. Diversification is interpreted to include diversification by type, characteristic and number of investments as well as by investment style of designated investment fund managers. No restrictions are placed on the selection of individual investments by the investment fund managers. The total fund performance and the performance of the investment fund managers is reviewed on a regular basis using an appointed professional independent advisor. As of December 31, 2025, there were no shares of the Company's stock held in plan assets.

***Cash Flows***

The Company expects to contribute approximately $4.6 million to its defined benefit plans and $1.0 million to its other postretirement benefit plans in 2026. The Company also expects to contribute approximately $19.1 million to its defined contribution plan in 2026 using cash on hand.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

***Estimated Future Benefit Payments***

The future estimated benefit payments for the next five years and the five years thereafter are as follows:

---

| | |
|:---|:---|
| **Estimated Future Benefits** | |
| 2026 | $7.7 |
| 2027 | 7.4 |
| 2028 | 7.1 |
| 2029 | 7.6 |
| 2030 | 7.1 |
| 2031 to 2035 | 37.5 |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

**Item 9A.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures.**

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company's Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of December 31, 2025.

Management's Report on Internal Control Over Financial Reporting appearing on page <u>[35](#ibaf335d4459d4d2499897b1ecd08d11c_73)</u> of this report is incorporated into this Item 9A by reference.

There has been no change in the Company's internal control over financial reporting during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**Item 9B.&nbsp;&nbsp;&nbsp;&nbsp;Other Information.**

During the year ended December 31, 2025, none of the Company's directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended.

**Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.**

Not Applicable.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**PART III**

**Item 10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance.**

Information under the headings "Election of Directors"; "Board Committees"; "Corporate Governance"; and "Delinquent Section 16(a) Reports" in the 2026 Proxy Statement is incorporated into this Item 10 by reference. Information regarding executive officers of the Company is located in Part I, <u>[Item 1](#ibaf335d4459d4d2499897b1ecd08d11c_16)</u>, of this report under the caption "Information about Our Executive Officers."

The Company has adopted a Code of Business Conduct and Ethics applicable to the Company's directors, officers (including the Company's principal executive officer, principal financial officer and principal accounting officer) and employees. The Code of Business Conduct and Ethics, along with the Audit Committee Charter, Nominating and Corporate Governance Committee Charter, Compensation Committee Charter and Corporate Governance Guidelines are available on the Company's website at www.idexcorp.com under "Investors." In the event the Company amends or waives any of the provisions of the Code of Business Conduct and Ethics applicable to the Company's principal executive officer, principal financial officer or principal accounting officer, the Company intends to disclose the same on its website.

The Company has insider trading policies and procedures that govern the purchase, sale and other dispositions of its securities by directors, officers, employees and contractors, as well as by the Company itself. We believe these policies and procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations and applicable listing standards. A copy of our Insider Trading Policy is filed with this Annual Report on Form 10-K as Exhibit 19.

**Item 11.&nbsp;&nbsp;&nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;**Executive Compensation.**

Information under the heading "Executive Compensation" in the 2026 Proxy Statement is incorporated into this Item 11 by reference.

**Item 12. &nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.**

Information under the heading "Security Ownership" in the 2026 Proxy Statement is incorporated into this Item 12 by reference.

**Equity Compensation Plan Information**

Information with respect to the Company's equity compensation plans as of December 31, 2025 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **<u>Plan Category</u>** | **Number of Securities<br>To be Issued Upon<br>Exercise of<br>Outstanding Options,<br>Warrants and Rights** | **Weighted-Average<br>Exercise Price of<br>Outstanding<br>Options, Warrants<br>and Rights** | **Number of Securities**<br>**Remaining Available for**<br>**Future Issuance Under**<br>**Equity Compensation**<br>**Plans** |
| Equity compensation plans approved by the Company's stockholders | 1222948 | $192.03 | 9364893 |
| Equity compensations plans not approved by the Company's stockholders |  |  |  |

---

**Item 13. &nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions, and Director Independence.**

Information under the headings, "Corporate Governance" and "Board Committees" in the 2026 Proxy Statement is incorporated into this Item 13 by reference.

**Item 14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services.**

Information under the heading "Principal Accountant Fees and Services" in the 2026 Proxy Statement is incorporated into this Item 14 by reference.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**PART IV**

**Item 15.&nbsp;&nbsp;&nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;**Exhibits and Financial Statement Schedules.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A)1. Financial Statements

Consolidated Financial Statements filed as part of this report are listed under Part II, <u>[Item 8. "Financial Statements and Supplementary Data."](#ibaf335d4459d4d2499897b1ecd08d11c_70)</u>

&nbsp;&nbsp;&nbsp;&nbsp;2. Financial Statement Schedules

Financial statement schedules are omitted because they are not applicable, not required, not material or because the required information is included in the Consolidated Financial Statements of the Company or the Notes thereto.

&nbsp;&nbsp;&nbsp;&nbsp;3. Exhibits

The exhibits filed with this report are listed on the "Exhibit Index," which precedes the signature page of this report.

**Item 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 10-K Summary.**

&nbsp;&nbsp;&nbsp;&nbsp;None.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**Exhibit Index**

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Description** |
| 3.1 | <u>[Restated Certificate of Incorporation of IDEX Corporation as amended to date (incorporated by reference to Exhibit 3.1 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-12312017xex31.htm)</u> |
| 3.2 | <u>[Third](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[Amended and Restated Bylaws of IDEX Corporation, effective as of](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[July 2](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[8, 2025](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[(incorporated by reference to Exhibit No. 3.1 to the Quarterly Report on Form 10-Q of IDEX Corporation for the quarter ended](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[June 30](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[, 2025](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)[)](https://www.sec.gov/Archives/edgar/data/832101/000083210125000032/ex31-idexamendedandresta.htm)</u> |
| 4.1 | <u>[Indenture between IDEX Corporation and Wells Fargo Bank, National Association, as Trustee, dated as of December 6, 2010 (Debt Securities) (incorporated by reference to Exhibit No. 4.1 to the Current Report of IDEX Corporation on Form 8-K filed December 7, 2010)](https://www.sec.gov/Archives/edgar/data/832101/000095012310111246/c61694exv4w1.htm)</u> |
| 4.2 | <u>[Third Supplemental Indenture between IDEX Corporation and Wells Fargo Bank, National Association, as Trustee, dated as of April 29, 2020, (as to 3.00% Senior Notes due 2030) (incorporated by reference to Exhibit No. 4.2 to the Current Report of IDEX Corporation on Form 8-K filed April 29, 2020)](https://www.sec.gov/Archives/edgar/data/832101/000119312520126298/d853224dex42.htm)</u> |
| 4.3 | <u>[Fourth Supplemental Indenture between IDEX Corporation and Wells Fargo Bank, National Association, as Trustee, dated as of May 28, 2021, (as to 2.625% Senior Notes due 2031) (incorporated by reference to Exhibit No. 4.2 to the Current Report of IDEX Corporation on Form 8-K filed May 28, 2021)](https://www.sec.gov/Archives/edgar/data/0000832101/000119312521176964/d186613dex42.htm)</u> |
| 4.4 | <u>[Fifth Supplemental Indenture between IDEX Corporation and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, National Association, as Trustee, dated as of August 21, 2024, (as to 4.950% Senior Notes due 2029) (incorporated by reference to Exhibit No. 4.2 to the Current Report of IDEX Corporation on Form 8-K filed August 21, 2024).](https://www.sec.gov/Archives/edgar/data/832101/000119312524204531/d852169dex42.htm)</u> |
| 4.5 | <u>[Note Purchase and Master Note Agreement, dated June 13, 2023, among IDEX Corporation, NYL Investors LLC, New York Life Insurance Company, New York Life Group Insurance Company of NY, New York Life Insurance and Annuity Corporation Institutionally owned Life Insurance Separate Account (BOLI 3), New York Life Insurance and Annuity Corporation Institutionally owned Life Insurance Separate Account (BOLI 3-2) and New York Life Insurance and Annuity Corporation Institutionally owned Life Insurance Separate Account (BOLI 30C) (incorporated by reference to Exhibit No. 4.1 to the Current Report of IDEX Corporation on Form 8-K filed June 14, 2023)](https://www.sec.gov/Archives/edgar/data/832101/000083210123000027/iexexhibit41.htm)</u> |
| 4.6\* | <u>[Description of Securities](iex-202512x31xex46descript.htm)</u> |
| 10.1\*\* | <u>[IDEX Corporation 2024 Incentive Award Plan (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-8, filed with the Commission on May 7, 2024)](https://www.sec.gov/Archives/edgar/data/832101/000119312524133175/d829830dex43.htm)</u> |
| 10.2\*\* | <u>[Revised and Restated IDEX Corporation Management Incentive Compensation Plan for Key Employees Effective January 1, 2022 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q of IDEX Corporation for the quarter ended June 30, 2023)](https://www.sec.gov/Archives/edgar/data/832101/000083210123000034/iex-20230630xex101.htm)</u> |
| 10.3\*\* | <u>[IDEX Corporation Form of Director Indemnification Agreement (incorporated by reference to Exhibit 10.2 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex102.htm)</u> |
| 10.4\*\* | <u>[IDEX Corporation Amended and Restated Stock Option Plan for Outside Directors, adopted by resolution of the Board of Directors dated as of November 20, 2003 (incorporated by reference to Exhibit 10.6 (a) to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2003)](https://www.sec.gov/Archives/edgar/data/832101/000095013704001504/c83337exv10w6xay.txt)</u> |
| 10.5\*\* | <u>[IDEX Corporation Incentive Award Plan (as amended and restated) (incorporated by reference to Appendix A of the Proxy Statement of IDEX Corporation on Schedule 14A, filed March 5, 2015)](https://www.sec.gov/Archives/edgar/data/832101/000119312515072666/d878233ddef14a.htm)</u> |
| 10.6\*\* | <u>[Third Amended and Restated IDEX Corporation Directors Deferred Compensation Plan (incorporated by reference to Exhibit No. 10.30 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2010)](https://www.sec.gov/Archives/edgar/data/832101/000095012311018609/c62090exv10w30.htm)</u> |
| 10.7\*\* | <u>[IDEX Corporation Supplemental Executive Retirement and Deferred Compensation Plan (incorporated by reference to Exhibit No. 10.31 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2010)](https://www.sec.gov/Archives/edgar/data/832101/000095012311018609/c62090exv10w31.htm)</u> |
| 10.8\*\* | <u>[Letter Agreements between IDEX Corporation and Eric Ashleman, dated January 14, 2008 and February 12, 2014 (incorporated by reference to Exhibit No. 10.14 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1014.htm)</u> |
| 10.9\*\* | <u>[Form of IDEX Corporation Stock Option Agreement effective February 2015 (incorporated by reference to Exhibit No. 10.17 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1017.htm)</u> |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

---

| | |
|:---|:---|
| 10.10\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Award Agreement effective February 2015 (incorporated by reference to Exhibit No. 10.18 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1018.htm)</u> |
| 10.11\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Award Agreement - Cash Settled effective February 2015 (incorporated by reference to Exhibit No. 10.19 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1019.htm)</u> |
| 10.12\*\* | <u>[Form of IDEX Corporation Performance Share Unit Award Agreement effective February 2015 (incorporated by reference to Exhibit No. 10.20 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1020.htm)</u> |
| 10.13\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Agreement for Directors effective February 2015 (incorporated by reference to Exhibit No. 10.21 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1021.htm)</u> |
| 10.14\*\* | <u>[Form of IDEX Corporation Stock Option Agreement effective February 2015 (incorporated by reference to Exhibit No. 10.22 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-20141231xex1022.htm)</u> |
| 10.15\*\* | <u>[Form of IDEX Corporation Restricted Stock Award Agreement effective February 2015 (incorporated by reference to Exhibit No. 10.23 to the Annual Report of IDEX Corporation on Form 10-K for the year ended December 31, 2014)](https://www.sec.gov/Archives/edgar/data/832101/000083210115000009/iex-12312014xex1023.htm)</u> |
| 10.16\*\* | <u>[Letter Agreement between IDEX Corporation and Eric D. Ashleman, dated January 21, 2021 (incorporated by reference to Exhibit 10.18 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2020)](https://www.sec.gov/Archives/edgar/data/0000832101/000083210121000017/iex-2020x2131xex1018.htm)</u> |
| 10.17\*\* | <u>[Amendment to Letter Agreement dated February 12, 2014, between IDEX Corporation and Eric D. Ashleman, effective as of April 24, 2017 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of IDEX Corporation for the quarter ended March 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210117000027/iex-2017x0331xex102.htm)</u> |
| 10.18\*\* | <u>[Form of IDEX Corporation Performance Share Unit Award Agreement - Stock Settled, effective February 2018 (incorporated by reference to Exhibit 10.26 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1026.htm)</u> |
| 10.19\*\* | <u>[Form of IDEX Corporation Restricted Stock Award Agreement, effective February 2018 (incorporated by reference to Exhibit 10.27 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1027.htm)</u> |
| 10.20\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Agreement for Directors, effective February 2018 (incorporated by reference to Exhibit 10.28 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1028.htm)</u>) |
| 10.21\*\* | <u>[Form of IDEX Corporation Performance Share Unit Award Agreement - Cash Settled, effective February 2018 (incorporated by reference to Exhibit 10.29 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-2017x1231xex1029.htm)</u> |
| 10.22\*\* | <u>[Form of IDEX Corporation Stock Option Agreement, effective February 2018 (incorporated by reference to Exhibit 10.30 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1030.htm)</u> |
| 10.23\*\* | <u>[Form of IDEX Corporation Stock Option Agreement - Cash Settled, effective February 2018 (incorporated by reference to Exhibit 10.31 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1031.htm)</u> |
| 10.24\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Award Agreement - Cash Settled, effective February 2018 (incorporated by reference to Exhibit 10.32 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1032.htm)</u> |
| 10.25\*\* | <u>[Form of IDEX Corporation Restricted Stock Unit Award Agreement, effective December 2015 (incorporated by reference to Exhibit 10.33 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1033.htm)</u> |
| 10.26\*\* | <u>[Form of IDEX Corporation Confidential Information, Work Product and Restrictive Covenant Agreement (incorporated by reference to Exhibit 10.34 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2017)](https://www.sec.gov/Archives/edgar/data/832101/000083210118000019/iex-20171231xex1034.htm)</u> |

---

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| 10.27 | <u>[Amended and Restated Credit Agreement, dated as of November 1, 2022, which amends and restates the Credit Agreement, dated as of May 31, 2019, by and among IDEX Corporation and certain of its subsidiaries, as borrowers, Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit; JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association, as co-syndication agents and issuers of letters of credit; HSBC Bank USA, National Association, Mizuho Bank, Ltd., and Bank of China, Chicago Branch, as co-documentation agents and the other lenders and financial institutions party thereto (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K of IDEX Corporation filed on November 2, 2022)](https://www.sec.gov/Archives/edgar/data/832101/000083210122000059/ex-101idexxcreditagreeme.htm)</u> |
| 10.28\*,\*\* | <u>[IDEX Amended and Restated Non-Employee Director Compensation Policy, effective January 1, 202](ex-1028idexamendedandres.htm)[6](ex-1028idexamendedandres.htm)</u> |
| 10.29\*\* | <u>[Letter Agreement between IDEX Corporation and Melissa S. Flores, dated as of January 7, 2021 (incorporated by reference to Exhibit No. 10.1 to the Quarterly Report on Form 10-Q of IDEX Corporation for the quarter ended March 31, 2022)](https://www.sec.gov/Archives/edgar/data/832101/000083210122000016/iex-20220331xex101.htm)</u> |
| 10.30\*\* | <u>[Letter Agreement between IDEX Corporation and Lisa M. Anderson, dated as of February 16, 2022 (incorporated by reference to Exhibit 10.31 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2022)](https://www.sec.gov/Archives/edgar/data/832101/000083210123000013/a1031letteragreementbetw.htm)</u> |
| 10.31\*\* | <u>[Letter Agreement between IDEX Corporation and Abhishek Khandelwal](https://www.sec.gov/Archives/edgar/data/832101/000083210124000009/iex-ex1030.htm)[, dated as of October 19, 2023 (incorporated by reference to Exhibit 10.30 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2023)](https://www.sec.gov/Archives/edgar/data/832101/000083210124000009/iex-ex1030.htm)</u> |
| 10.32\*,\*\* | <u>[Letter Agreement between IDEX Corporation and Roopa Unnikrishnan, dated as of](ex-1032letteragreementbe.htm)[February 25, 2022](ex-1032letteragreementbe.htm)</u> |
| 10.33\*,\*\* | <u>[Letter Agreement between IDEX Corporation and Akhil Mahendra, dated as of](ex-1033letterxagreementb.htm)[May 20, 2025](ex-1033letterxagreementb.htm)</u> |
| 10.34\*,\*\* | <u>[Letter Agreement between IDEX Corporation and](ex-1034letteragreementbe.htm)[Sean M. Gillen, dated as of](ex-1034letteragreementbe.htm)[Nove](ex-1034letteragreementbe.htm)[mber 26](ex-1034letteragreementbe.htm)[, 2025](ex-1034letteragreementbe.htm)</u> |
| 19 | <u>[IDEX Insider Trading Policy (incorporated by reference to Exhibit 19 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2024)](https://www.sec.gov/Archives/edgar/data/832101/000083210125000010/iex-20241231xex19.htm)</u> |
| 21\* | <u>[Subsidiaries of IDEX](iex-202512x31xex21.htm)</u> |
| 23\* | <u>[Consent of Deloitte & Touche LLP](iex-20251231xex23.htm)</u> |
| 31.1\* | <u>[Certification of Chief Executive Officer Pursuant to Rule 13a-14 (a) or Rule 15d-14 (a)](iex-20251231xex311.htm)</u> |
| 31.2\* | <u>[Certification of Chief Financial Officer Pursuant to Rule 13a-14 (a) or Rule 15d-14 (a)](iex-20251231xex312.htm)</u> |
| 32.1\*\*\* | <u>[Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code](iex-20251231xex321.htm)</u> |
| 32.2\*\*\* | <u>[Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code](iex-20251231xex322.htm)</u> |
| 97 | <u>[IDEX Corporation Policy on Recoupment of Incentive Compensation (incorporated by reference to Exhibit 97 to the Annual Report of IDEX Corporation on Form 10-K for the fiscal year ended December 31, 2023)](https://www.sec.gov/Archives/edgar/data/832101/000083210124000009/ex97idexcorporationpolic.htm)</u> |

---

---

| | |
|:---|:---|
| \*,\*\*\*\*101 | The following materials from IDEX Corporation's Annual Report on Form 10-K for the year ended December 31, 2025 formatted in Inline XBRL (Extensible Business Reporting Language): (i) the Consolidated Balance Sheets at December 31, 2025 and 2024, (ii) the Consolidated Statements of Income for the three years ended December 31, 2025, (iii) the Consolidated Statements of Comprehensive Income for the three years ended December 31, 2025, (iv) the Consolidated Statements of Equity for the three years ended December 31, 2025, (v) the Consolidated Statements of Cash Flows for the three years ended December 31, 2025, and (vi) Notes to Consolidated Financial Statements. |
| \*,\*\*\*\*104 | Cover Page Interactive Data File (Formatted Inline XBRL and contained in Exhibit 101) |

---

**\*&nbsp;&nbsp;&nbsp;&nbsp;**Filed herewith.

**\*\*&nbsp;&nbsp;&nbsp;&nbsp;**Management contract or compensatory plan or agreement.

\*\*\*&nbsp;&nbsp;&nbsp;&nbsp;Furnished herewith.

\*\*\*\*&nbsp;&nbsp;&nbsp;&nbsp;In accordance with Rule 406T of Regulation S-T, the XBRL related information in Exhibits 101 and 104 to this Annual Report on Form 10-K shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be part of any registration statement or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

------

<u>[**Table of Contents**](#ibaf335d4459d4d2499897b1ecd08d11c_13)</u>

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| IDEX CORPORATION | IDEX CORPORATION |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;SEAN M. GILLEN |
|  | Sean M. Gillen |
|  | Senior Vice President and Chief Financial Officer  |

---

Date: February 19, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/ ERIC D. ASHLEMAN | Chief Executive Officer, <br>President and Director<br>(Principal Executive Officer) |  |
| Eric D. Ashleman | Chief Executive Officer, <br>President and Director<br>(Principal Executive Officer) | February 19, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;SEAN M. GILLEN | Senior Vice President and Chief Financial Officer (Principal Financial Officer) |  |
| Sean M. Gillen | Senior Vice President and Chief Financial Officer (Principal Financial Officer) | February 19, 2026 |
| /s/ ALLISON S. LAUSAS | Vice President and<br>Chief Accounting Officer<br>(Principal Accounting Officer) |  |
| Allison S. Lausas | Vice President and<br>Chief Accounting Officer<br>(Principal Accounting Officer) | February 19, 2026 |
| /s/ MARK A. BECK | Director |  |
| Mark A. Beck | Director | February 19, 2026 |
| /s/ MARK A. BUTHMAN | Director |  |
| Mark A. Buthman | Director | February 19, 2026 |
| /s/ ALEJANDRO QUIROZ CENTENO | Director |  |
| Alejandro Quiroz Centeno | Director | February 19, 2026 |
| /s/ CARL R. CHRISTENSON | Director |  |
| Carl R. Christenson | Director | February 19, 2026 |
| /s/ LAKECIA N. GUNTER | Director |  |
| Lakecia N. Gunter | Director | February 19, 2026 |
| /s/ KATRINA L. HELMKAMP | Non-Executive Chair of the Board and Director |  |
| Katrina L. Helmkamp | Non-Executive Chair of the Board and Director | February 19, 2026 |
| /s/ STEPHANIE J. DISHER | Director |  |
| Stephanie J. Disher | Director | February 19, 2026 |
| /s/ MATTHIJS GLASTRA | Director |  |
| Matthijs Glastra | Director | February 19, 2026 |
| /s/ L. PARIS WATTS-STANFIELD | Director |  |
| L. Paris Watts-Stanfield | Director | February 19, 2026 |

---

## Exhibit 4.6

**Exhibit 4.6**

**DESCRIPTION OF THE REGISTRANT'S SECURITIES**

**REGISTERED PURSUANT TO SECTION 12 OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

As of the date of the Annual Report on Form 10-K of which this exhibit is a part, IDEX Corporation (the "Corporation") has one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock.

**DESCRIPTION OF CAPITAL STOCK**

The following summary description relating to our capital stock is based upon our Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation") and our Amended and Restated Bylaws (the "Bylaws"). The summary does not purport to be complete, and is qualified by reference to our Certificate of Incorporation and Bylaws, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part.

**Capitalization**

Our authorized capital stock currently consists of 150,000,000 shares of common stock, par value $.01 per share, and 5,000,000 shares of preferred stock, par value $.01 per share.

**Common Stock**

Subject to the rights of the holders of any preferred stock and except as provided below, each holder of common stock on the applicable record date is entitled to receive such dividends as may be declared by the Corporation's Board of Directors (the "Board") out of funds legally available therefor. In the event of liquidation, dissolution or winding-up of the Corporation, each stockholder of record on the applicable date has the right to share equally and ratably in any distribution of our assets after payment of liabilities (including payments with respect to any outstanding shares of preferred stock).

Each holder of common stock is entitled to one vote for each share held of record on the applicable record date on all matters presented to a vote of stockholders. Our Certificate of Incorporation does not provide for cumulative voting rights. A majority vote of the voting power of the shares of capital stock present or represented by proxy at a meeting is required for all action to be taken by stockholders, except with respect to matters relating to (i) the election of directors in a contested election, which then requires a plurality of the votes cast, or (ii) adopting amendments to Article VIII or Article IX of our Certificate of Incorporation, each of which requires the affirmative vote of the holders of not less than 80% of the outstanding shares of stock with voting rights. Article VIII provides for our classified board of directors and Article IX sets forth that any amendments to Article VIII or any amendment to our Certificate of Incorporation to provide for cumulative voting rights in the election of directors requires not less than 80% of the outstanding shares of stock with voting rights.

Holders of common stock do not have preemptive, subscription, redemption, sinking fund or conversion rights.

Our common stock is listed on the New York Stock Exchange under the symbol "IEX."

------

**Preferred Stock**

The Corporation's Board has been authorized, subject to certain limitations set forth in the Certificate of Incorporation, to issue shares of preferred stock in one or more series, by resolution providing for the issuance of such series, and to (i) fix the number of shares which will constitute such series and the designation thereof, (ii) determine the voting rights of shares of such series, (iii) determine the terms and conditions, if any, under which such series may be redeemable, (iv) determine the rate of any dividends payable with respect to shares of such series and any preferences or relations to dividends payable with respect to shares of other classes of our capital stock, (v) determine the rights of shares of such series upon our liquidation, (vi) determine if shares of such series are convertible into or exchangeable for shares of another class or classes of our capital stock and the rates or prices at which shares of such series are convertible or exchangeable, and (vii) determine such other preferences and relative, participating, optional or other special rights and qualifications of shares of such series as are not inconsistent with the terms of the Certificate of Incorporation.

The issuance of preferred stock, however, could adversely affect the voting power of holders of common stock and restrict their rights to receive payments upon liquidation of the Corporation. It could also have the effect of delaying, deferring or preventing a change in control of the Corporation.

**Anti-Takeover Effects of Certain Provisions**

Certain provisions of the Delaware General Corporation Law ("DGCL"), our Certificate of Incorporation and Bylaws summarized in the paragraphs above and in the following paragraphs may have an anti-takeover effect and could make the following transactions difficult: acquisition by means of a tender offer; acquisition by means of a proxy contest or otherwise; or removal of incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in the best interests of the Corporation, including transactions that might result in a premium over the market price for shares of common stock.

*Authorized but Unissued Shares*

The Corporation's authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the Corporation by means of a proxy contest, tender offer, merger or otherwise.

*Undesignated Preferred Stock*

The authority that our board of directors possess to issue preferred stock could potentially be used to discourage attempts by third parties to obtain control of the Corporation through a merger, tender offer, proxy contest or otherwise by making such attempts more difficult or more costly. Our board of directors may be able to issue preferred stock with voting rights or conversion rights that, if exercised, could adversely affect the voting power of the holders of common stock.

------

*No Cumulative Voting*

The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors unless the company's Certificate of Incorporation provides otherwise. Our Certificate of Incorporation does not provide for cumulative voting and prohibits any provision imposing cumulative voting in the election of directors from being added unless such action is approved by the affirmative vote of the holders of not less than 80% of the outstanding shares of stock with voting rights.

*Classified Board of Directors*

Pursuant to our Certificate of Incorporation, the Corporation's Board is divided into three classes, with the number of directors in each class as nearly equal as possible. The directors in each class serve for staggered three-year terms. Only one class of directors will be elected at each annual meeting of the stockholders, with the other classes continuing for the remainder of their respective three-year terms.

*Removal of Directors; Vacancy*

Our Certificate of Incorporation and Bylaws provide for the removal of any of the Corporation's directors only for cause and only by the affirmative vote of at least a majority of the voting power of the Corporation's then outstanding capital stock entitled to vote in the election of directors. Furthermore, any vacancy on the Corporation's Board, however occurring, including a vacancy resulting from an increase in the size of the Board, shall only be filled by the affirmative vote of a majority of the remaining directors of the class in which such vacancy occurs, or by the affirmative vote of a majority of the remaining directors of the other two classes if there is no director remaining in the class in which such vacancy occurs.

*Special Meetings of the Stockholders*

Unless otherwise permitted by applicable law, our Bylaws provide that special meetings of the stockholders may be called only by (i) the Chairman of the Board, (ii) the Board, pursuant to a resolution approved by a majority of the entire Board or (iii) the Secretary of the Corporation upon the written request of stockholders of record as of the record date who hold, in the aggregate, at least a majority of the voting power of the outstanding shares of capital stock of the Corporation subject to the procedural requirements of our Bylaws.

*Stockholder Advance Notice Procedures*

Under our Bylaws, to be properly brought before an annual meeting of stockholders, any stockholder proposal or nomination for election to the Board must be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation not later than the Close of Business (as defined in the Bylaws) not less than 90 days nor more than 120 days prior to the one-year anniversary of the preceding year's annual meeting; provided, however, that if the date of the annual meeting is more than 30 days before or more than 60 days after such anniversary date, notice by the stockholder must be delivered not later than the Close of Business on the 90th day prior to such annual meeting or, if later, the Close of Business on the 10th day following the day on which public disclosure of the date of such annual meeting was first made. Such notice must contain information specified in our Bylaws as to the director nominee or proposal of other business, information about the stockholder making the nomination or proposal and the beneficial owner, if any, on behalf of whom the nomination or proposal is made.

------

*Exclusive Forum*

Our Bylaws provide that, unless the Corporation consents in writing to the selection of an alternative forum, the sole and exclusive forum for (i) any derivative action or proceeding brought in the right of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to the Corporation or our stockholders, (iii) any action asserting a claim against the Corporation arising pursuant to any provision of the DGCL, our Certificate of Incorporation or our Bylaws or (iv) any action asserting a claim against the Corporation governed by the internal affairs doctrine shall be the Court of Chancery of the State of Delaware, in each such case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.

*Delaware Anti-Takeover Statute*

We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a public Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years after the date of the transaction in which the person became an interested stockholder, unless (i) before that person became an interested stockholder, the corporation's board of directors approved the transaction in which the interested stockholder became an interested stockholder or approved the business combination; (ii) upon completion of the transaction that resulted in the interested stockholder's becoming an interested stockholder, the interested stockholder owns at least 85% of the voting stock outstanding at the time the transaction commenced (excluding stock held by directors who are also officers of the corporation and by employee stock plans that do not provide employees with the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii) following the transaction in which that person became an interested stockholder, the business combination is approved by the corporation's board of directors and authorized at a meeting of stockholders by the affirmative vote of the holders of at least two-thirds of the outstanding voting stock not owned by the interested stockholder. Under Section 203, these restrictions also do not apply to certain business combinations proposed by an interested stockholder following the announcement or notification of one of certain extraordinary transactions involving the corporation and a person who was not an interested stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the corporation's directors, if that extraordinary transaction is approved or not opposed by a majority of the directors who were directors before any person became an interested stockholder in the previous three years or who were recommended for election or elected to succeed such directors by a majority of such directors then in office. "Business combination" includes mergers, asset sales and other transactions resulting in a financial benefit to the stockholder. An "interested stockholder" is any entity or person who, together with affiliates and associates, owns (or, within the previous three years, did own) 15% or more of the corporation's outstanding voting stock.

## Exhibit 10.28

![](ex-1028idexamendedandres001.jpg)

IDEX Corporation Amended and Restated Non-Employee Director Compensation Policy (Effective January 1, 2026) This Amended and Restated Non-Employee Director Compensation Policy, effective January 1, 2026 (the "Policy"), has been established by IDEX Corporation (the "Company") to provide each member of the Company's Board of Directors (the "Board") who is not an employee of the Company (a "Director") with compensation for services performed as a Director. Each Director shall, automatically and without further action of the Company, receive cash compensation and equity-based compensation in respect of shares of the Company's common stock ("Shares") pursuant to the terms and conditions set forth in this Policy, unless such Director declines the receipt of such cash or equity-based compensation by written notice to the Company or except as otherwise provided herein. This Policy shall remain in effect until it is revised or rescinded by further action of the Board. Annual Cash Compensation The annual cash compensation set forth below is payable in equal quarterly installments, in arrears within thirty (30) days following the end of each quarter in which the service occurred, pro-rated for the number of days served as a Director in any partial quarter (unless deferred under the section below entitled "Deferral Elections"): 1. Annual Board Service Retainer: Each Director: $100,000 2. Annual Committee Service Retainer (Chair): a. Chair of the Audit Committee: $20,000 b. Chair of the Compensation Committee: $15,000 c. Chair of the Nominating and Corporate Governance Committee: $15,000 3. Annual Non-Executive Chair Service Retainer: Non-Executive Chair: $100,000 Equity Compensation Equity awards issued pursuant to the Policy shall be granted under and subject to the terms of the IDEX Corporation 2024 Incentive Award Plan, as may be amended from time to time, or any successor thereto (the "Plan"), and the Director shall electronically accept an equity award agreement thereunder as approved by the Board (or a duly authorized committee thereof). 1. Initial Grant. On the date of a Director's initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Director shall receive a grant of restricted stock units ("RSUs") in an amount equal to $175,000, divided by the closing price of a Share on the New York Stock Exchange on the date of grant, rounded up to the next five whole Shares (an "Initial Grant"); provided, that if a Director is first appointed to the Board on a date other than an Annual Grant Date (as defined below), such Director shall be granted, on the date of such appointment (or, if such date is not a market trading day, the first market trading day thereafter), a number of RSUs determined by (i) dividing (x) $175,000, by (y) the closing price of a Share on the New York Stock Exchange on the date of grant, and (ii) EX-10.28

------

![](ex-1028idexamendedandres002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 2 multiplying such quotient by a fraction the numerator of which is the number of days between the date of grant and the next Annual Grant Date and the denominator of which is three hundred and sixty five (365), rounded up to the next five whole Shares. 2. Annual Grant. On the date of the first meeting of the Board held immediately following each annual meeting of the Company's stockholders (each, an "Annual Grant Date"), each Director (other than the Non-Executive Chair) then in office who has not given notice as of the Annual Grant Date of his or her intent to resign from the Board shall receive a grant of RSUs in an amount equal to $175,000, divided by the closing price of a Share on the New York Stock Exchange on the Annual Grant Date, rounded up to the next five whole Shares (the "Annual Grant"). A Director elected for the first time to the Board on an Annual Grant Date shall only receive an Initial Grant in connection with such election, and shall not receive an Annual Grant on such Annual Grant Date. 3. Annual Non-Executive Chair Grant. On each Annual Grant Date, the Non-Executive Chair shall receive a grant of RSUs in an amount equal to $225,000, divided by the closing price of a Share on the New York Stock Exchange on the Annual Grant Date, rounded up to the next five whole Shares (which grant shall be in lieu of the Annual Grant), provided, that the Non- Executive Chair has not given notice as of the Annual Grant Date of his or her intent to resign from the Board. All RSUs issued pursuant to this Policy on the Annual Grant Date shall vest in full on the earliest to occur of (i) the earlier of the first anniversary of the Annual Grant Date or the date of the next annual stockholders meeting if it is at least 50 weeks after the prior year's meeting, subject to the Director's continuous service through such date, (ii) the date on which the Director ceases to serve on the Board for any reason after achieving at least six years of continuous service on the Board, (iii) the date of the Director's death, (iv) the date on which the Director ceases to serve on the Board by reason of the Director's disability, and (v) the occurrence of a Change in Control (as defined in the Plan) subject to the Director's continuous service through such date. All Initial Grant RSUs issued pursuant to this Policy shall vest on the earliest to occur of (i) the first anniversary of the date of grant, (ii) the date of the Director's death, (iii) the date on which the Director ceases to serve on the Board by reason of the Director's disability, or (iv) the occurrence of a Change in Control (as defined in the Plan) subject to the Director's continuous service through such date. Settlement of the RSUs shall be in the form of Shares at the time of settlement (unless deferred under the section below entitled "Deferral Elections"), subject to such other terms and conditions set forth in the applicable award agreement evidencing such RSUs. To the extent any RSUs have not vested at the time of a Director's cessation of service on the Board, such RSUs shall be forfeited by the Director and cancelled for no consideration. Notwithstanding the foregoing, the Board may, in its sole discretion, determine to grant additional equity awards under the Plan to a Director at such time and upon such terms and conditions as determined by the Board, provided, that in no event shall the aggregate value of all equity and cash awards granted to a Director under this Policy during any calendar year (measured at the time of grant in accordance with applicable accounting standards) exceed the maximum value that may be granted to any Director during such calendar year as set forth in the Plan.

------

![](ex-1028idexamendedandres003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 3 Stock Ownership Guideline Each Director shall maintain direct ownership of Shares equal to or greater in value to five times the current Annual Board Service Retainer (the "Ownership Guideline"). No Director shall be permitted to sell Shares until the Director satisfies the Ownership Guideline, and after a Director meets the Ownership Guideline, the Director may not sell shares if the sale would put the Director below the Ownership Guideline. Shares directly owned, as well as unvested and deferred RSUs, shall count toward satisfying the Ownership Guideline. Deferral Elections 1. Cash Compensation. A Director may elect to defer any cash compensation payable with respect to a calendar year of service in accordance with the Third Amended and Restated IDEX Corporation Directors Deferred Compensation Plan, as may be amended from time to time, or any successor thereto. 2. RSUs. A Director may elect to defer the settlement of Shares issuable with respect to any RSUs granted to the Director with respect to a calendar year of service, subject to the terms and conditions set forth in this Section, a deferral election form previously adopted by the Board (or a duly authorized committee thereof) and Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and the regulations thereunder. The Director may elect to defer settlement of all or a portion of the RSUs granted to the Director with respect to a calendar year of service by filing a completed deferral election form with the Company. The Director must file the deferral election form no later than December 31 of the prior calendar year for the calendar year in which service is to be provided; provided, that if the Director is first appointed or elected to the Board during a calendar year, such Director may elect to defer settlement of RSUs within 30 days of such initial appointment or election to the Board with respect to RSUs that relate to service performed after the election. Each deferral election made with respect to a calendar year shall be irrevocable with respect to such calendar year. Pursuant to the deferral election form, the Director must irrevocably elect the specified date(s) and increment(s) with respect to which the Director shall receive Shares issuable upon the settlement of those RSUs that the Director has elected to defer (each, a "Settlement Date"). If the Director fails to elect a Settlement Date, settlement of the RSUs shall occur on the earlier of (i) the second anniversary of the date of grant of the RSUs and (ii) the date of the Director's "separation from service" (within the meaning of Section 409A of the Code). All deferral elections shall be made in accordance with rules and procedures established by the Company and Section 409A of the Code and the regulations thereunder. Pursuant to the applicable deferral election form, the Director shall receive Shares issuable in respect of the RSUs on the earliest to occur of (x) the Settlement Date(s) elected by the Director (or, if the Director fails to elect a Settlement Date, the earlier to occur of (i) the second anniversary of the date of grant of the RSUs and (ii) the date of the Director's separation from service), (y) a "change in control event," within the meaning of Treasury Regulation Section 1.409A-3(i)(5), and (z) the date of the Director's death or Disability (within the meaning of Treasury Regulation Section 1.409A- 3(i)(4)), each as specified in the applicable deferral election form. Expenses The Company shall reimburse each Director for ordinary, necessary and reasonable out-of-pocket travel expenses to cover in-person attendance at and participation in Board and committee meetings. To the extent that any such reimbursements are deemed to constitute compensation to the Director, such amounts shall be reimbursed no later than December 31 of the year following the year in which the

------

![](ex-1028idexamendedandres004.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Page 4 expense was incurred. The amount of any expense reimbursements that constitute compensation in one year shall not affect the amount of expense reimbursements constituting compensation that are eligible for reimbursement in any subsequent year, and the Director's right to such reimbursement of any such expenses shall not be subject to liquidation or exchange for any other benefit. Section 409A To the extent applicable, the Policy shall be interpreted in accordance with Section 409A of the Code and the regulations and other interpretive guidance issued thereunder. Notwithstanding any provision in the Policy, any deferral election form or any other agreement evidencing amounts subject to the Policy to the contrary, if the Company determines that any amounts subject to the Policy may not be either exempt from or compliant with Section 409A of the Code, the Company may, in its sole discretion, adopt such amendments to the Policy, any deferral election form or any other agreement relating to the Policy, adopt other policies or procedures or take any other actions that the Company determines are necessary or appropriate to (i) exempt such amounts from Section 409A of the Code and/or preserve the intended tax treatment of such amounts, or (ii) comply with the requirements of Section 409A of the Code; provided, that this Section shall not create any obligation on the Company to adopt any such amendment, policy or procedure or take any such other action.

------

## Exhibit 10.32

![](ex-1032letteragreementbe001.jpg)

IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com Personal and Confidential February 25, 2022 Dear Roopa, We are pleased to offer you the position of Senior Vice President, Strategy & Corporate Development effective March 21, 2022 for IDEX Corporation (IDEX or the Company), based remotely, and reporting directly to me. The following terms apply to this offer: • Your annual base salary will be Four Hundred Thousand Dollars and Zero Cents ($400,000.00), payable on a biweekly basis. You will be eligible for review of your salary with consideration for an increase in March 2023. While we hope that you have a long and mutually beneficial relationship, your employment is considered "at will" and will not be for any fixed term or definite period and may be terminated by you or IDEX at any time. • As of the effective date of this appointment, you will be eligible for participation in our Management Incentive Compensation Plan (MICP), as established each fiscal year, which provides annual incentive earnings opportunity based on business unit and personal performance. Your MICP target level of incentive compensation will be sixty percent (60%) of your annual base pay. Your 2022 MICP pay-out will be prorated as of your starting date. The actual pay-out under the plan could be more or less than the target level and will depend on IDEX's performance and your performance. Attached is a copy of the current MICP Compensation Programs Booklet. • You will be eligible to receive a Company car allowance of One Thousand Five Hundred Dollars and Zero Cents ($1,500.00) per month, paid on a bi-weekly basis. • You will be eligible for the full range of benefits, including: the IDEX 401(k) Savings Plan, medical and dental coverage, short-term and voluntary long-term disability coverage, and life insurance. Summaries of these benefit plans are attached. • You will be eligible to participate in the Executive Medical Physical Program. IDEX has partnered with the Center for Partnership Medicine at Northwestern Memorial Hospital to provide you with the opportunity to have a full medical examination on an annual basis. The cost of the examination will be paid by IDEX. • You will be eligible to enroll in the Executive Long-Term Disability program, which provides additional income in the case of total and permanent disability. This program is fully paid by IDEX. You will be issued an individual policy that provides several additional benefits above and beyond the voluntary Group LTD plan that is in place for employees. EX-10.32

------

![](ex-1032letteragreementbe002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com • Based upon your position, you are eligible to participate in the IDEX Corporation Supplemental Executive Retirement and Deferred Compensation Plan. The purpose of the plan is to provide non- qualified retirement compensation benefits above IRS limits and to provide participants with the ability to defer other amounts of compensation. You will also be eligible for the Supplemental Retirement Contribution portion of the SERP. • Subject to approval from our Board of Directors, you will be eligible for equity grants beginning with the 2023 annual grant in the form of a combination of performance stock units and stock options under the IDEX Incentive Award Plan (IAP) at our annual grant as established each fiscal year. The grant value for your position is currently targeted at Four Hundred Thousand Dollars ($400,000). Your actual award in any year is dependent upon current program design and your performance. This plan is designed to provide an incentive and reward to key employees who are in a position to make substantial contributions to the success of IDEX. For 2022, as we are past our annual grant date, you will receive an equity award as of your starting date that is equal in grant value and form of award as your annual target grant. • The initial price at which the option awards are granted will be the closing price of IDEX common stock on the grant date. Your options may be exercised after they become vested, and for a period of up to ten years from the date they were awarded. Currently, options vest at the rate of 25% per year. • In the event of a "Change in Control", as defined in the Amended and Restated IDEX Corporation Supplemental Executive Retirement Plan, that results in your termination from service within twenty-four (24) months of the Change in Control, the Company shall be obligated to pay your base salary at the rate then in effect and your then current target annual bonus (MICP or equivalent pay) for a minimum of twenty-four (24) months following the date of termination (for a total payment of two (2) times both base salary and target annual bonus). This payment shall not be applicable in the event of your voluntary termination. • If, in the future, your employment with IDEX is terminated without cause ("cause" defined as willful misconduct or fraudulent behavior), IDEX will pay you twelve (12) months base salary at the then current monthly base rate plus your targeted annual incentive bonus in exchange for you signing, and not revoking, an IDEX-standard Severance & General Release Agreement. These payments are subject to tax withholdings and deductions. Such benefit will not be applicable in the event of your voluntary termination. IDEX does require agreement to a Confidential Information, Work Product and Restrictive Covenant Agreement. You will be asked to sign this electronically upon your start with the Company.

------

![](ex-1032letteragreementbe003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com This offer of employment is subject to your satisfactory completion of a drug and alcohol abuse screening test, to be scheduled at a qualified laboratory, and a background screening. Please indicate your acceptance of this offer by signing on the line provided below and return a signed copy to me. Roopa, we have discussed the importance of this role to IDEX. We are confident that your leadership skills and experience can make a significant contribution to the continued success of IDEX, and that this position will be a positive professional step for you. Sincerely, /s/ ERIC D. ASHLEMAN Eric D. Ashleman Chief Executive Officer and President ...................................................................................................... /s/ ROOPA UNNIKRISHNAN Acceptance of Employment Offer Roopa Unnikrishnan February 26, 2022 Date Attachments: • Confidential Information, Work Product and Restrictive Covenant Agreement • Benefits Highlights Guide • MICP Compensation Programs Booklet • SERP Overview Booklet

------

## Exhibit 10.33

![](ex-1033letterxagreementb001.jpg)

IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com Personal and Confidential May 20, 2025 Dear Akhil, We are pleased to recognize your promotion to the executive leadership team as Vice President Corporate Development, effective May 26, 2025, for IDEX Corporation (IDEX or the Company), based in Northbrook, IL, and reporting directly to me. The following terms apply to this offer: • Your annual base salary will be Four Hundred Twenty-Five Thousand Dollars and Zero Cents ($425,000.00), payable on a biweekly basis. You will be eligible for a review of your salary with consideration for an increase in March 2026. While we hope that you have a long and mutually beneficial relationship, your employment is considered "at will" and will not be for any fixed term or definite period and may be terminated by you or IDEX at any time. • As of the effective date of this appointment, you will remain eligible for participation in our Management Incentive Compensation Plan (MICP), as established each fiscal year, which provides annual incentive earnings opportunity based on Company and personal performance. Your new MICP target level of incentive compensation will be fifty-five percent (55%) of your annual base pay. Your 2025 MICP will be pro-rated based on time in your former role and pay structure and your time in this new role and pay structure. The actual pay-out under the plan could be more or less than the target level and will depend on IDEX's performance and your performance. You must remain continuously employed through the bonus payment date and meet all other Plan terms to be eligible to receive an annual bonus payment for a particular fiscal year. • You will be eligible to receive a Company car allowance of One Thousand Five Hundred Dollars and Zero Cents ($1,500.00) per month, paid on a bi-weekly basis. • You will remain eligible for the full range of benefits, including: the IDEX 401(k) Savings Plan, medical and dental coverage, short-term and voluntary long-term disability coverage, and life insurance. • You will be eligible to participate in the Executive Medical Physical Program. IDEX has partnered with the Center for Partnership Medicine at Northwestern Memorial Hospital to provide you with the opportunity to have a full medical examination on an annual basis. The cost of the examination will be paid by IDEX. EX-10.33

------

![](ex-1033letterxagreementb002.jpg)

IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com • You will be eligible to enroll in the Executive Long-Term Disability program, which provides additional income in the case of total and permanent disability. This program provides additional benefits above the voluntary Group LTD plan that is in place for employees and is fully paid by IDEX. • Based upon your position, you remain eligible to participate in the IDEX Corporation Supplemental Executive Retirement and Deferred Compensation Plan. The purpose of the plan is to provide non- qualified retirement compensation benefits above IRS limits and to provide participants with the ability to defer other amounts of compensation. You will also be eligible for the Supplemental Retirement Contribution portion of the SERP. • Subject to approval from our Board of Directors and in accordance with and subject to the terms of the IAP, you will be eligible for equity grants under the IDEX Incentive Award Plan (IAP) at our annual grant as established each fiscal year. The annual grant value for your position beginning in 2026 is currently targeted at Four Hundred Thousand Dollars ($400,000). Your actual award in any year is dependent upon current program design and your performance. This plan is designed to provide an incentive and reward to key employees who are in a position to make substantial contributions to the success of IDEX. In all circumstances, the terms of the above-referenced plan documents govern eligibility and payment or benefit under the respective plans. • If, in the future, your employment with IDEX is terminated without cause ("cause" defined as willful misconduct or fraudulent behavior), IDEX will pay you twelve (12) months base salary at the then current monthly base rate plus your targeted annual incentive bonus in exchange for you signing, and not revoking, an IDEX-standard Severance & General Release Agreement. These payments are subject to tax withholdings and deductions. Such benefit will not be applicable in the event of your voluntary termination.

------

![](ex-1033letterxagreementb003.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IDEX Corporation 3100 Sanders Road Suite 301 Northbrook, IL 60062 United States www.idexcorp.com Please indicate your acceptance of this offer by signing on the line provided below and return a signed copy to me. Akhil, we have discussed the importance of this role to IDEX. We are confident that your leadership skills and experience can make a significant contribution to the continued success of IDEX, and that this position will be a positive professional step for you. Sincerely, Eric D. Ashleman Chief Executive Officer and President \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Acceptance of Employment Offer Date Akhil Mahendra May 20, 2025

------

## Exhibit 10.34

![](ex-1034letteragreementbe001.jpg)

EX-10.34

------

![](ex-1034letteragreementbe002.jpg)

------

![](ex-1034letteragreementbe003.jpg)

------

![](ex-1034letteragreementbe004.jpg)

------

## Ex-21

**Exhibit 21**

---

| | |
|:---|:---|
| **SUBSIDIARIES OF IDEX CORPORATION** | **SUBSIDIARIES OF IDEX CORPORATION** |
| **SUBSIDIARY** | **JURISDICTION OF INCORPORATION** |
| Flow Management Devices, LLC | Arizona, USA |
| ADS Environmental Services Pty Limited | Australia |
| Fast and Fluid Management Australia Pty., Ltd. | Australia |
| IDEX Holdings GmbH | Austria |
| iPEK Spezial TV GmbH | Austria |
| BarbIDEX International SRL | Barbados |
| Toptech Systems NV | Belgium |
| IDEX do Brasil Servicos e Vendas Ltda. | Brazil |
| IJ Research, Inc. | California, USA |
| ADS Environmental Technologies Inc. | Canada |
| Fluid Management Canada Inc. | Canada |
| Iridian Spectral Technologies, Ltd. | Canada |
| Quadro Engineering Corp. | Canada |
| Viking Pump of Canada, Inc. | Canada |
| IDEX Dinglee Technology (Tianjin) Co., Ltd. | China |
| IDEX Technology (Suzhou) Co., Ltd. | China |
| IDEX Trading (Shanghai) Co., Ltd | China |
| Richter EP (Nanjing) Co. Ltd. | China |
| Roplan Machinery (Ningbo) Co., Ltd. | China |
| Roplan Sales (Ningbo) Co., Ltd. | China |
| SFC KOENIG Flow Control (Suzhou) Co. Limited | China |
| Mott Corporation | Connecticut, USA |
| ABEL 1 LLC | Delaware, USA |
| Abel Pumps, LP | Delaware, USA |
| ADS Corp. | Delaware, USA |
| ADS LLC | Delaware, USA |
| Advanced Flow Solutions, Inc. | Delaware, USA |
| Advanced Thin Films, Inc. | Delaware, USA |
| AirTech Group, Inc | Delaware, USA |
| AirTech Holdings, LLC | Delaware, USA |
| AirTech-Pump Holdings Corp. | Delaware, USA |
| AirTech-Valve Holdings Corp. | Delaware, USA |
| Akron Brass Company | Delaware, USA |
| Band-It-IDEX, Inc. | Delaware, USA |
| CVI Laser, LLC | Delaware, USA |
| Digested Organics LLC | Delaware, USA |
| Fluid Management Operations, Inc. | Delaware, USA |
| Fluid Management, Inc. | Delaware, USA |
| Hale Products, Inc. | Delaware, USA |
| IDEX Health & Science LLC | Delaware, USA |
| IDEX Holdings, Inc. | Delaware, USA |
| IDEX Holdings 1, Inc, | Delaware, USA |
| IDEX MPT Inc. | Delaware, USA |

---

------

---

| | |
|:---|:---|
| **SUBSIDIARY** | **JURISDICTION OF INCORPORATION** |
| IDEX Service Corp. | Delaware, USA |
| IDEX US Holdings, Inc. | Delaware, USA |
| IJ Research Acquisition, Inc. | Delaware, USA |
| Liquid Controls Holdings LLC | Delaware, USA |
| Micro-LAM, Inc. | Delaware, USA |
| MyTana LLC | Delaware, USA |
| Nexsight LLC | Delaware, USA |
| Nova Technologies Corporation | Delaware, USA |
| Pulsafeeder, Inc. | Delaware, USA |
| SFC Koenig LLC | Delaware, USA |
| Subterra AI, Inc. | Delaware, USA |
| Superior Technical Ceramics Acquisition Inc | Delaware, USA |
| US Valve Corporation | Delaware, USA |
| Viking Pump, Inc. | Delaware, USA |
| Warren Rupp, Inc. | Delaware, USA |
| Toptech Systems, Inc. | Florida, USA |
| IDEX SAS | France |
| Abel GmbH | Germany |
| AIRTECH Europe GmbH | Germany |
| AWG Fittings GmbH | Germany |
| Balco Precision GmbH | Germany |
| IDEX Europe GmbH | Germany |
| IDEX Leasing GmbH | Germany |
| iPEK International GmbH | Germany |
| LUKAS Hydraulik GmbH | Germany |
| Melles Griot GmbH | Germany |
| PP AWG GmbH | Germany |
| Richter Chemie-Technik GmbH | Germany |
| SFC Koenig Beteilgungs GmbH | Germany |
| SFC Koenig GmbH | Germany |
| thinXXS Microtechnology GmbH | Germany |
| Vetter GmbH | Germany |
| IDEX Sourcing Corporation | Illinois, USA |
| Ascorp Energies India Private Limited | India |
| Atul Sugar Screens Private Limited | India |
| IDEX India Private Limited | India |
| Veco Precision India Private Limited | India |
| Banjo Corporation | Indiana, USA |
| IDEX Pump Technologies (Ireland) Limited | Ireland |
| Asco Filtri SpA | Italy |
| Banjo Europe S.r.l. | Italy |
| IDEX Italy S.r.l. | Italy |
| S.A.M.P.I. S.p.A. | Italy |
| IDEX Health & Science KK | Japan |
| IDEX Korea, Ltd | Korea |
| AEGIS Flow Technologies, L.L.C. | Louisiana, USA |

---

------

---

| | |
|:---|:---|
| **SUBSIDIARY** | **JURISDICTION OF INCORPORATION** |
| Maltidex International Ltd | Malta |
| IDEX Mexico S.A. de C.V. | Mexico |
| Gast Manufacturing, Inc. | Michigan, USA |
| M10 Edge Holdings, LLC | Michigan, USA |
| 603 OPTX, LLC | Michigan, USA |
| KZValve LLC | Nebraska, USA |
| Fast & Fluid Management B.V. | Netherlands |
| Gast Jun-Air Europe B.V. | Netherlands |
| IDEX International B.V. | Netherlands |
| IDEX Optical Technologies B.V. | Netherlands |
| LouwersHanique B.V. | Netherlands |
| Millux B.V. | Netherlands |
| Muon B.V. | Netherlands |
| Veco B.V. | Netherlands |
| Envirosight LLC | New Jersey, USA |
| Pipeline Renewal Technologies Limited Liability Company | New Jersey, USA |
| Roplan Sales Inc. | Oregon, USA |
| Hurst Jaws of Life, Inc. | Pennsylvania, USA |
| WinCan Poland S.P.Z.O.O | Poland |
| Precision Polymer Engineering International Limited | Saudi Arabia |
| IDEX Asia Pacific Pte. Ltd. | Singapore |
| Abel Equipos, S.A. | Spain |
| Airtech Europe Spain S.L. | Spain |
| Roplan Sales AB | Sweden |
| Velcora Holding AB | Sweden |
| SFC Koenig AG | Switzerland |
| WinCan AG | Switzerland |
| PPE, LLC | Texas, USA |
| Asco Filtration Trading Ltd | United Arab Emirates |
| IDEX Middle East FZE | United Arab Emirates |
| Band-It Company Limited | United Kingdom |
| CVI Laser Limited | United Kingdom |
| FTL Seals Technology Limited | United Kingdom |
| Gast Group Limited | United Kingdom |
| Godiva Limited | United Kingdom |
| Godiva Products Limited | United Kingdom |
| Hale Products Europe Limited | United Kingdom |
| IDEX UK Investment Ltd | United Kingdom |
| IDEX UK Ltd. | United Kingdom |
| Matcon Group Limited | United Kingdom |
| Matcon Limited | United Kingdom |
| M190 Edge Ltd | United Kingdom |
| Precision Polymer Engineering Limited | United Kingdom |
| Roplan Limited | United Kingdom |
| Seals Limited | United Kingdom |

---

------

---

| | |
|:---|:---|
| **SUBSIDIARY** | **JURISDICTION OF INCORPORATION** |
| Tecan Limited | United Kingdom |
| Viking Pump Hygienic Limited | United Kingdom |
| WinCan Europe Limited | United Kingdom |
| Trebor International, Inc. | Utah, USA |
| Superior Technical Ceramics Corporation | Vermont, USA |

---

## Ex-23

**Exhibit 23**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement Nos. 333-18643, 333-102882, 333-104768, 333-70450, 333-70452, 333-123558, 333-150142, 333-166981, 333-205935 and 333-279179 on Form S-8, and Registration Statement No. 333-277309 on Form S-3 of our reports dated February 19, 2026, relating to the consolidated financial statements of IDEX Corporation and subsidiaries (the "Company"), and the effectiveness of the Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K of IDEX Corporation for the year ended December 31, 2025.

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;DELOITTE & TOUCHE LLP |
| Chicago, Illinois |
| February 19, 2026 |

---

## Exhibit 31.1

**Exhibit 31.1**

**Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002**

I, Eric D. Ashleman, certify that:

1. I have reviewed this annual report on Form 10-K of IDEX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| February 19, 2026 | /s/ ERIC D. ASHLEMAN |
| | Eric D. Ashleman |
| | *Chief Executive Officer and President* |

---

## Exhibit 31.2

**Exhibit 31.2**

**Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002**

I, Sean M. Gillen, certify that:

1. I have reviewed this annual report on Form 10-K of IDEX Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| February 19, 2026 | /s/ SEAN M. GILLEN |
| | Sean M. Gillen |
| | *Senior Vice President and Chief Financial Officer* |

---

## Exhibit 32.1

**Exhibit 32.1**

**Certification of Chief Executive Officer**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accompanying Annual Report on Form 10-K of the Company for the annual period ended December 31, 2025 (the "<u>Report</u>") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| February 19, 2026 | /s/ ERIC D. ASHLEMAN |
| | Eric D. Ashleman |
| | *Chief Executive Officer and President* |

---

## Exhibit 32.2

**Exhibit 32.2**

**Certification of Chief Financial Officer**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the accompanying Annual Report on Form 10-K of the Company for the annual period ended December 31, 2025 (the "<u>Report</u>") fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| February 19, 2026 | /s/ SEAN M. GILLEN |
| | Sean M. Gillen |
| | *Senior Vice President and Chief Financial Officer* |

---

<br>